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Endocrinology : more than just a sliding scale
The study of hormones is one of the more nascent and
elusive branches of medicine. The idea that invisible
chemicals released from diminutive glands can cause
darkening of the skin, racing metabolism, and growth of
gigantic proportions is as mystifying to the lay patient as it
is to most physicians.
The general public confusion about what endocrinology entails became apparent to me on several clinical
rotations. During a paediatric endocrinology consult for a
child with short stature, the mother
inquired about her daughter's
diabetes. When I expressed surprise
that the child was diabetic, she
replied that she was not, but
assumed that this was the role of an
endocrinology consult. As diabetes
comprises a substantia l portion of
the endocrinology practice, many lay
people assume that this condition
and subspecialty are interchangeable.
As further illustration, an
elderly patient informed me that she
regularly saw her "bone doctor."
She was unfamiliar with the term
endocrinology; her understanding of
the person who treated her osteoporosis was that she was a bone specialist.
The public confusion about the practice of endocrinology is understandable if one cons iders the history of the
subspecialty. The word 'hormone' was not conceived until
1905, when Starling described "the chemica l messengers,
which speeding from cell to cell along the bloodstream, may
coord inate the activities and growth of different parts of the
body."1 As early as Hippocrates (400s BC), physicians had
an idea that certain glands could produce surprising effects
on the entire body. However, the thymus gland was not
discovered until the time of the Alexandrians (300s BC) ; the
pituitary, pineal, and thyroid glands were noted by Galen in
170 AD; Eustachi discovered the adrena ls in the 1500s;
Langerhans found the pancreatic insula in 1869, and the
parathyroids were unknown until the work of Sandstrom in
1880.2 It is thus unsurprising that the field of endocrinology
is one of the more unfamiliar subspecia lti es as the glands
that control this system had on ly been described 130 years
ago. In comparison to a field such as cardio logy, whose
organ and effects have had the benefit of centuries of study;
endocrino logy is only beginning to be unravelled.
As a medical subspecialty, endocrinology began to
gain recognition in North America in 1916 when the Society
of Interna l Secretions was formed .3 Today, The Endocrine
Society (USA) and The Society of Endocrino logy (UK) are
two of the main governing bodies. These organizations have
recognized the confusion that the co ncepts of hormones and
endocrino logy can produce and have designed websites to
educate the public. Our role as physicians is to do the same.
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One of the keys to compliance with therapy and a strong
doctor-patient relationship is patient understa nding. If our
patients do not understand what the pituitary gland is,
where it is located, and what effects it has, they are unlikely
to be satisfied with a diagnosis of pituitary dysfunction, nor
will they have confidence in our proffered therapies. One of
the central roles of the endocrinologist is thus that of
educator.
Familiarity with the field of endocrino logy is
necessary not only for budding
hormone speciali sts, but for all
physicians. A common ward misconception is that the endocrinology
consult service exists to manage the
insulin sliding scale. Our patients will
be better served by an understanding
that hormones play a role in every
organ system, in every disease, in
every patient. The Endocrine Society
has summarized this central role of
endocrinology in their Strategic PlanVision for the Field of Endocrinology:

"Endocrinology will be widely accepted as the fundamental science of molecular, cellular, and systems communication that underpins human health and disease.
It will be recognized as an interdisciplinary scientific
and clinical specialty that integrates basic and clinical
research with patient care. It will define the ways in
which the body's communication systems signal organ
coordination,function and dysfunction. "3

This issue of the UWOMJ is dedicated to the stimulating field of endocrinology. The feature and departmental
articles in this issue display the breadth of issues and
challe nges encountered in an endocrinology practice.
As in clinical practice, the topic of diabetes remains a
major focus of articles in this issue. Commonly-presenting
scenarios, such as the evidence for blood glucose selfmonitoring, diagnosis of metabolic syndrome, diabetes
associations with coronary artery disease and managing
laboratory va lues and side effects of common medications
taken by those with diabetes will help consolidate our
knowledge in the area. These articles are published
alongside more uncommon issues in diabetes management,
such as cystic fibrosis-related diabetes, 'diabulimia,' and
how urban planning influences diabetes.
There are many current 'hot topics' within the
domains of endocrinology. This issue's articles on bioidentical hormone therapy, bariatric surgery, drug doping and
gender testing in athl etes shed light on current developments and may help us better educate our patients on the
evidence behind the often-sensationalized media stories.
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We wish to extend a large th a nk you to the departmental ed ito rs, feature article writers and facu lty reviewers
for their commitment to educating others about endocrinology. Special th anks to Pencilla Lang, Ed Weiss, and Pat
Montaleo ne, for their tireless work in overseein g the
compi lation, layout, print and online publication, awards
and finances for the journal. Enjoy!
Tiffany Kwok
Editor-in-Chief

Laura Hinz
Senior Associate Editor
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Bariatric surgery: Lots to lose, much to gain
Edward S. Weiss (Meds 2012) and Sandeep Dhaliwal (Meds 2013)
Faculty reviewer: Dr. Andreana Butter, Department of Surgery, UWO

Introduction
The treatment of obesity has long been considered to fall
under the rubric of "lifestyle modification," with diet and
exercise making up a large part of the prescription to the
patient seeking to lose extra pounds. Unfortunately, it has
been shown that behavioural modification has only a
modest effect on long-term maintenance of weight loss, with
the average dieter losing less than 5kg with diet and
exercise alone.1
In recent years, it has become increasingly clear that
more aggressive therapy may be a superior option to treat
obesity, especially when overweight and its sequelae
preclude the pursuit of exercise, or when the behavioural
milieu is such that modification is unlikely to succeed. While
pharmacological treatment of obesity has shown some
limited success/ it is bariatric surgery that appears, at this
time, to offer obese people the highest probability of drastic
and permanent weight loss, with its attendant benefits on
physical, as well as emotional health.

Types of bariatric surgery
Surgical interventions for the obese are not new, having
been mentioned by early sources such as the Talmud (circa
500 CE) and the Greek historian Claudius Aelian (circa 200
CE). 2 •3 However, the modern age of bariatric surgery began
in the 1950s, when surgeons at the University of Minnesota
began removing variable lengths of small bowel to try to
reduce the absorption of food in obese patients. The
untoward side effects of this procedure- diarrhea, micronutrient deficiencies, kidney stones, polyarthritis, and even
cirrhosis 4 - led to experimentation with alternate surgical
strategies. In the 1960s, surgeons attempted gastric bypass,
based on the observation that patients who underwent
partial gastrectomy for the treatment of peptic ulcers were
unable to gain significant weight following their operationss
In this procedure, the stomach was asymmetrically split,
with only a small upper pouch remaining in continuity with
the small bowel. Patients found that the reduced size of
their stomachs caused them to become satiated early, with
overconsumption becoming particularly unpleasant.
These early procedures are, respectively, representative of the two primary strategies in bariatric surgery:
malabsorptive procedures, which aim to lower the rate of
absorption of ca lories consumed; and restrictive procedures, which aim to limit the actua l intake of food by
provoking early satiety. Further refinement has led to three
different procedures which are now commonly performed
as a method of treating obesity (Figure 1).

Adjustable
gastric band
(AGB)

Figure l . lllustration of three common bariatric surgical
procedures.

Adjustable gastric banding
Gastric banding was introduced as a bariatric procedure in
the late 1970s. In its first incarnation, the gastric band was a
non-adjustable plastic mesh applied circumferentially
around the upper portion of the stomach, creating a sma ll
pouch which restricted overconsumption. Refinement in the
years following led to the creation of the adjustable gastric
band (AGB), which consists of a hollow silicone ring
connected by a narrow tube to a subcutaneous access port.
In this manner, the size of the upper stomach pouch can be
adjusted by the infusion of saline through the port and into
the band. If, for example, the rate of weight loss is deemed to
be too slow, the band can be tightened and the pouch made
smaller. Conversely, if a patient with a gastric band were to
become pregnant and require a higher caloric intake, the
band can be loosened by removing fluid .
There are several relative benefits to AGB . Although
performed laparoscopically like most modern bariatric
operations, band placement is relatively less invasive. It
involves no staples, transections, or anastomoses, and is
thus associated with the lowest rates of post-operative
complications and mortality compared to other procedures.6·7 Weight loss is more gradual than with more
invasive malabsorptive procedures, but the percentage of
excess weight lost has been found to be similar in some
long-term studies. 8 The adjustability of the band and the
potential for easy reversability are additional factors that
make the gastric band an attractive choice.
Although major complications from gastric banding
are quite rare, there are, nonetheless, some drawbacks to
the procedure. Studies have reported unwanted pouch
enlargement as a complication in 10-15% of patients, as
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Roux-en-Y
Vertical sleeve
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well as band slippage and distal stomach prolapse in 2-4%;
these often necessitate reoperation or band removal. 8
Additionally, it has been found that in patients classified as
"super-obese" (8MI > 50), weight loss and improvement in
comorbidities such as type 2 diabetes are superior in other
types of procedures. 9

Vertical sleeve gastrectomy
Vertical sleeve gastrectomy (VSG) evolved in the milieu of
increasing recognition of the effectiveness of restrictive
procedures, combined with the rapid adoption of automated
surgical staplers in the 1970s. In this procedure, the fundus
and greater curvature of the stomach are removed through
vertical stapled resection, resulting in a tubular or bananashaped sleeve with a volume of around 15% of the original
stomach. 10 Although purely restrictive in intent, it is thought
that lower circulating levels of ghrelin, a hunger-inducing
hormone produced in the gastric fundus, may contribute to
the weight loss seen by patients. 11
The benefits of VSG are similar to those of other
restrictive procedures. Although long-term results have not
yet been published' , studies suggest that short-term weight
loss is comparable or superior to that of patients who have
undergone gastric bandingY The procedure also spares the
absorptive function of the small bowel, although it is recognized that there is a potential for impaired vitamin 812
absorption due to the lack of intrinsic factor production.
Technically, a partial gastrectomy is simpler than many of the
malabsorptive procedures, and it can also be converted to a
gastric bypass in the event of failure to lose weightY However, it appears that more long-term results will be required
before VSG is a standard part of the bariatric repertoire.

Roux-en-Y gastric bypass
The Roux-en-Y gastric bypass (RYG8) is widely becoming one
of the most popular surgical options for weight loss. A
technically complex procedure, it involves the creation of a
small restrictive stomach pouch, but additionally reconstructs the small bowel to promote a malabsorptive state. In
the traditional procedure, the jejunum is transected approximately SOcm distal to the ligament of Treitz. The distal limb
of the jejunum is anastomosed to the reduced upper stomach
pouch, while the proximal limb, which transmits bile and
pancreatic secretions from the duodenum, is anastomosed
approximately a meter down the distal limb. Unlike a sleeve
gastrectomy, an RYG8 leaves the rest of the stomach in situ,
making the operation potentially reversible if necessary.
Weight loss stimulated by RYG8 has been found in
some studies to be superior to that of purely restrictive
procedures, and health-related quality of life has also been
shown to be significantly betterY This benefit over other
procedures has been attributed partially to the malabsorptive state, but also to changes in taste preference and the
aversive sequalae of the dumping syndrome, which is an
unpleasant combination of gastrointestinal and vasovagal
disturbances that often results from the ingestion of sugar-

laden meals following gastric bypass. Furthermore, the exact
extent of intestinal bypass can be adj usted in order to
promote ever further weight loss, though this does run th e
risk of developing micronutritional deficiencies.
Complications following RYG8 are, as expected,
somewhat higher than with purely restrictive procedures.
However, operative mortality has been reported to be les s
than 1%/ 4 and the primary complications are related to
malabsorption of vitamin 812 and iron; these can be easily
corrected with supplementation.9

Benefits of bariatric surgery
There is little doubt that bariatric surgery is effective for
weight loss. A meta-analysis looked at the outcomes of
22,000 patients who underwent some sort of bariatric
surgery, and found that the average loss of excess weight was
61.2%.14 The study also reported that the majo rity of patients
also experienced a resolution of pre-existing type 2 diabetes,
hypertension, hyperlipidemia, and obstructive sleep apnea .
Operative mortality was, on average, less than 1%, which is
deemed to be much lower than the risk of premature
mortality from the health consequences of obesity.
Aside from the physical health benefits of bariatri c
surgery, it appears that treatment can also have a substantial
impact on emotional and mental health as well. Numerous
studies have shown that people living with obesity have
significantly higher rates of mood and anxiety disorders, as
well as decreased se lf-esteem and self-acceptance. 15•16
Successful weight loss following bariatric surgery often
results in improvement in these domains as well. 16
While at first glance it may appear that surgical
management of obesity has the disadvantage of being
relative ly expensive, severa l studies have borne out the
assumption that the increased expense in the short term is, in
fact, less costly than the medical management of severe
obesity and its comorbidities, which can often amount to
$10,000 per patient per year or more in Ontario. 17 Additionally, it has been found that obese patients who undergo
bariatric surgery are more likely to be employed and not
dependent on social welfare support compared to before
their surgeries, which only furthers the case for surgery in
the very obese.18

Access to bariatric surgery
With the alarming reminders of the growing "obesity
pandemic" forefront in the public mind, and the growing
awareness of bariatric surgery as an effective treatment
option, it is not surprising that demand for surgical treatment
is far higher than the available supply in Canada. A recent
study that polled Canadian bariatric surgeons found that the
average wait time for publicly-funded procedures performed
locally is around five years. 19 In response to the extreme
demand, provincial governments have been increasingly
funding bariatric surgery performed out-of-province and outof-country. Ontario, for example, funded over 1,500 out-ofcountry procedures in 2008-2009, at a cost that far exceeds
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the comparable cost in Canada. 20 Meanwhile, those with
suitable financial means often take advantage of privatelyrun clinics, which offer procedures not funded by provincial
health plans. Gastric banding, for example, is ava ilable at a
cost of around $16,000, with wait times in the range of
weeks to severa l months. Others, seeking a less-expensive
alternative, have been known to travel to Mexico and India,
where the procedures can be done in short order at a
fraction of the Canadian price.
Perhaps in recognition of the dire situation s urrounding the inequity of access to bariatric surgery, several
provincial governments have announced new funding
strategies to increase access to weight loss procedures.
Ontario is investing $75 million to increase its bariatric
surgical capacity by nine-fold in the next few years/ 0 and
Quebec intends to shorten waiting times to six months
through a significant infusion of new funds .2 1 These sorelyneeded expansions are expected to make a vast difference in
the morbidity and mortality of those suffering from severe
obesity.

9.

10.

11.

12.

Conclusion
13.
In the absence of effective primary prevention, bariatric
surgery appears to be the most promising treatment option
for obesity and its resultant comorbidities. While the
optimal surgica l approach has yet to be decided, it is clear
that procedures for weight loss will continue to evolve in
order to maximize benefit and reduce the risk of complications. Inequitable access to these procedures represents a
major barrier to successful treatment of severe obesity on a
population level, but the recognition by provincial funding
agencies that these treatments are beneficial is leading to
positive change and an overall increase in the well-being of
Canadians suffering from obesity.

14.

15.

16.
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Metabolic syndrome
Julie Huang (Meds 2012) and Jai Jayakar (Meds 2013)
Faculty reviewer: Dr. Terri Paul, Department of Medicine, UWO
Introduction
Metabolic syndrome (MetS) is a common disorder characterized by the cluste ring of risk factors for developing
cardiovascular disease (CVD) and type 2 diabetes mellitus
(T2DM) . Though the idea of MetS has existed for over 80
years, the co ncept was not further developed until 1988;
since then our understanding of this disorder has bee n
continuously evolving. The precise definition and criteria
for diagnos is of MetS has bee n rapidly changing in recent
years. 1·3
The s igns that characterize MetS include central
obesity, dys lipidemia, hyperglycemia and hypertension. It is
believed that the diagnosis of MetS is a greater predictor for
the development of CVD a nd T2DM than the consideration
of these risk factors independently.4 In keeping with its
classification as a 'syndrome,' there has not been a single
cause identified in th e etiology of MetS, and there is still
much that is unknown about its pathophysio logy. Indeed, it
is even unclear whether MetS is a 'true' syndrome where the
symptoms are related by pathophysiology, or whether the
diso rder is si mply a collection of common independent risk
factors from differing disease phenotypes.4 Nevertheless,
insulin resistance is the most commonly acce pted mechanis m through which MetS develops.5
There have been many definition s of MetS released
by separate in stitutions s ince the WHO released the first
formalized criteria in 1999. Each of th e criteria considers
sim ilar parameters that reflect both our understanding in
the pathophysiology of MetS, as well as the clinical prese ntation of the disorder. There are differe nces betwee n
guidelines in cutoff values and the combinations of symptoms that will allow a diagnosis. This article will review
three guidelines - the WHO, ATPIII a nd the IDF - as these
appear to be the most commonly used criteria in the cu rre nt
literature.
Current guidelines- review and comparison
Th e s pecific deta il s of th e criteria are s umma ri zed in Table 1
for comparison. The first set of diagnostic crite ria was put
forth by the WHO diabetes group in 1999. Insulin resistance
or impaired glucose to lera nce or dia be tes, hyperten s ion,
dyslipid e mi a, obesity a nd mi croa lbuminuri a were defined
as the components of MetSl These criteria were felt to be
difficult to measure in the clinic; the ora l glu cose tolerance
test a nd albumin measurement were not feasible tests that
could be easily done in the clinic. In response, the US
National Cholesterol Education Program : Adu lt Treatme nt
Pan el Ill (NCEP :ATP III or ATPIII) in 2001 released a new
set of criteria where insulin resistance was measured by a
fasting glucose test, a simp ler test tha n the oral gl ucose
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tolerance test. The combination of risk factors and cut-off
levels also differed from the WHO criteria. The ATPIII
criteria, however, still had their shortcom ings. Although
easier to use in the clinic, the ATPIII guidelines were not
suitable for an international population; for example, ethnic
differences in BMI were not addressed.
In 2004, in order to clear the confusion between
multiple guidelines and to create an internationally applica ble guidelin e, the International Diabetes Federation released a unified definition in 2005 (updated in 2006V Like
the ATPIII, th e IDF used criteria that could be easily tested
in the clinic. The most significant change in the IDF criteria
was the use of central obesity as a necessary component for
diagnosis. Also important was the attempt to make the
criteria applicable for a worldwide population by releasing
cut-off levels for central obesity that were specific for
different ethnicities. The cutoff values were generally lower
than leve ls present in the other criteria, and the specific
values were obtained usi ng anthropometric studies of
differe nt populations.2
In addition to th e three guidelin es that have been
outlined, it is important to note other guidelines released by
institutions such as the American Association of Endocrinology, the National Hea rt, Lung, and Blood Institute (NHLBI) .
These are all s imilar, but differ s lightly in cutoff levels.
Prevalence and predictive value
MetS is a very common disorder. The literature suggests a
preva lence ranging from 14-32%. 3·6•7 Specific prevalence
depend s on geographic location, population characteristics
such as ethnicity, and the criteria used to define MetS. The
majority of studies suggest that a higher prevalence of MetS
is identified using the IDF criteria than the ATPIII criteria. 6·7
The importance of MetS lies in its abi lity to predict
more significa nt disease, primarily T2DM and CVD. While
th e re is strong evidence to suggest that MetS is a good
predictor of T2DM, the ability to predict CVD in MetS is
co ntrovers ial. 8 In addition to T2DM and CVD there have also
been studies suggesting that MetS can predict other
diseases a nd outcomes, including chronic kidney disease,
sexual dysfun ction, hypogonadism, polycystic ovarian
ovarian syndrome (PCOS) , fatty liver and all-ca use mortality.9·11
The litera ture s uggests that MetS is a strong predictor of developing T2DM . The s pecific predictive ability
differs be tween differe nt s tudies and between criteria. A
numbe r of separa te studies have compared the ability of the
ATPIII criteria and the IDF criteria in predicting diabetes in
differe nt populations. In th e articles reviewed, the predictive value of MetS ranges, with articles listing an increased
RR of 3.08 all the way to 10.10?· 11 ·12·13 Comparing sets of
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Metabolic syndrome
WHO

ATP Ill

Impaired glucose tolerance or insulin
resistance or a diagnosis ofT2DM
Plus any two of the following:
Dyslipidemia
Triglycerides ~ 1.7 mmoljL
or HDL<0.9 mmoljL (males)
or HDL<1.0 mmoljL (females)
Microalbuminuria
Albumin excretion > 20119/min
Hypertension
>140/90 mmHg

IDF
Central obesity w / ethnic specific
values or BMI> 30

Any three or more of the following:

Plus any two of the following:

Raised Triglycerides
1.7mmoljL

~

Raised Triglycerides
1.7mmoljL

~

Reduced HDL cholesterol

Reduced HDL cholesterol

< 1.03 mmol/L (males)
< 1.29 mmoljL (females)

< 1.03 mmoljL (males)
< 1.29 mmoljL (females)

Hypertension
or ~85 diastolic (mmHg)

~130

~130 systolic

Hypertension
systolic
(mmHg)

or

~85

diastolic

Raised fasting plasma glucose
Obesity
BMI > 30 or waist:hip ratio > 0.9 in
males, >0.85 in females

Central Obesity
>102 em (male), >88cm (female)

Raised fasting plasma glucose
Fasting plasma glucose ~100mgjdL
or previously diagnosed T2DM

Table 1. Summary of the WHO, ATPIII and IDF criteria for metabolic syndrome

criteria, it has been suggested that the ATPIII criteria
appears to be more effective at predicting diabetes but these
results are not necessarily definitive.6 ·7.1° In comparison to
established methods for predicting diabetes, studies have
found no advantage. 12 MetS using the ATPIII criteria shows
a lower sensitivity and a higher false-positive rate when
compared to the Diabetes Risk Score, a standard method to
measure risk of developing diabetes.11
Whether MetS is able to predict CVD is unclear and
controversial. The MetS criteria does not include absolute
CVD risk factors that are included in standardize·d risk
assessment methods such as age, smoking, and family
history. 8 Regardless, studies have shown that individuals
diagnosed with MetS do show a statistical increase in
developing CVD, and that it is an important risk factor for
CVD cause and mortality.14·15 This calculated increase in risk
is fairly consistent between different criteria - the WHO,
ATPIII and the IDF.14 When compared to existing methods
for predicting CVD, one study demonstrated that a diagnosis
of MetS had a lower sensitivity and higher false-positive rate
compared to the Framingham Score in predicting CVD. 11
Other studies suggests that despite the ability of MetS to
predict CVD mortality, it does not do so beyond the ability of
its individual components. 13
Discussion

sources of confusion. While MetS is able to predict diabetes
and CVD to an extent, its efficiency and effectiveness are
controversial. For instance, the JDF criteria has been
criticized for missing high risk patients that do not show
central obesity.7 The ability of MetS to predict disease has
been shown to be no more effective than existing methods.11.12 Other studies suggest that the risk associated with
MetS is no greater than the risk associated with its individual components. 13 This brings into question the clinical
value of diagnosing MetS.
Nevertheless, there is convincing evidence for the
use of MetS. Recently, a report has been published supporting the use of MetS as an important public health tool. 16 It
acknowledges the limitations that MetS has in predicting
DM and CVD, but it also stresses that combined with other
clinical tools and other existing guidelines, MetS can be
useful in helping patients understand their level of risk and
its potential impact on their health in the future . Underlining how separate risk factors can be interrelated can have
an important role in helping both clinicians and patients
address risk factors, especially if lifestyle modification is the
goal.
Recent research has been focused on addressing the
limitations and confusion that surrounds MetS. Most
recently, in October, the IDF and AHA have jointly released a
new guideline that attempts to unify the MetS criteria. 17

MetS identifies individuals that are at risk of developing
CVD and T2DM, but its ability to do so is confounded by the
existence of multiple criteria, and a lack of knowledge of this
disorder. A formal definition of MetS was created only in the
last 10 years, and there have been few long-term studies on
MetS. The resulting lack of evidence and an incomplete
knowledge of its pathophsyiology are also significant

Other areas of recent research include establishing more
evidence to better refine the MetS criteria, with a particular
focus in different subpopulation and ethnic groups. With
the incidence of childhood T2DM on the rise, there is a need
to develop standardized criteria for MetS diagnosis in the
pediatric population.18
In summary, MetS is a useful tool to identify individuals at risk for developing T2DM and CV. There are many
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issues that limit its clinical value, including confusion
between the existence of multiple guidelines, controversy in
the research, lack of evidence, and a poor understanding of
its pathophysiology. Nevertheless, it is important to
appreciate the function of MetS, especially as the incidence
of CVD and T2DM continues to rise in today's society.

11.

12.
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Addressing the new teen trend of "diabulimia": Moral quandaries of a pediatric
endocrinologist
Julie Hughes (Meds 2012)
Faculty reviewer: Dr. Louis C. Charland, Departments of Psychiatry and Philosophy, UWO

The management of diabetes mellitus in adolescents has
grown increasingly nuanced as insu lin resistance appears at
ever-younger ages and technology advances into hitherto
unattainable realms . Hence, it is in the midst of an already
complex milieu that a new syndrome has managed to
emerge largely unnoticed. This rarely researched and thus
largely mysterious condition has been dubbed "diabulimia"
by the media; the scientific community has yet to name it.
Diabulimia refers to the practice of withholding insulin in
order to lose weight. 1 It typically co-exists with other
disordered eating behaviour (DEB; e.g., extreme restriction,
use of laxatives, etc.) or fu ll-scale eating disorders. 2 DEB is
particularly worrisome in the context of pediatric diabetes
for two reasons:
(a)

It is dangerous. Eating disorders in diabetics are
associated with poor metabolic control, greater need
for hospitalization, a higher rate of microvascular
complications (in particular retinopathy and
nephropathy), and premature mortality.1· 3· 4· 5· 6

(b)

It is common. A startling 51% of adolescents in a
Toronto study reported DEB, and over 10% met
diagnostic criteria for an eating disorder. 2 The root
of this rather extraordinarily high prevalence is
unknown, but there have been postulations: diabetic
children are encouraged to pay a great deal of
attention to their diets and also tend to have higher
BMls than their peers, which may increase anxiety
about weight. 7 The problem seems to increase with
age : deliberate insulin omission is reported by
roughly 2% of preteens, 15% of mid-teens, and 3039% of older teens.u

The remainder of this paper will focus on ethical
concerns that may arise in the care of these patients. As
Carney insightfully notes, "Behavioural disorders accompanied by questionable beliefs ... expose the frailties of medicolegal knowledge.''8 If we attempt to understand these
frailties and grapple with those issues for which "there is no
'right' decision, only a decision that is thoughtfully made
and perhaps 'more right' than the alternatives,"we will
gradually strengthen the ethical foundations on which
medicine relies. 9

Case 1
You receive an urgent page informing you that Erica,
a 15-year-old patient of yours, is in diabetic ketoacidosis at the hospital. You go to see her and discover

that she has been skipping many of her in sulin doses
for months and does not wish to be treated for her
ketoacidosis with insulin. She is terrified at the
prospect of gaining weight and equates taking in sulin
with weight gain and loss of control. What should you
do?
Though literature on diabulimia is scant, much has been
written on the ethics of compulsory treatment for anorexia
nervosa, and the essential difficulty in both circumstances is
the same. It li es in balancing two of the most sacredly held
principles of bioethics: beneficence and autonomy.8· 10• 11 Put
in another fashion, this is a tension between positive rights
(i.e., the right to health) and negative rights (i.e., the right
not to be hospitalized or treated aga inst one's wi ll).8
Before moving on any further, it is crucial to get the
question straight. In this case, there is in fact more than one
question . The first is this: should a clinician respect a
competent patient's autonomy if his or her own vision of the
patient's best interests differs from th e patient's (assuming
that what the patient desires the clinician to do lies within
ethical bounds)? That question has been considered in
depth and resolved .12 It is not a very difficult one when well being is considered from a holistic point of view, since "a
respect for autonomy clearly emerges from a beneficencebased ethic"Y In the case of eating disorders, however, we
have a cluster of more complicated questions, ones in which
beneficence and autonomy truly do conflict: they are
questions regarding the nature of competence, how mental
illness can affect it, and what to do when it is fragi le or
absent.
Competence requires the ability to understand and
remember information about treatment options, appreciate
the personal reality of relevant benefits a nd risks, weigh and
consider various possibilities, and express a choice.11 · 14• 15
While an eating disorder certainly does not automatically
remove a patient's capacity to make medical decisions,
concern is valid and needs to be explored on a person-byperson and task-by-task basis. Anorexia, the most studied of
the eating disorders, has variable and unpredictable effects
on concentration, beliefs, and information processing.U· 16· 17•
18 19
·
Patients frequently express contradictory convictions:
for example, they usually do not want to die, yet they also do
not want to eat enough to live.20 Whether these difficulties
are of a nature that can be adequately captured on standard
tests of competence (e.g., the MacCAT-T) is a matter of
debate. 18· 19· 2 1 Some propose that pathological values derived
from the eating disorder may cause a cognitive impairment
greater than that detected by current tests. 18• 21
The extent to which the cognitive distortions of
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anorexia are present in diabulimia is unknown and difficult
to surmise, since both severe malnutrition (which may or
may not be present in diabulimia) and the mental illness
itself contribute to them. The latter should not be underestimated, for "the types and range of relationships that
patients may have with the eating disorder are similar to
the relationships they may have with people". 14 Thus,
establishing the competency of a patient with any eating
disorder requires a careful and thoughtful evaluation. In
Ontario, a hearing before the Consent and Capacity Review
Board is sometimes necessary, though this is impractical
when urgent care is required .22
If it is determined that a patient is not competent to
refuse a specific medical intervention, the treatment team
must then discuss the issue with a substitute decision maker
(in pediatrics, usually the parents) and offer appropriate
counsel. For patients who do not have an advance directive,
the guiding standard generally applied is that of "best
interests".18· 23 This raises a new question : even with legal
permission, is it good judgment to treat Erica against her
will? Forced treatments are highly psychologically distressing and may jeopardize recovery if used excessively. 20·24 All
costs must be counted and the patient's wishes should be
respected whenever possible, even if he or she is not
competent. 25
Nonetheless, in Erica's case, we suggest that the
standard of best interests would involve administering
insulin. There is good rationale, indeed probably better
rationale than for forced feeding in anorexia : she is in an
acutely life-threatening situation, the intervention is of
known medical benefit, there are no viable alternatives, and
her true wishes cannot be reliably ascertained due to the
cognitive effects of her illness.8·10·11 · 14· 20· 25 Further, because
an eating disorder is normally an expression of emotiona l
distress rather than a genuine attempt at a slow suicide,
there is a particularly strong "duty to protect". 8· 10· 11 This
scenario is not akin to withdrawing care at end-of- life;
patients with eating disorders do recover and frequently go
on to lead full, happy lives. 11 · 14· 15
It goes without saying that Erica will need other
care. Her ability to consent to (or refuse) each intervention
should be considered independently by a clinician attuned
to possible changes over time.14 ' 24 The process of eva luating
competence can be given more thought and time once she is
stable. Fortunately, compulsory treatment given sensitively
does not seem to negatively affect the therapeutic relationship. IO,t4
Conceptually, perhaps the most important point here
is that the underlying rationale is not a lack of respect for
autonomy but a beli ef that true autonomy is occasionally
impossible. Hence, the goal is not to privilege the clinician's
view over the patient's, but to give what the patient's
genuine self, rather than her mentally ill se lf, wou ld want,
with the ever-present hope that in the future she will regain
the ability to choose freely and even healthfully. Clinicians
should strive for the model achieved in a British Columbia
eating disorders program in which "the team is always
working towards empowering the patient to achieve her

own agency and at the same time must remain cognizant of
the power of the anorexia, which may mask the authentic
14
wishes of the patient to seek wellness." A blind and
unconsidered adherence to the wishes of a patient who is in
severe psychiatric distress and desperate medical need
helps no one.
Case 2
You head back to your office. Laura, a 12-year-old
with Type I diabetes, is coming to see you for a
routine check-up. Upon reviewing her chart, you
discover that her sugar levels are rather high and she
has lost about 10 pounds. What is your approach?
This particular scenario is not ethically complex, yet it is
important, because if you were to discover that Laura has a
full-scale eating disorder, you would have a window of
opportunity to simultaneously avert suffering and avoid the
ethical complexities of the previous case. Call it
"preventative ethics", if you will. You might accomplish
these goals by (a) treating her early, and (b) working with
Laura, her family, and an interdisciplinary team to prepare
an "advance directive" that could be used to guide treatment
if she should lack decision-making capacity in the future.14
Evidence suggests that DEB persists for at least five years in
over 90% of cases; a "wait-and-see" approach is not wise. 1
Unfortunately, physicians feel that they lack training
in caring for adolescents with these difficulties, and routine
care is likely inadequate.5 Recommendations for those
hoping to achieve successful early intervention include
yearly screening questions beginning in the preteen years,
attempts to normalize eating behaviour and bolster self
esteem early in the course of illness, and a low threshold for
referral to specialized eating disorder services. 1· 15 Last but
never least, according to patients, the "key to a meaningful
intervention is to be recognised by the therapist as a
person". 26
In sum, "diabulimia" illuminates the ethical importance of early intervention in mental illness and raises
important moral issues that the field of pediatric endocrinology will need to address in coming years. Such discussion is an integral part of the rapid evolution of society and
medicine, for as Macdonald so aptly put it, "Ethics - the
making of va lue judgments, of weighing our actions against
shared standards- is a task inherent to clinicallife." 25
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Introduction
Among the many rising global health epidemics, diabetes
mellitus can be argued to be one of the most concerning
ones with over 246 million people affected worldwide
currently and 380 million people expected by 2025.1 Type 2
diabetes mellitus (T2DM), or non-insulin dependent
diabetes, accounts for 95 % of all cases of diabetes/ and
results in significant morbidity and long-term complications
affecting multiple organ systems, such as microvascular
pathology in the retina, peripheral neuropathy, nephropathy, and most importantly, macrovascular disease affecting
arteries supplying the heart, brain, and lower extremities.2
In fact, the risk of developing cardiovascular complications
in T2DM is two- to fourfold higher for men and women
respectively, relative to a non-diabetic population.2
Tight blood glucose control is one of the pillars of
patient-centred self-management, but the role for testing
glucose levels in order to achieve tight control has been met
with many challenges and debate. Technology that allows
for self-monitoring of blood glucose levels has only been
commercially viable since the early 1980's. 3 While there has
been evidence to suggest the benefit of using selfmonitoring of blood glucose (SMBG) for diabetic individuals
on insulin (patients with either TlDM or T2DM on insulin) ,
there has been limited research and controversy on
whether the high personal and financial cost burden of
SMBG is beneficial for most non-insulin dependent T2DM
patients. 4 This article will explore the challenges and gaps of
knowledge in using SMBG for the management of patients
with T2DM, as well as identify recommendations and
improvements that can be made to aid patients in their
disease management.
Current evidence
The current clinical evidence supporting the use of SMBG on
improving the outcomes of non-insulin dependent T2DM
patients is controvers ial and inconclusive. Most published
trials of SMBG use the glycosylated hemoglobin (AlC)
(HbAlC) levels as a surrogate marker for overall glycemic
control and risk of secondary complications, but the
methods utilized with respect to the intervention (e.g.
frequency of SBGM, follow-up, and education) have been
heterogeneous and hence difficult to generalize. 5
A recent key study conducted by the DiGEM
(Diabetes Glycemic Education and Monitoring) Trial Group
used an open, parallel group randomized control trial
methodology. It was concluded that there was no convincing evidence to recommend routine SMBG for all T2DM
patients, nor any evidence of improved glycemic control
relative to usual care monitored by HbAlC levels. 6
However, in contrast, a meta-analysis conducted by
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jansen et al. looking at 13 randomized controlled trials was
able to report conclude that SMBG improved the HbAlC by
more than 0.40% and this reduction nearly doubled after
providing medical feedback. 7 Similarly, Towfigh et al.
concluded from their meta-analysis of 9 randomized control
trials that T2DM patients not on insulin using SMBG had a
statistica lly significant although modest improvement in
8
glycemic control relative to those without SBMG.
Moreover, a study by McGeoch et al. suggested that
there may be a subset of T2DM patients who benefit from
SBMG.9 Specifically, they conducted a systemic review of 3
randomized trials and 13 observational studies published
since 1990. Based on results from a patient group managed
with oral hypoglycemic agents and/or diet alone, their
conclusion was that only larger studies with a higher initial
HbAlC of > 8% showed improvement in glycemic control
with SMBG.
Challenges and Limitations
It has been difficult to consolidate data and compare
research on SMBG in T2DM patients due to inconsistency of
outcome measures, as well as a lack of using other measures
beyond the HbAlC value to monitor efficacy. Welschen et al.
suggest that additional factors such as quality of life, wellbeing, patient satisfaction, and hypoglycemic episodes
should also be comprehensively incorporated into the
outcome measures.10
Another limitation of the current literature is that
many studies have not reported use of a validated or
standardized algorithm for patients to implement changes
in therapy. For example, in the juvenile Diabetes Research
Foundation study, patients were instructed to calculate
their insulin dose and adjust it according to their blood
glucose levels according to standardized protocols.U Use of
such protocols not only allows for more consistency by
reducing confounding factors affecting the outcome measures, but also helps to encourage patient self-education and
interpretation around SMBG. Accordingly, both education
and ongoing support have been cited as areas requiring
further development in adopting a SMBG intervention for
T2DM patients who need more guidance on the course of
action when observing a high blood glucose level. 12 In fact,
patients with chronic hyperglycemia may develop increased
anxiety, feel more burdened with their health care, and even
perform inappropriate actions if they do not possess an
adequate understanding of normal fluctuations of blood
glucoseY
Recommendations
While there has been a lack of consensus on whether to
adopt SMBG as part of routine care for all T2DM patients,
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there has been so me agreement that certain subpopulations
may benefit from regular SMBG. Specifically, tight glycemic
control is very important during pregnancy as preventing
fetal malformation, stillbirth, neonatal hypoglycemia, and
respiratory distress.13 Furthermore, changes in HbA1C
levels are too slow and retrospective to be used as an
accurate measure of glycemic control during this sensitive
time period.14 Similar parallels can be drawn with other
special circumstances such as new diagnosis of T2DM,
initiation or change in medication, or concurrent illnesses
where SMBG may prove to be ofbenefit. 9
Given that a goal of SMBG is to promote selfmanagement skills in the T2DM patient, identification of
behavioural and personal characteristics which may
predispose a patient to maximally benefit from SMBG would
likely result in improved and long-term outcomes. For
instance, "ideal" patients have been identified as those who
know how to take a reading, interpret the reading relative
to target values, formulate a connection between deviant
readings and prior behaviour, create and implement action
plans, and evaluate glucose readings in a non-judgmental
framework. 15

4.

5.

6.

7.

8.

Conclusion and Future
Tight glycemic control is an important goal of selfmanagement in T2DM in order to prevent secondary
complications. While there has been evidence supporting
the use of SMBG for insulin-dependent diabetes, most
research studies lack sufficient consistency and homogeneity in methodology, clinical follow-up, and patient populations to make a conclusive recommendation for its use in
the routine daily management ofT2DM patients.
Future areas for productive research in this area
include developing more educational and ongoing support
for T2DM patients to improve understanding of blood
glucose readings and their associated clinical implications.
Also, defining other relevant outcomes for SMBG beyond the
A1C would be relevant. There may be subpopulations of
T2DM patients who would benefit more from SMBG due to
their need for tighter glycemic control during special
circumstances, such as during pregnancy, new diagnosis, a
change of medications, or other co-morbidities. Despite the
current challenges with consolidating evidence on the
benefits of SMBG for the T2DM patient population, it
remains possible that SMBG can play an important role in
the glycemic control with the appropriate supportive
clinical education and follow-up of patients.

9.

10.

11.

12.

13.
14.

15.

References
1.

2.

3.

International Diabetes Federation, Diabetes atlas
(3rd edn.), International Diabetes Federation,
Brussels (2006).
Kannel WB, McGee DL. Diabetes and cardiovascular
diseases: the Framingham Study. JAMA. 1979; 241:
2035-2038.
Varanauskiene E. Can blood glucose self-monitoring

UWOMJ 179:1

I Spring

improve treatment outcomes in type 2 diabetes?
Di abetes Res Clin Pract. 2008 Dec 15;82 Suppl
2:S112-7.
DTB. Self-monitoring of blood glucose in diabetes.
Drug Ther. Bull.9. 2007 : 65-69.
Bergenstal RM, Gavin JR. Global Consensus Conference on Glucose Monitoring Panel: The role of selfmonitoring of blood glucose in the care of people
with diabetes: report of a global consensus conference. Am J Med. 2005;118 (Suppl): 1S-6S.
Farmer A). Wade AN, French DP, Simon ). Yudkin P,
Gray A, Craven A, Goyder L, Holman RR, Mant D,
Kinmonth AL, Neil HA. Blood glucose self-monitoring
in type 2 diabetes: a random ised controlled trial.
Health Techno! Assess. 2009 Feb;l3 (15):iii-iv, ix-xi,
1-50.
j.P.jansen. Self-monitoring of glucose in type 2
diabetes mellitus: a Bayesian meta-analysis of direct
and indirect comparisons. Curr Med Res Opin. 2006
Apr;2 2(4) : 671-81.
Towfigh A. Romanova M, Weinreb )E, Munjas 8,
Suttorp M). Zhou A. Shekelle PG. Self-monitoring of
blood glucose levels in patients with type 2 diabetes
mellitus not taking insulin: a meta-analysis. Am J
Manag Care. 2008 jul;14(7):468-75.
McGeoch G, Derry S, Moore RA. Self-monitoring of
blood glucose in type-2 diabetes: what is the
evidence? Diabetes Metab Res Rev. 2007 Sep;23
(6):423-40.
Welschen LM, Bloemendal E, Nijpels G, Dekker JM,
HeineR). Stalman WA, Souter LM. Self-monitoring of
blood glucose in patients with type 2 diabetes who
are not using insulin: a systematic review. Diabetes
Care. 2005 jun;28(6):1510-7.
)DRF CGM Study Group. )DRF randomized clinical
trial to assess the efficacy of real-time continuous
glucose monitoring in the management of type 1
diabetes: research design and methods. Diabetes
Techno! Ther. 2008 Aug;10(4) :3 10-21.
Peel E, Douglas M, Lawton). Self monitoring of blood
glucose in type 2 diabetes: longitudinal qualitative
study of patients' perspectives. BMJ. 2007 Sep 8;335
(7618):493. Epub 2007 Aug 30.
No authors listed. Self-monitoring of blood glucose
in diabetes. Drug Ther Bull. 2007 Sep;45(9):65-9.
Saudek CD, Kalyani RR, Derr RL. Assessment of
glycemia in diabetes mellitus: hemoglobin Ale. J
Assoc Physicians India. 2005 Apr;53 :299-305.
McAndrew L, Schneider SH, Burns E, Leventhal H.
Does patient blood glucose monitoring improve
diabetes control? A systematic review of the literature. Diabetes Educ. 2007 Nov-Dec;33(6) :991-1011;
discussion 1012-3.

2010

15

"Voice and very forme becometh womanish": Contemporary medical views of the

Castrati
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During the 17th and 18'h centuries, surgeons and parents
attempted a bizarre endocrinologica l experiment: the
castration of prepubescent boys for the preservation of
their treble voices. The Baroque passion for highly ornamented, technically difficult, soprano-range music, combined with social restrictions to the training and performance of fema le singers, created unique opportunities for the
castrati, or as they were more euphemistically call ed, the
musici.1 Church choirs offered a reliable income and noble
patrons promised prestige and influenceY At the same
time, Italian opera seria was becoming an internationally
popular entertainment, opening up fantastic possibilities of
wealth and renown for its castrati stars. 1 Accordingly,
ambitious families with slender means and abundant
offspring chose to castrate younger sons with promising
voices - openly through the 17'h century, and with increasing shame and secrecy into the 19'h century. 3
From the perspective of modern endocrinology, the
effects of removing both testes before puberty are significant. Without testes, a castrato would not pass through
puberty, resulting in a prepubescent penis, sexual dysfunction, and sterility. More systemically, he would have no
male-pattern body or facial hair and a "eunuchoid" body
habitus (long limbs relative to torso, as the long bone
epiphyses would not fuse) . A lifetime of low testosterone
would bring dry skin (arising from low sebaceous gland oil
secretion), fine wrinkles, osteoporosis, a higher than
average fat to muscle ratio, decreased libido, and possibly
an increased risk of depression. The larynx would remain
small, with short vocal chords, while the pharynx and lungs.
dependent on growth hormone, rather than testosterone,
for development, would reach adult proportions. resulting
in a high frequency voice with adult power and resonance.4
Such is the lens 21" century medicine might use to view the
castrati.
Yet this radical redesign of human male development occurred four centuries before the discovery of
testosterone. What were contemporary medical perceptions of the castrati? What explanations did physicians offer
for the effects of castration? In short, what did they see, and
how did they make sense of it?

Technique
Although medicine at this time brought new attention to the
study of anatomy, its practitioners still operated without
reliable anaesthesia or sterile technique. Furthermore,
castration was a somewhat clandestine medical procedure;
it contravened Roman law in Italy, where the majority of
castrati were made, and amputation of any part except
when medically required was punishabl e with excommuni-

cation under ecclesiasticallaw. 5 Early in the Baroque period
church and state turned a blind eye to castration for musical
purposes, but over time it became necessary to invent
medical excuses for the operation. 1 Italian medical texts
tended to avoid the subject, 6 and existing contemporary
accounts of the procedure come mainly from hostile
sources.
An influential 7 Dutch physician and anatomist,
Reginer de Graaf (1641-1673), provides a critical description of castration. He gives two techniques: compression of
the spermatic cords with a split stick until they were
crushed, and complete removal of the testes "by the roots."
He notes with disapproval that "ce rtain men earned a rich
living" offering castration as a cure for hernias, but observes
that "this cruel and dangerous way of curing hernias has
gone so much out of fashion ... that you will hardly find
anyone who earns even a crust of bread by castrating men.'' 8
In Italy, however, hernias were offered as an excuse for
castrating young singers for centuries after de Graafs text
was published.3
"Eunuchism Display'd", an anonymous English
pamphlet circulated in the early 18th century, adds further
details to de Graafs account. In addition to noting two
techniques sim ilar to those above, the author describes
attempts at anaesthesia: administration of opium, which the
author reports to have a high mortality, and compression of
what the text terms "the jugular veins," perhaps meaning
the carotid arteries, to render the patient "stupid and
insensible." 9 Both authors are at pains to express their
disapproval of castration; their emphasis upon the suffering
and danger of the procedure may partly arise from their
underlying moral objections, as circumstantial evidence
suggests the operation may have been relatively safe and
mild .1

Effect
Although accounts of castration itself are scarce, medical
writers often devoted space to describing its effects.
Predictably, many noted an effect on voice; the British
surgeon john Marten ( d.1737) claimed castration was
"[e]xperimentally known to change and advance the
smallness and sweetness of the Voice."10 Other writers
described the castrato voice in less fl attering terms, for
example, "squealing" in "Eunuchism Display'd," and "soft
and shirle" in a mid-17th century translation of the "workes"
of the French surgeon Ambroise Pare (1510-1590) .11
Medical writers a lso noted a lack of beards among
castrati, and there was general consensus about their
inferti lity. The sexuality and sexual function of castrated
men, however, was a much more controversial topic. For
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example, one contemporary British physician impli es
castration removes both ability and desire for sex, 12 while
another claims quite the opposite:
Eunuchs love Women passionately, and being of a
weaker Mind after than before Gelding, are the more
susceptible of thi s Passion ... It cannot be expres'd to
what Point they will push their irregular Desires
when their Fancy is once inflam'd ... 10
This confusion mirrors castrati's reputation in
popular culture, which both mocked them as impotent 13 and
credited them with a myriad of lovers of both genders.3
As implied in the above quotation, contemporary
physicians considered castration to profoundly shape mind
and behaviour, as well as body. A castrato, according to
john Marten, has diminished "Strength, Activity, and Vigour
of his body, and acuteness of his Reason and judgement. " 10
The author of "Eunuchism Display'd" further claims that
castrati have "no Courage or Bravery of Soul, but [are] ever
timerous and fearful," 9 and contemporary medical authors
tend to agree.10•12 •14 The Dutch physician Ysbrand van
Diemerbroek (1609-1674) succinctly summarizes the
general view by concluding that castration makes one
"slower in all the Exercises both of Body and Mind."14
Different authors emphasise different attributes of
castrati, but a general outline of 17'h and 18'h century
medical descriptions would include a high voice, beardlessness, infertility, altered sexuality, physical and mental
weakness, and cowardice.
Explanations
Medical rationales for this collection of castrati traits are
complicated by the somewhat chaotic state of European
medicine during the 17'h and 18th centuries. The classical
tradition, centred around the works of Galen of Pergamum
(129-199 CE), had guided academic medicine through the
Middle Ages, but new ideas from anatomy, alchemy, and
various branches of natural philosophy were beginning to
change medical writers' understanding of the body.15
The central problem was how castration could have
such profound effects in apparently unrelated parts of the
body. According to Galen, the testes help to convert blood
into semen - the source of fertility and of sexual desire, in
Galenic physiology - and aid the heart in producing the
body's strength and ':innate heat." Castrated men therefore
are not only sterile, but also "chilled ... and all their strength
collapses." Their cool, weak bodies are not able to produce
a deep voice, beard, or body hair, which spring from heat
and strength. 16
In Galenic physiology, gender difference arises from
differences in bodies' heatjcold, and to a lesser extent,
dryness/moisture ratios : "The female is less perfect than
17
the male for one, princpal reason - because she is colder."
Castration removes a man's heat advantage, bringing him
down the spectrum of gender towards "imperfect" women:
"the whole body is made feminine by excision of the

testicles." 16 Yet the castrated man does not become a
woman; he is "not female or male but some third kind ." 17
The ideas of loss of heat and a shift towards a
feminine body inform the work of many 17'h and 18'h
century medical authors. The British physician john Bulwer
(1606-1656) directly cites Galen's explan ations, especially
for the high voice of castrati. He also alludes to a "certain
aire" - perhaps similar to Galen's "strength" or "power" given off by the testes, "by whose mediation virility is
reconciled, the body acquires stre ngth and firmenesse, is
made more lively; at length, the principall members do
more perfectly execute their office." Loss of the testes is
therefore a loss of "well-being." 12
It also makes the castrato more like a woman, which
is by no means a value-neutral transformation. Bulwer
contends that to castrate a man for any reason except an
"otherwise incurable disease" is unconscionable: "willingly
to degenerate into the Nature of women, suffering themselves to be transformed from the Masculine to the Feminine appearance (a false Copy) is to offer as great an Injury
to Nature as the malice of mans refractory wit can be guilty
of." 12 Ambroise Pare, too, cites Galen's views on the subject,
and elaborates upon the significance of degenerating "into a
womanish nature": "for they remaine without beards, their
voice is weake, their courage failes them, and they turne
cowards; and seeing they are unfit for all humane actions,
their life cannot but be miserable." 11 Loss of heat brings not
only female physical characteristics, but also moral ("they
turne cowards") and social ("unfit for all humane actions")
dimensions of 17'h and 18'h century femininity. 18
john Martin also relies on Galen's ideas about the
testes producing heat, but diverges from Galen and Bulwer
about the effect of castration on sexuality. Since he considered semen to be the source of sexual desire, Galen held that
castrated men would be essentially asexual. Martin explains
his claims about the "irregular Desires" of the castrati by
suggesting organs newly described by anatomists could be
additional sources of semen: "the kind of aqueous Seed in
the prostata or seminal bladders irritates their Privities."
This "aqueous Seed," combined with castrati's "weaker" that is, more female - mind, makes them more susceptible
to desire. 10 A belief that emasculation could undermine
sexual restraint is in keeping with contemporary ideas
about female sexuality in medical writing and in popular
imagination.18
For example, Shakespeare's King Lear
describes his unfilial daughters as sexually voracious,
despite an outward show of chastity:
Behold yond simpering dame ...
That minces virtue, and does shake the head
To hear of pleasure's name;
The fitchew, nor the soiled horse, goes to 't
With a more riotous appetite.
Down from the waist they are Centaurs,
Though women all above. (IV, ii, 132-9) 19
Like the castrati, women have weak minds and
ineffectual "seed" (ovaries were commonly - although not
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ineffectual "seed" (ovaries were commonly - although not
universally- viewed as imperfect testes). 18
Diemerbroek is not content to use heat alone as his
explanation for the consequences of castration. He employs
more complicated reasoning partly drawn from the alchemy-inspired physiology of the radical medical theorist
Paracelsus (1493-1541) .15 According to Diemerbroek, the
testes exude a "lustful seminal Breathing," which travels
through the body, heating the blood and making the
"Spirits" (active principles conveyed by nerves from the
brain) more "smart and vigorous." Without this breathing,
the blood grows cold, and the "sulphury and oily Particles of
the Blood" cannot be separated from the "more dry and
salter Particles," resulting in more languid Spirits. Furthermore, the blood that would normally have been consumed
in producing semen builds up, with the "effeminate" result
of"extraordi nary Corpulency" and a "more dull" mind.14
The British physician Thomas Willis (1621-1675)
combines Paracelsian alchemy with ideas about fermentation from contemporary natural philosophy to explain the
castrati. The principles of salt, sulphur, and spirits are
concentrated and fermented by the testes, as grapes are
fermented to make wine; and from this "Seminal Ferment"
arises "abundance of heat, great strength, a sounding Voice,
and a manly eruption of Beard and Hair." As a result of
castration, "men grow womanish," being cold, weak, high voiced, and without a beard.
As an anatomist, de Graaf focuses on the anatomical
basis for the way the testes affect the rest of the body. He
suggests the newly-discovered lymph vessels "draw from
the testicles, along with the thinner and more watery part of
semen, other more noble parts and give a share of these to
the heart and other parts of the body." Without these
"nobler parts" of semen, a castrated male "changes in such a
way as almost to acquire the physical condition of a female.''8
Although these exp lanations for the effects of
castration diverge in the details, a few common elements
emerge. They all postulate some mechanism for action at a
distance - vital heat seminal breathing, seminal ferment,
noble parts of semen - in order to explain what the authors
see as castration's dramatic changes to the body and mind.
They also tend to portray these changes as a shift from a
male state of being toward s (but not to) a femal e one.

voice of a castrato was worth "cut[ting] out the strength of
the entire body."16
Quite apart from the philosophical implications,
making a son more like a daughter had significant social and
economic consequences. Castrati were technically forbidden to enter the priesthood (although exceptions were
made) , and professions outside music which did not admit
1
women were not welcoming of "womanish" men. Since
their transformation into women was incomplete, they
could not claim a female social role, such as marriage or
joining a convent. 1 Consequentially, castrati had a profound
incentive to succeed as singers; an application from a young
castrati to a famous conservatorio in Naples makes this
point clear: "since he is a eunuch, music ... is the only
1
profession to which he wishes to apply himself." This
desperation, combined with the extremely rigorous early
training it motivated, may have contributed as much as
physiology to the voices contemporary audiences considered incomparable.
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Introduction
Diabetes has become a global epidemic and rates continue
to increase. Over 3 million Canadians have diabetes and
approximately 90% of them have type 2 diabetes. Diabetes
can lead to a reduced life expectancy and quality of life, and
an increased risk of cardiovascular disease, kidney disease,
blindness, and amputation. In addition to these personal
health costs, diabetes may cost the Canadian healthcare
system $16.9 billion per year by 2020.1
The epidemic of type 2 diabetes is closely associated
with a rise in obesity, poor diet quality, and physical
inactivity. The failure of individual-level interventions such
as medications and dietary counselling to forestall the
epidemic has led to a strong interest in population-level
approaches.2 There is growing recognition that aspects of
the physical and social environment can have a powerful
influence on health and health-related behaviours, at the
individual, neighbourhood, and population levels. This
article will explore the emerging interdisciplinary study of
health with respect to the built environment and will
discuss some of the important contributions of this field to
understanding and addressing the diabetes epidemic.
What is the study of the built environment?
An interdisciplinary programme of study has emerged in the
literature that examines the influence of the built environment on health outcomes. The built environment describes
the physical layout of communities and encompasses landuse patterns, homes, schools, workplaces, stores, parks,
roads, and transportation systems.3 Studies of the built
environment acknowledge that aspects of our physical
surroundings can shape choices about diet and physical
activity - both important contributors to the development
of diabetes.
Research in this field involves many diverse disciplines, including public health, epidemiology, nutrition,
urban planning, geography, economics, sociology, anthropology, and leisure studies. Each of these disciplines has its
own approach, expertise, and methodology when it comes
to examining the relationship between health and the built
environment. This article focuses particularly on the
contributions of urban planning and geography. Study
methodology genera lly falls into three categories: 1)
interviews or questionnaires on residents' perceptions of
their environments; 2) systematic observations of area
characteristics (i.e. number and type of restaurants in a
given neighbourhood); and 3) analysis of existing data sets,
often using Geographic Information System (GIS) .4 GIS
allows the integration, presentation, and analysis of data

with spatial references, for example overlaying a database
of supermarkets with a map of census boundaries. These
disciplines and methodologies can reveal unique information about the diabetes epidemic and provide potential
targets for intervention.
What can studies of the built environment tell us about
patterns of diabetes?
One of the key associations between diabetes and the built
environment is through food choices and diet. Studies have
looked at how the food environment, which includes
supermarkets, food stands, convenience stores, and restaurants, can differ by neighbourhood and how this relates to
various health outcomes. One study of food store availabil ity
and neighbourhood racial composition found that none of
the predominantly African-American census blocks examined in East Harlem had supermarkets or grocery stores. 5
Another study found that fast-food restaurants were more
likely to be found in lower income and higher traffic areas in
King County, WA. 6 Neighbourhood fast-food exposure has
been associated with poorer diet quality and increased body
mass index (BMI) , particularly for local residents who do
not own cars.7 ·8 According to a 2009 review article, residents with more access to supermarkets and limited access
to convenience stores and fast-food generally have better
diets and lower obesity rates. 9 Moreover, those most
affected by disparities in access to healthy food tend to live
in low-income, minority, and rura l neighbourhoods.9 These
studies suggest that food choices and diet are influenced by
multiple aspects of the built environment, including number
and type of food stores, and that differences in neighbourhood access to healthy foods often reflect other demographic features (i.e. race, socioeconomic status).
The built environment has also been studied in
relation to physical inactivity, another important contributor to obesity and the development of diabetes. Aspects of
the built environment related to physical activity include
access to recreation facilities, neighbourhood safety, open
spaces, walking and cycling infrastructure, and length and
nature of commute. 4 Researchers in California estab lished
an association between obesity, physical inactivity, and
commute time, as well as between obesity and vehicle miles
10
of travel. One study found that greater neighbourhood
physical activity resources were associated with lower
insulin resistance, even after adjusting for age, sex, race/
ethnicity, family history of diabetes, education, and income.11 The same study found that insulin resistance was
a lso inversely related to neighbourhood healthy food
resources, a lthough this association was less robust. 11
Furthermore, a longitudinal study found that better
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neighbourhood resources, based on a composite score for
healthy foods and physical activity, were associated with a
38% lower incidence of type 2 diabetes.2 Thus, certain
features of contemporary North Am erican urban design,
such as a strong dependence on motorized trans port and
neighbourhood features that exclude opportunities to stay
active, may be fuelling the diabetes e pidemic.
A highly comprehensive s tudy of di a betes and
neighbourhood environments was co nducted in Toronto
and released in 2007. 12 It received attention in the popular
press, reflecting the nation's growing recognition for
interdisciplinary solutionsY The researchers examined 140
Toronto neighbourhoods, and assessed the relationship
between diabetes and factors such as socioeconomic status,
ethnic composition, crime rates, car ownership, public
transportation, access to healthy food , opportunities for
physical activity, and access to health care and other
services. Neighbourhoods with high rates of diabetes tended
to have a higher proportion of visible minorities, immigrants, and low socioeconomic status residents. 14 Features
of the built environment, however, played a significant role
in mediating these effects. For example, poor, immigrant
neighbourhoods had lower rates of diabetes than expected
if they were found to be activity-friend ly with good infrastructure, whereas more affluent neighbourhoods tended to
have low rates of diabetes regardless of whether they were
activity-friendly or ha d good access to healthy foods .15· 16
Neighbourhoods with the highest rates of diabetes were in
the more suburbanized northwest and east parts of the city,
where there were not only high levels of poverty and visible
minority residents, but also worse public transit, few
opportunities for physical activity, poor access to healthy
food, and low concentration of family physicians and
diabetes education programmesY The complex relationship
between diabetes, socioeconomic status, and neighbourhood resources was also s hown in a Scottish study in the
year 2007. Deprived areas were found to have lower than
expected rates of type 2 diabetes when they were surrounded by less deprived areas with better resources.18

be mad e more activity-friendly by improving si dewalks and
bicycl e paths, building recreation spaces, and instituting
mixed land-use patterns in more suburban areas to provide
better wa lkin g des tinations. Diets may be improved by
providing incentives for grocery s tores to move into hi ghneed areas, improving publi c tra nsit so at-risk peo ple can
access healthy food, and developing poli cies that promote
healthier choices at fas t-food res ta urants. 17 The Ontario
Profess iona l Planners Institute has recognized the important relations hip between community design and publi c
health .20 However, making these kinds of changes would
require co llaboration between a diversity of stakeholders a t
all level s, including city planners, public health researchers,
policymakers, community organizations, and grassroots
initiatives.

What are the implications of built environment research on controlling the diabetes epidemic?

3.

Conclusion
The interdisciplinary s tudy of health and the built e nvi ronment is an impo rtant and growing field that can offer a
unique contribution to chronic disease research. The built
environment affects hea lth at the individual, neighbourhood, and population level and can account for many of the
spatial and demographic patterns in diabetes prevalence.
Looking at diabetes rates from the perspective of the built
environment can enhance our understanding of the emergent epidemic and can identify new targets for disease
control and prevention.
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Introduction
Drug doping has a long history in sports. As the medical
world introduced new pharmaceutical agents to restore
muscle mass or improve blood oxygenation, the sports
world in turn has sought to use these agents for similar
gains. The progress in sports doping has catalyzed a parallel
effort to detect doping abuse, with research labs explo iting
new and improving old analytical technologies. The result is
an endless race where each side tries to stay one step ahead.
The next showdown will be at the 2010 Olympics in
Vancouver, which will feature the most elaborate antidoping program in the history of the Games. A new $8.9million anti-doping lab will test abo ut 2,400 urine and blood
samples-- twice as many as the previous winter Olympics in
Torino.1 While the lab wi ll be testing traditional doping
agents like testosterone, it is also equipped to deal with two
doping agents that have recently plagued the sports world:
analogues of erythropoietin (EPO) and human growth
hormone (hGH). This article will outline the current
methods to detect EPO and hGH doping, and discuss the
future of the sports doping race.
Erythropoietin
Erythropoietin is a glycoprotein hormone primarily
produced in the kidneys that stimulates red blood cell
production. Recombinant huma n erythropoietin (rHuEPO)
has been available since the 1990's for clinical use in
patients with anem ia; however, its therapeutic benefits have
also extended to the sports world. rHuEPO can bolster an
athlete's red blood cell count and greatly improve his or her
aerobic capacity. 2 It has additional appeal as a doping agent
because it is difficult to distinguish from naturally occurring
EPO, and its therapeutic benefit lasts well after the original
hormone clears from the body.
While rHuEPO was swiftly banned by the World
Anti-Doping Association (WADA) in the 1990's, no method
of detection was approved until a few months before the
2000 Sydney Olympics. A French anti-doping lab developed
the method based on isoelectric focusing and a novel double
immunob lotting technique.3 Some forms of rHuEPO have
different patterns of glycosylation than endoge nous EPO,
resulting in different sets of isoelectric points (the pH at
which a molecule has neutral charge). When placed in a gel
with a pH gradient and an electric fie ld, they will focus into
bands where the pH is equivalent to their isoelectric point.
These bands can later be marked by immunoblotting with
monoclonal anti-Epo antibodies. The gel is blotted a second
time under acidic conditio ns, which transfers only the antiEpo antibodies to the second gel for subseq uent visualization.
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This direct method of detecting rHuEPO abuse has
several shortfalls. For one, epoetin-omega and epoetindelta, two available forms of rHuEPO, cannot be distinguished from endogenous EPO. Secondly, the detection
window is roughly 7 days before circu lating rHuEPO levels
become too low. 4 To overcome these limitations an alternative strategy has been proposed that looks at secon dary
blood markers ofrHuEPO abuse.
The first attempts at detecting rHuEPO abuse in
sports relied on simple tests such as measuring the hematocrit or hemoglobin. By 1993, sophisticated hematological
analyzers came to market that allowed labs to make
comprehens ive measurements of secondary blood markers
such as hemoglobin, percent reticu locytes, seru m so luble
transferrin receptors, EPO concentrations a nd percentage
hypochromic red cells. 5 The lack of sensitivity and specificity
of these individual markers for detecting rHuEPO abuse led
to the development of multiparametric models, which
examine changes in groups of markers. Some models have
been shown to detect EPO abuse after 14 days ofwashout. 6
Indi rect testing of rHuEPO abuse has not been
favoured over direct testing. A positive result is not evidence that an ath lete has taken the banned substance, since
variability in blood marker profiles has been seen naturally
and in athletes who train at high altitude. At the moment
indirect testing has been relegated to serve as a screening
tool for rHuEPO abuse.
Human growth hormone
Human growth hormone (hGH) is produced naturally by the
pituitary gland to stimulate growth in the human body.
Patients with hGH deficiency were originally treated using
hGH obtained from cadavers, but now are treated with
recombinant hGH (rhGH). Starting in the 1980s, athletes
have been using rhGH to in crease lean muscle mass, reduce
fat content and increase strength. However, the International Olympic Committee (IOC) placed hGH on its list of
forbidden substances in 1989. Similar to erythropoietin,
rhGH abuse is difficult to detect because of its similarity in
structure to hGH . Furthermore, detection tests cannot rely
on hGH levels since hGH secretion is pulsatile and a plethora
of factors, suc h as exercise, stress, hypoglycemia and
increased temperature, can naturally increase levels.
Detecting rhGH abuse is considered the current greatest
challenge to the anti-doping community.7
Recent research and advances in technology have
all owed for some success in detecting hGH misuse as of the
2004 Olympic Games in Athens, Greece. Since hGH is a
peptide with a very short half-life and less than 0.1% is
excreted into urine, the most effective doping tests have
been restricted to blood samples. Urine samples can be used
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to detect hGH using highly sensitive immunoassays.
However, the problem of confounding factors causing
variability in hGH levels can only be accounted for by
performing o ut-of-competition tests to allow for comparison.
Blood tests have proven more effective and powerful
and two methods are currently being eva luated. The first is
a direct method for detecting rhGH in serum. This approach
uses the fact that injected rhGH is exclusively a 22 kDa
isoform, a pure molecular substance, while natively circulating hGH is present as a mixture of many forms. The test
looks for an increase in the ratio of the 22 kDa isoform of
hGH to the total hGH in the blood beyond a pre-determined
threshold.8 For it to be effective, the test must be administered 24-36 hours after hGH injection . The second method
tests for an increase in marker proteins influenced by hGH
levels. These marker protein s have longer half-lives than
hGH, making them much easier to detect.
A sure-fire method for detection and control of hGH
doping remains elusive. The direct approach is the one
currently accepted by WADA. However, promising research
may yield a test using the marker-based approac h in the
near future. Genomic and proteomic profiling are currently
being researched to discover new markers of rhGH abuse.
One pilot study looked at the ge ne expression in leucocytes,
which are altered directly by both GH and IGF-1. The hope is
to characterize a gene fingerprint for rhGH abuse. Proteomic
methods are being applied in a sim ilar manner to create
protein profiles using two dimensional electrophoresis and
surface-enhanced laser desorption/ionization time of flight
mass spectrometry (SELDI-TOF MS). 9 · 10
The race continues - next generation sports doping
New methods of doping are on the horizon and anti-doping
labs will need to respond . Two new classes of experimenta l
drugs, selective androgen receptor modulators (SARMs) and
myostatin inhibitors, have been shown in clinical trials to
boost lean muscle m ss without the side effects seen in
testosterone or steroid use. While neither drug is on the
market yet, the substances have already been banned by
WADA and work is underway to detect their abuse. 11
A new frontier of sports doping is approaching with
progress made in gene therapy technology. The idea is to
introduce exogenous ge nes into an ath lete's cell s to produce
virtually any protein or hormone in vivo. Current gene
therapy trials are purely experim enta l and hum an use is still
a long time away; however, the potential of this technology
has a lready been demons trated and has drawn much
attention . Gene doping presents the ultimate doping
detection chall enge since the newly expressed protein is
identical to the endogenous protein in terms of structure
and mechanism of synthesis.12 To date, no definitive method
of detection is ava ilable, a lthough work is being done using
DNA microarrays and gene express ion profiling.
At the moment the doping community has an edge
over anti-doping efforts despite the immense progress
made over the last decade in detection technology. In some

regards thi s result is a testament to the wide. range of
pharmaceutical products developed to combat d1sease. As
the medical community tirelessly works to advance therapeutics, the doping race will still carry on.
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On August 19, 2009, South African middle distance runner
Caster Semenya set a world record in the women's 800m
event at the world championships in Berlin. Closely following her stunning victory, the world athletics governing body,
the International Association of Athletics Federation (IAAF)
ordered her to undergo a process known as "gender
verification testing." A relative unknown just three weeks
prior, Caster was unceremoniously thrust onto the world
stage and has become a poster victim for a controversia l
practice that has been going on for decades .U Subsequently,
Australian newspapers announced that Caster had no
ovaries or uterus, but did have undescended testes, and was
in fact "intersex."2•3 In order to explore the potential social
and legal implications of such testing it is important to
understand the history of so-called gender verification, as
well as its medical advantages and pitfalls.

Science and medicine
The term "gender verification" is problematic because, as
was detailed out in an open letter to South African journalist
Mercedes Sayagues, gender is "the dominant society's views
on how women and men should look, behave, what roles
they should play in society, how they should perform ... "4·5
Sex refers to a biological dichotomy, whether one is male or
female. 5 Normal sexual differentiation is initially determined by chromosomal pattern, XX usually being female
and XY usually being male. The presence of the SRY gene on
the Y chromosome induces the undifferentiated go nad to
commit to testis generation. The differentiated testis then
begins to secrete hormones that lead to the promotion of
the male internal genitalia, and the regression of the
primitive female internal genitalia. Subsequent conversion
of testosterone to dihydrotestosterone (DHT) in the skin of
the external genitalia leads to virilization of these structures
and a complete male phenotype. The absence of the SRY
gene leads to the regression of the male internal genitalia
and a female phenotype.6 Of course, sexual differentiation is
a complex process, and disorders of sexual differentiation
(DSDs) may be chromosomal, gonadal or phenotypic
(hormonal), leading one or more of these elements to be
misaligned. 6 ·7
In 1968, in an effort to prevent male imposters from
competing in the Olympics the IOC implemented mandatory
"gender verification" of all female competitors.6 ·7·8 The test
was a simple buccal smear that was then analyzed for the
presence of sex chromatin (inactive X chromosomes or Barr
bodies). The Barr-body test, though enticing in its simplicity
raised significant concerns in the medical community. The

test screened out XY females with no advantage over other
females as is the case with complete androgen insensitivity
(CAIS) or 46 XY jXO gonadal dysgenesis, whi le allowing
those athletes with potentially advantageous conditions
such as XX females with inadequately treated congenital
adrenal hyperplasia (CAH) or XXY males to compete.5·6 ·7·8
Furthermore, the test was inappropriate in the first place
since women with DSDs do not exhibit "characteristics
relevant to sports performance ...outside the range of
possibility for XX females ." 6 ·7

History
Given what we now know to be true of DSDs, it may seem
preposterous that the practice of sex verification was
routine at the Olympics for more than 30 years. However,
instances of subversion are not unheard of. In 1957 Herman
Ratjen of Germany confessed he had been forced under the
Nazi regime to compete as a female in the 1936 Berlin
Olympics.6·8 Suspicion subsequently turned on hypermasculine female ath letes from the Eastern Bloc following a
number of female athletes undergoing gender reassignment
surgery and subsequently living as men in the 1950s and
60s. Finally, in possibly the most high profile example, the
1932 women's lOOm sprint gold medalist Stella Walsh was
revealed to have chromosomal mosaicism and ambiguous
genitalia during an autopsy following her death in 1980.7·9
Initial attempts at gender verification in 1966 and
'67 involved parading female athletes in front of a panel of
medical experts in the nude, or even direct gynecological
examination. 6•7·8·9 This method of sex verification was
fraught with ethical dilemmas and was ultimately abandoned in favor of the simpler and "less demeaning" buccal
smear in 1968. The Barr-body test, originally conceived as a
screening tool, became the definitive test of an athlete's
femininity was used by the IAAF and IOC until 1992 when
the IAAF abandoned the practice.6·8·9 Rather than follow the
IAAF's example, the IOC switched from chromatin testing to
analysis for Y chromosome material using PCR amplification, which it continued unabashedly until 2000. It is worth
noting that since the advent of laboratory sex testing, no
male imposter has ever been caught trying to infiltrate
women's athletic events.6·9•10

Social and legal implications of sex testing
Dr. Renee Richards, a nationally ranked men's tennis player,
underwent a sex reassignment operation in 1975. In 1976
she attempted to enter the United States Tennis Open as a
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woman. The United States Tennis Association (USTA)
informed Dr. Richards that in order to enter, she had to pass
a gender verifi cation test; the first time such a test had been
implemented by the USTA. Dr. Richards a rgued to the New
York Superior Court successfu lly that the test was adopted
for the sole purpose of preventing her from competing in
the Open, and that moreover, the medical community
regarded the test as "insufficient.. .and grossly unfair". 10
Although this is the on ly case that rules on the issue of
gender verification in sports as a matter of law, in 1985
Spanish national hurdler champion Maria Patino was
disqualified from the World University Games and banned
from international competition. Subseq uently she went on
to become the first woman to publicly protest this method
of disqualification, and was eventua lly reinstated. 6·8
Given the IAAF and IO Cs deplorable record of
defending the rights of female athletes it should come as no
surprise that as recently as 2006 an Ind ian woman, Santhi
Soundarajin, was stripped of her silver medal at the Asian
Games after failing a gender test. Ms. Soundarajin was later
diagnosed with complete androgen insensitivity syndrome
and was so psychologically traumatized by the experience
that she has not competed since. 11· 12 •13 Further confusing the
matter is the fact that in the same year the IAAF released a
policy on gender verification listing women with CAIS
(among other conditions) as eligi ble to participate in
international competition.13 In fact, the IAAF listed women
with virtually all DSDs as eligib le to compete, even those
with conditions that theoretically might accord some
physical advantages (i.e. CAH, androge n producing tumours,
and PCOS) .14 In light of this, the IAAF's policy statement then
begs the question : What is the validity or necessity of
gender verification in the first place, and why does the IAAF
persist in using it?
Strict a nti -doping rules guarantee that all winners
and a random se lection of other competitors provide urine
samples under the supervision of officials. These rules likely
provide enough dis-incentive for men to masquerade as
women that such an issue is very unlikely to arise at
ali. 5·6·7 Granted, the current guide lin es for gender verification
are substantially different than they were in 1968. They
include stipulations that there be no compu lsory standard
gender verification, that determination of sex not be done
solely on laboratory based testing, and a medical evaluation
be performed by a gynecologist, endocrino logist, psychologist and an internist. 14 What is unclear upon reading the
IAAFs policy on gender verification are the circumstances
under which a challenge of a competitors gender may be
legitimately raised. Article 12 of The United Nations
Universal Declaration of Hum an Rights (UNUDHR) guarantees a person against "arbitrary interference w ith his
privacy ... and attacks upon his honor and reputation ."15 Since
the criteria for a legitimate chal lenge to a competitor's
gender are not outlin ed in the IAAFs policy, it can be said
that gender verification testing represents an arbitrary
interference with an ath letes' privacy. In 1996 the Norwegian parliament passed a law making genetic testing for the
purposes of gender verification in sport illegal in Norway.7

Furthermore, as argued by Pamela Fastiff, gender testing (as
it was originally conceived and undertaken between 19681992 or 2000 in the case of the IOC) likely violates the
fourth ame ndm ent of th e American Constitution, as we ll as
10
female ath letes' rights to equal protection under the law.
The fourth ame ndment guarantees "the right of the people
to be secure in their persons ... against unreasonable search
and seizures".10 The ruling in the Renee Richards case
upheld as a matter of law that the USTA could only use the
gender test as a means to prevent fraud, and not to disqualify women with DSDs or transsexuals. 9 Given this ruling and
the arbitrary way in which gender verification testing
continues to be applied, there are no valid circumstances
under which a female ath lete s hould have to fear disqualification on the grou nds of failing a gender test.
Since no man has ever been caught masquerading as
a female, it would appear that gender testing in any format
is neither achieving its ostensible goal, nor serving athletes'
best interests. Singling out young women with rare disorders and publicly humiliating them not only causes lasting
psychological damage, but demonstrates the stunning
insensitivity of the IAA F and IOC. From thi s analysis, it is
clear that the only valid reason for co nducting gender
verification of any kind would be to ensure that young
women like Caster receive the medical atte ntion a nd
psychological support they need, rather than to expose
them to public scrutiny and scandal.
References

1.

2.

3.

4.

5.

6.

Genel M. Gender Verification No More? MedGenMed.
2000; 2(3). Available: http:/ fwww. medscape.com/
viewarticle/408918. (Accessed Nov 14 2009)
Wente M. Caster Semenya, the poster victim. The
Globe and Mail. 2009 Sep 23. Available: http :/ 1
www.theglobeandmail.comfnewsjopinionsfcastersemenya-the-poster-victi m1article 1299103.
(Accessed Nov 14 2009)
Chase C. Semenya withdraws from race amidst
gender questions. Yahoo! Sports. 2009 Sep 11.
Available:
http:/ fsports.ya hoo. comfolympics/
vancouver /blogjfou rth_place_medal /post?
urn=oly,188930. (Accessed Nov 14 2009)
Cooper D, London L, Eland N, et a l. Runner Caster
Semenya: ge nder, sex and di scrim ination. 2009 Aug
26. In : Gender Masala [blog] . Avai lable: http:/ 1
www.ips.orgfblog/ mdg3 I 2 0 09/08 I runner-CasterSemenya-gender-sex-and%20-discrimination.
(Accessed Nov 14 2009)
Pilgrim ). Martin D, Binder W. Far from the finish
line : transsexualism and athletic competition.
Fordham Intell ectual Property Media & Entertainment Law journal. 2003;13:495-549.
Dickinson BD, Gene! M, Rabinowitz CB, et al. Gender
verification of female Olympic athletes. Med Sci
Sports Exerc. 200 2 Oct;34(10):1539-42; discussion
1543.

UWOMJ 179:1 I Spring 2010

26

Gender verification testing

7.

8.

9.
10.

11.

12.

13.

14.

15.

Tian Q, He F, Zhou Y, Ge Q. Gender verification in
athletes with disorders of sex development. Gynecol
Endocrino l. 2009 Feb;25(2): 117-21.
Elsas LJ, Ljungqvist A, Ferguson-Smith MA, et al.
Gender verification of female athletes. Genet Med .
2000 jul-Aug;2(4):249-54.
Ferris EA. Gender verification testing in sport. Br
Med Bull. 1992 jul;48(3):683-97.
Fastiff PB. Gender Verifi catio n Testing: Ba la ncing the
Rights of Female Athletes with a Scandal-Free
Olympic Games. Hastings Law Quarterly. 1992
Spring; 19(937):937-62.
Bhowmick N, Thottam, j. Gender and Ath letics:
India's Own Caster Semenya. Time. 2009 Sep 1.
Available:
http:/ jwww.time.comjtimejworld/
articlej0,8599,1919562,00.html. (Accessed Dec 1,
2009)
Siedlberg S. The Unreliability of Sex testing in
Athletics. Organisation Intersex International.
http:/ jwww.intersexualite.org/
Available:
unrelisexttestA THcp.pdf. (Accessed Dec 1, 2009)
Saner E. The gender trap. The Guardian. 2008 jul 30.
Available: http:/ jwww.guardian.co.uk/sport/2008/
jul/30/olympicgames2008.ge nder. (Accessed Dec 1,
2009)
International Association of Athletics Federations
Medical and Anti-Doping Comm issio n. IAAF policy
on gender verification. Monte Carlo: IAAF; 2006.
General Assembly of the United Nations. Universal
Declaration of Hum an Rights. 1948.

•

K\.'W'<tUn l

ltEAUUCME

ALLIANCE

Immediate Needs:
Family Practice, Psychiatry, Internal Medicine
GP/Anesthesia, GP/Obs, General Surgery
Paediatrics, Anesthesia

•
•
•
•
•

Location - Southwest Ontario
Clinton Public Hospital
Goderich Alexandra Marine & General Hospital
Seaforth Community Hospital
St. Marys Memorial Hospital
Stratford General Hospital

GWEN DEVEREAUX - Physician Recruitment Leader
Phone: 519.527.8403- Fax: 519.527.8414
Email: gwen.devereaux@hpha.ca

D~sc.o\leY w~ett t~e

Rural Ontario Medical Program
CCIII\-

olo foy

tjOU ...

9"Core a l'lo<i eLtct.ve
rot&~ti.ol'loS """ f!!""-.ll:J
""-tcl•c•IO\ot a"'GI select
spec•a lt•es
9"AcCO""-""-Oclat•o"'
al'lo<i travel ful'lo<i•"'-9
for cler~ &~l'lo<i
res.Gie"'ts
9"Facultl:J
t:levetop""e"'t

.. . New preceptors
weleo""-t!

&~lW&~!:jS

e;cper~IO\oCts

to

.,.._ec;l.c&~l

trll.IO\otts for
over twe"'tl:J
l:JeMS.

UWOMJ 179:1 I Spring 2010
27

Profile of Dr. Robert Hegele
Gordon Tsang (Meds 2012) and Joyce T. W. Cheung (Meds 2013)
Dr. Robert Hegele has been working in London, Ontario as a
clinician-scientist with the University of Western Ontario
(UWO) and the Robarts Research Institute since 1997. He
obtained his medical degree from the University of Toronto
in 1981, and went on to do a residency in Internal Medicine
and sub-specialization in Endocrinology and Metabolism. He
pursued further training in cardiovascular disease and
genetics by doing fellowships at Rockefeller University in
New York and the Howard Hughes Medical In stitute in Salt
Lake City, Utah. Dr. Hegele then returned to Canada,
beginning his career at St. Michael's hospital in Toronto
before finally settling in London, Ontario as a clinicianscientist at UWO. Dr. Hegele is the current Director of the
Blackburn Cardiovascular Genetics Lab and runs a tertiary
referral lipid clinic. Throughout his career, he has won
numerous awards for his genetics research, and has made
numerous discoveries.
Robert Hegele was born in Toronto to parents who
emigrated from Russia. He recalls having a wide range of
interests in his youth and demonstrated this by going on to
pursue an undergraduate degree in music. Though Dr.
Hegele did not have a ny early strong aspiratio ns towards
medicine, he cites his parents an influence in steering him
and his brother towards pursuing medicine (his brother, Dr.
Richard Hegele, is currently the Chair of the Department of
Laboratory Medicine and Pathobiology at the University of
Toronto). His mother was a medical student herself in
Europe, but her studies were unfortunately interrupted due
to World War II. Becoming a physician was also a logical
choice for Dr. Hegele, providing him the opportunity to earn
a comfortable living while giving him enough time for the
pursuit of activities outside of his medical career.
We asked Dr. Hegele if there were any mentors that
stood out during his time in medical school, and memorable
experiences that he cou ld recall.
"I still remember patients I saw in
first time I did a physical exam, a
tion of a depressed patient. What
were my personal relationships
also teachers and colleagues."

medical schoo l, the
psychiatric eva lualater propelled me
with patients, but

The presence of mentors guided Dr. Hegele's
interests in medical school, playing an important part in
influencing him to choose endocri nology as a specialty. He
also fell into a role of a researcher serend ipitously. Initi ally
desiring to teach, Dr. Hegele was told that in order to work
at an academic centre, he had to also participate in research.
"People such as Dr. Hollenberg (1970-81) and Dr.
Burrow (1981-88) were the Chairs of Medicine while
I was in schoo l. This tradition of endocrinologists as
departmental chairs goes back to the discovery of
insulin. So almost every chair of medicine in Toronto
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in the 20th century was an endocrinologist. Many of
my mentors at Toronto General Hospital were
endocrinologists, and they were the ones who
encouraged me to pursue endocrinology."
We asked Dr. Hegele how he was able to endure
through the many years of training to become an academic
physician.
"It's a balance and reward [system], so we've all
learned, but it's a different level [in doing research],
your reward system is spread over a much longer
time frame. Surgeons are the opposite, they need to
be gratified almost moment to moment, and that's
instantaneous. Somebody who is involved in research, you need to defer that gratification for years."
A typical week for Dr. Hegele involves teaching,
research and seeing patients in his clinic. Approximately
80% of his time is spent in research and 20% in the clinic
setting where he sees patients and teaches medical students
and post-graduate trainees rotating through the lipid clinic.
In the lab, Dr. Hegele and his team at the Blackburn Cardiovascular Genetics Lab work to understand the function of
genes that are changed by disease. Where he differs from
most physicians and researchers is that even though his
position requires that he spend more time writing grants
than filling in charts, he is never far away from his patients
and truly has a unique perspective on their disease.
"Every research project started with a patient.
Cardiology refers people with heart disease or severe
cholesterol disorder or diabetes. We can now read
the patient's whole genome profile using their spit or
blood on a microarray. It a llows me to try and find
the molecular basis of their disease. Instead of
indirectly deducing that a patient has inherited a
gene from their family history, we can now know
more definitively by screening their personal genetic
profiles. We first started to look at two to three genes,
now we're up to more than 30 genes for heart
disease. Many genes that had no known function
before recently; we try to learn what the gene
product does, hoping to work backwards and
eve ntually come up with a treatment.
"We see patients with lipid problems that are right off
the scale. Often the usual drugs in the typical
cardio logy or community practice don't work [for
these patients] . Studying their genetic profile to help
come up with some new treatment, that would be
[my goal]. Whether it's a drug or comp letely novel
treatment plan, my goal in the next 5 years is to come
up with something brand new for my patients with
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severe dyslipidemia."
Many researchers are often poached by other
universities, lured away by various reasons. Dr. Hegele is no
stranger to recruitment, but has fortunately chosen to
remain at UWO.
" .. .One thing I like about London is that I have almost
2000 patients, and have established a perso nal
relationship with each one. I wouldn't want to
suddenly leave and not have the chance to say
goodbye. I already did it once in Toronto, and it was
difficult. The second thing is that I have a great
balance and quality of life he re. It's very manageab le,
the medical school and stude nts a re great, colleagues
are great, my family is happy, I live close to work a nd
I have a really nice house ... we' re really enjoying living
in London."
The recent economic downturn has affe cted the
distribution of federal funding in many ways. We as ked Dr.
Hegele whether the recent downtown has affected hi s
research.
"My time [spent in research] has increased. It's
tougher to get research funding now, but I am a coapplicant on an NIH (National Health Institute) grant,
part of the Obama stimulus package to NIH . I'm lucky
to be a part of that. It's not quite the sa me in Canada.
In general, I personally haven't felt it as badly, but
research-like all aspects of the economy-has been
hurting a little more."

exercis ing and music. He also travels frequently to various
co nfere nces and meetings aro und the world, but sti ll takes
th e tim e to enjoy hi s expe ri ences. One memorable event he
recounted for us was an opportunity to see a footba ll match
in Ma nchester, England ea rli er this year.
Before leaving hi s lab, Dr. Hegele s howed us a piece
of med ica l memora bili a that he inherited from Dr. James 8.
Collip, a former dean of Medicine at UWO (1947-1961) an d
the famo us bi ochemi st who worked with th e Ba nting, Best
and Macleod research team to purify in su lin so that it cou ld
be used for testing in clini ca l trials. It was Dr. Collip's desk
from hi s years at UWO .
Thi s des k-where Dr. Collip worked-serves as a
so urce of inspiration for Dr. Hegele in his scie ntific research,
and a remind er of his ultimate goal of improving the quality
of life for his patients.
Does he have so me last words of advi ce for cu rre nt
medical stud ents?
"Work ha rd, and play hard. Don 't cut corners, but
when you're relaxing, fully enjoy relaxing as well. You
need to get exposure of a wide range of career
options from the beginning ... try to identify what you
really like to do beca use that's what matters over th e
long term."

We thought it would be interesting to get his
thoughts on what he would like to see happen in the future,
both in his career a nd in endocrinology.
"''d really like trying to do something directly
tangible (i.e. guidelines and clinical trials of new
medications), so the bench research and experiments
may dim inish as I get older. I will focus more on
translating the benefit to patients and health care
providers on the front lin e. I liked th e fact that
endocrinology as a subspecia lty was scientific ... when
I was training, a lot of clinician-scientists were
endocrinologists. That has changed now to some
extent. I also am committed to training. But there is
an increased need for clinician-scientists in all field s
in Canada. There need to be talented people who can
speak both the language of medicine and of basic
research . So I would want to see more MD/PhDs in
the future and would try to foster that. I have three
MD/PhDs working with me now - Piya Lahiry, Ma tt
Lanktree and Chris Johansen. I want to make sure
that there is a new generation of medical trainees
who maintain an interest in science."

Dr. Rob ert Hegele
(Seen in th e background is a photograph of Dr. james B. Collip.)

Additional information
Read more abou t Drs. Gerard Burrow and Charles Hollenberg a nd
the development of academic medicine at the University of Toronto
at: http:/ jwww.deptmedicine.utoro nto.ca/ About_Us/History.htm
Read more about Dr. Hegele's research at the Robarts Research
Institute website: http :/ /www.robarts.cajro b-hegele

Outside his career in medicine, Dr. Hegele enjoys
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Common side effects of diabetes medications
Kalpa Shah (Meds 2012)
Faculty reviewer: Dr. Terri Paul, Department of Medicine, UWO
In Canada an estimated 3 million individuals are affected by
diabetes and the incidence of type 2 diabetes mellitus
(T2DM) is expected to continue to rise.1 As the prevalence of
T2DM rises, a larger portion of the population will be using
diabetic medications, which underscores the importance of
being familiar with the side effects of these therapies. The
article will discuss some of the main classes of diabetic
medications, their side effects and contraindications to use.
The sid e effects of commonly used diabetic medications will
be explored and discussed through a series of vignettes.

cemia since she was elderly and ate a very light breakfast
when she took her medication . Other situations when
3
hypoglycemia is more likely to occur include:

Case 1

Other side effects associated with the use of sulfonylureas include weight gain, rash (including photosensitivity)
and nausea. Contraindications to the use of these drugs are
sulfa allergy, pregnancy or lactation, type 1 diabetes
mellitus (since there needs to be some functional beta cells
in the pancreas for the drug to act on), cardiovascu lar
disease, and impaired liver or renal function. 4

An 82-year-old woman who lives alone is found by
her daughter one morning confused, disoriented and
sweating profusely. Her daughter is concerned that
she is having a heart attack and calls the ambulance.
The paramedics arrive and, on discovering the
patient has diabetes, check her blood sugar. It is 2.0
mmol/L. She is given glucose and transported to the
ER. As the physician treating her in the ER, you ask
her the following:
•

How long have you had DM?
2 years

•

What medications are you taking?
Metformin and glyburide

•

Have you been eating appropriate meals?
You find out that she has often just been
having tea for breakfast but has been
routinely taking her diabetes medications.
She admits to often feeling "shaky" in the mid
morning.

The patient is hypoglycemic which is confirmed by
her low blood sugar. Although hypoglycemia is common ly
associated with patients using insulin to control their
diabetes, it is a lso a major adverse effect of ins ulin secretagogues - medications that stimulate the beta cells in the
pancreas to produce insulin. There are two classes of ins ulin
secretagogues: sulfonylureas and meglitinides. Sulfonylureas have been a mainstay of oral therapy for T2DM since
the 1950s. They exert their effect by binding to the potas sium channel in the pancreatic beta cells, which increases
the resting potential of the cell. As a result, the cell is more
sensitive to depolarization leading to a calcium influx and
insulin secretion.2 Since sulfonylureas cause insulin release
their major si de effects are hypoglycemia, as seen in this
case, and weight gain.
In this case, the patient was more prone to hypogly-

30

•
•
•

•
•

after exercise or a missed meal
when the drug dose is too high
with the use of longer-acting drugs (such as glyburide)
in patients who are undernourished or abuse alcohol
in patients with impaired renal or cardiac function or
gastrointestinal disease

Case 2

A 65-year-old man has had diabetes for 8 years. He
was initially treated with metformin and glyburide
but as his control worsened, his glyburide was
stopped and he was switched to insulin 30/70 taking
50 units BID along with his metformin. He comes to
clinic complaining that he has gained 40 lbs over the
past 3 months. His blood sugars before meals at
breakfast are in the range of 5- 8 mmol/L. He only
occasionally checks at supper time but they are often
7 - 10 mmol/L. he says that he feels shaky and
sweaty every morning at 10 am and must have a
snack. He has been eating a sandwich and cookie as a
mid morning snack. The same thing happens after
supper, in the early evening when he feels that he
must snack throughout the evening.
After asking him to check some blood sugars 2 hours
after eating, you discover that he is having a low
blood sugars of 2.5 mmol/L.
He is having symptomatic lows that he is over
treating by snacking excessively and this is contributing to
his weight gain. You could suggest switching to a shorter
acting insulin analogue mixture such as Mix25 (humalog
and NPH) or Novomix (novorap id and NPH) and adjusting
dose. The ultra fast acting insulin will not last as long as the
regular insulin 30/70 and he will no longer have the urge
for a morning and evening snack. Another alternative is to
transfer him to multiple daily injection (MDI), with fast
acting insulin before meals and a long-acting insulin at
bedtime.
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Prototype drugs

Action in the body

Side effects

Sulfonylureas

Glyburide,
glipizide, glimepiride

increases insulin secretion

Hypoglycemia
Weight gain, nausea, rash, GI
symptoms, blurred vision

Meglitinides

repaglinide,
nateglinide

increases insulin secretion

Hypoglycemia
upper respiratory infection, headache, diarrhea, weight gain

Biguanides

metformin

enhances insulin sensitivity

GI symptoms, lactic acidosis

Thiazolidinediones

rosiglitazone,
pioglitazone

enhances insulin sensitivity

Cardiac events, heart failure,
edema, weight gain, fractures

alpha-glucosidase inhibitors

acarbose, miglito l

reduces absorption of
glucose from gut

GI symptoms (diarrhea, flatulence
cramping)

DPP-4 inhibitors

sitagliptin

inhibits breakdown of
GLP-1 (a gut hormone that
enhances insulin secretion)

upper respiratory infection, headache, sore throat

Table 1. Summa ry of major classes of diabetic medications. Ad apted from Th e Medical Letter.11

He returns in 1 month after starting the new
regimen and has lost 5 lbs.
Case 3

A 45-year-old woman presents with newly diagnosed
diabetes and is started on metformin 500 mg TID. She
returns 1 week later saying she ca nnot tolerate the
medication due to upset stomach and diarrhea.
There are two classes of insulin sensitizers - medications that improve insulin action in the body: biguanides
(which include metformin) and thiazolidinediones. Metformin is a first line oral hypoglycemic agent and some of
the mechanisms through which it exerts its effects are: 1)
decreasing hepatic glucose output 2) increasing insulinmediated glucose utilization in muscle and liver 3) lowering
serum free fatty acid concentrations thus reducing substrate
availability for gluconeogenesis. It is believed that these
effects are mediated through the activation of AMPactivated protein kinase. 5
The most common side effects of metformin are
gastrointestina l (GI) and include a metallic taste in the
mouth, diarrhea, abdominal discomfort, nausea and mild
anorexia. These effects are reversib le upon stopping the
drug or reducing the dosage. 5 Metformin should be started
slowly and with food to minimize side effect of Gl upset as is
ill ustrated in Case 3. Patients should be started with one pill

or ha lf a pi ll at mealtime once per day and this dose should
be increased slowly as the patient tolerates it. The patient
can titrate their dose themse lves every 5- 7 days up to a
maximum of 4-5 tablets daily.
Another rare but serious side effect of metformin is
lactic acidosis. As a result the following are contra indications to starting metformin therapy: impaired renal function, liver disease, alcohol abuse, heart failure, past history
of lactic acidosis, decreased tissue perfusion or hemodynam ic instability. 5
Case4

A SO-year-old man with newly diagnosed type 2
diabetes mellitus has blood sugars in range of 8-12
mmol/L. He is started on Metformin and pioglitazone
as initial therapy. He returns to your clinic in 3
months for follow up and his blood sugars are under
much better control with fasting blood sugar of 5-7
mmoljL. However, he complains of a weight gain of
10-11 lbs (5 kg) and says his ankles and legs are
puffy. You examine him and discover he has significant pedal edema that extends up his calves. He is not
short of breath and has no signs of heart failure.
Pioglitazone has been associated with fluid retention, weight gain, heart failure, loss of bone mineral density
and fractures. 6·7·8 This patient is experiencing side effects of
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weight gain and edema from his pioglitazone therapy. His
weight ga in is due in part to fluid retention; the rest may be
due to the proliferation of new ad ipocytes.
Pi oglitazo ne belongs to the thiazolidinedione class of
dru gs. Thiazolidinediones are ins ulin sensiti zers that
increase the action of ins ulin by acting on adipose, muscle
and liver to increase glu cose utilization a nd reduce glucose
production . It is believed that the thiazolidinediones exert
their effect by binding to peroxisome proliferator-activated
receptors (PPARs), which regulate gene expression. 9 Fluid
retention is caused by the binding of PPAR receptors in the
nephron, which causes reabsorption of sodium and resultant fluid retention.10 This fluid retention often manifests as
peripheral edema and may a lso precipitate heart failure in
susceptible patients. PPAR receptors are a lso found in
skeletal muscle, adipose tissue, pancreatic beta cells, liver,
heart, and kidneys, which accounts for the varied effects of
thiazolidinedione therapy.9
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McCune-Albright syndrome: An unusual case of nasal obstruction
Anna Burianova (Meds 2012) and Julie Lebert (Meds 2013)
Faculty reviewer: Dr. Stan van Uum, Department of Medicine, UWO
Introduction

Discussion

Nasal obstruction is one of the most common symptoms
pediatric patients present to their physicians with. These
symptoms are most often caused by allergic rhinitis and
inflammation associated with viral upper respiratory tract
infection, and thus it is easy to attribute all cases of nasal
congestion to the more common entities in a busy clinical
practice. The following case 1 describes a patient with
McCune-Albright syndrome (MAS), which presents as a rare
cause of nasal obstruction. It is used to illustrate the need to
maintain a high index of suspicion and a broad differential
diagnosis, especially for cases not responding to initial
treatment measures . Furthermore, it emphasizes the need
to consider the presentation of the overall patient, and not
just the presenting symptom.

Epidemiology and clinical presentation

Case report
An otherwise healthy 14-year-old girl presented with
complaints of right-sided nasal obstruction. She failed to
improve with a regimen of decongestants care as well as a
course of antibiotics and mucolytics. Therefore, a computerized tomographic (CT) scan was ordered which revealed an
enlarged inferior turbinate bone with significant right nasal
obstruction, and a "ground glass" appearance of the inferior
turbinate, middle turbinate, ethmoid sinus, sphenoid sinus
and crista galli.
She was further referred to the Department of
Surgery and Pediatrics, where a review of systems found
commencement of menstruation at 10.5 years, with a
growth spurt of 8.5 inches in her 12th year. Her physical
examination revealed a larger right inferior turbinate and
an irregular shaped 1.5 x 0.5 em cafe-au-lait macule on her
right forearm. Based on these findings, a diagnosis of MAS
was suspected. Further laboratory results showed normal
growth hormone and prolactin levels. No distant sites of
additional bone involvement were identified on bone scan,
and all ophthalmologic tests were normal.
An endoscopic (submucosal) turbinoplasty was
performed to relieve the nasal obstruction, and the subsequent histopathologic analysis of the biopsy displayed
curvilinear trabeculae of woven bone surrounded by
moderately cellular fibroblastic proliferation, again consistent with fibrous dysplasia. On follow-up evaluations,
endoscopy revealed a stable inferior turbinate with no
recurrence of the nasal obstruction. The post-operative
follow-up CT scan demonstrated no change in size or shape
of the lesion at 2 years following biopsy, and formal ophthalmologic examinations every 6 months have since
revealed no change in vision.

McCune-Albright Syndrome (MAS) ha s historically been
identified based on th e presentation of the typical triad of
symptoms observed in this case: polyostotic fibrous
dysplasia, cafe-au-lait pigmentation and precocious puberty.2 It is a rare disease which has been described in all
races, with an estimated prevalence between 1/100,000
and 1/l,OOO,OOOY Females are more often affected than
males with a ratio of 2-6:1, and are also more often observed to have sexual precocity.4•5 However, because
autonomous hyperfunction of nearly every endocrine organ
has been associated with MAS, a more clinically relevant
definition which is broader than the original triad has been
proposed Y More extensive manifestations of MAS have also
been reported, including hepatobiliary disease, cardiac
arrhythmias and CHF, pulmonary dysfunctions, proximal
renal tubules malfunction, and sudden or premature
death .1·4·5
Fibrous dysplasia (FD) is a benign tumour of fibrous
tissue, where the normal components of bone fail to
differentiate into mature structures. The growth of chondrocytes and immature spindle fibroblast-like cells results in
calcification and a ground-glass appearance, with the
histological hallmark being an extensive proliferation of
fibrous tissue within the bone marrow.6·7The most common
site of involvement is craniofacial and may result in exophtalmy, tooth development abnormalities, visual disturbances, facial asymmetry, hearing abnormalities, leontiasis
ossea and, as seen in this patient, nasal obstruction.1·6 FD
can also be found in the proximal femur, pelvis and vertebral column and typically affects medullary rather than
cortical bone.1 Under-mineralization makes the bones prone
to fractures and deformities, and patients often present with
bone pain.3 Although malignant transformation is rare
(0 .4%), it is more common in MAS patients (4%). 1
Cafe-au-lait spots are pigmented cutaneous markings, which are present at birth or develop shortly thereafter.2 They are distinguished by the jagged "coast of Maine"
shape of their borders, and typically found on the nape of
the neck or crease of the buttocks. 3 Their distribution tends
to follow the lines of Blaschko, with a tendency to stop at
the midline on the same side as the predominant bone
lesion. 4 •7
Precocious puberty in girls is defined as the development of secondary sexual characteristics before the age of 8
years. Although the exact onset of puberty in this patient
was unknown, it usually affects females with MAS between
the ages of 1 and 6 years and is gonadotropin-releasing
hormone-independent. 8
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Many other endocri nopathi es are often associated
with this syndrom e: pituitary gland ab norm alities include
growth hormone and prolactin hypersecretion; adrena l
gland disorders include hypercortisolism, acromegaly and
Cushing's syndrome; thyroid gland disorders include
hyperthyroidism, nodular goiter, and follicular adenoma;
and parathyroid gland abnormalities ca n include parathyroid adenoma, and hyperparathyroidism. 1

Genetics and molecular basis
The sporad ic occurrence of MAS, its variable presentation
and the pattern of skin pigmentation initially led to the
hypothesis that this disorder is secon dary to an autosomal
dominant mutation occurring early in embryogenesis.5
Molecular stud ies have sin ce identified a missense mutation
in the GNASl gene, w hich codes for th e alpha subunit of a
guanine nucleotide-binding regu latory protein, Gs0 . 1'3 Gsa is
involved in the stimu lation of adenylyl cyclase; mutations
associated with this syndrome are gain of function mutations .9 The constitutiona l activatio n of Gs leads to increased
levels of intrace llular signaling molecule cAMP, which in
turn lead to increased production of a variety of different
molecules. The up-regulated molecules can includ e melanin,
estradiol, testosterone, thyroxine, growth hormone and
cortiso l (Fig lJ_l Generally s uch mutatio ns are not co mpatible wi th life; however, it is thought that these patients
survive as mosaics because the cha nge in the GNASl gene
occurs during the early embryon ic postzygotic stage. 3 This
mosaicism is seen in part as th e pattern of cafe-au-lait spots,
and is further s upported by the wide spectrum of clinical
presentations observed in patients. 4 The phenotype and
severity is determined by the ce ll line involved in the

mutation, while the severity relates to the point in develop3
ment that the mutation occurred.

Diagnosis and treatment
The diagnosis of MAS is usually made based on clinical
findings. The evaluation of patients should therefore be
guided by knowledge of the spectrum of tissues that may be
involved, with specific testing for each. Although genetic
testing is not routi nely avai lable, genetic counseling shou ld
be offered with th e assurance that there is no vertical
transmission of the disease. 3
Because there is no specific treatment to correct for
the mutation of Gsa. treatment needs to focus on controlling
the spectrum of symptoms that may a rise from this syndrome. For females, testolactone has been the mainstay of
treatment as it decreases serum estradiol an d estro ne levels
by competitive inhibition of aromatase.1 Ketoconazole and
spironolactone possess anti-androgenic activity and are
effective in males.1 PTU, methimazole and radioactive iodine
are useful in hyperthyroid states, and octreotide suppresses
GH secretion and slows acromegalic growth.1 Surgical
therapy can be used to remove the source of hormone
hypersecretion, and is useful in cases refractory to medical
therapy. 1 Surgical resection is the only cure for fibrous
dysplasia, but may be technically difficult in the sku ll and
facial regions. In these cases, the risk of co mplete resection
must be carefully weighed against the potential benefits. 1
There is no proven medical therapy, though bisphosphonates have been used to reduce the incidence of fractures
and reduce bony pain. Calcium, vitamin D and phosphorus
supplemen ts may also be used. 3

Figure 1. Molecular mechanism of McCune-Albright syndrom e.J
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Small bowe l intussusception from mestastatic melanoma
Bret t Howe (Meds 20 10)
Facult y rev iewers: Drs. Robert Humphrey and W ill iam J. Wall, Department of Surgery, UWO

Case r e por t
A 46-year-old female presented to hospital with sudden
onset lower abdominal pain, associated with nausea, and
decreased flatus and bowel movements over a 24 hour
period.
Frequent bilious vomiting developed shortly
thereafter and her pain worsened. Ten years ago she had
excision of a melanoma of the scalp combined with a
modified radical neck dissection. No evidence of recurrence
had been noted.
Physical exam revealed a mobile, firm, tender mass
in the lower abdomen . Abdominal ultrasound identified
fluid filled loops of small bowel, suggesting an obstruction.
Abdominal series was non-specific but a CT scan suggested
a closed loop obstruction in the mid-ileum without evidence
of ischemia (Figure 1).
At laparotomy, an ileal -ileal intussusception was
identified, resulting in a segment of ischem ic ileum and a
high grade small bowel obstruction. No effort was made to
reduce this segment as the suspected pathology was
metastatic melanoma based on the history. A 90.0cm
segment of small bowel was resected and a primary
anastomosis was performed. The remainder of the laparotomy revealed no evidence of metastatic disease. The
specimen was opened in the operating room revealing a 2
em pedunculated darkly pigmented polyp as the lead point.
Final pathology was consistent with metastatic melanoma
to the mucosa and submucosa of the small bowel. The
patient had an uneventful recovery, but Jess than a year
later developed metastatic melanoma to her lungs.
Dis cussion
Melanoma is a malignant tumour arising from melanocytes
that are found in the integument as well as the inner ear, GJ
tract mucosa, and eyes (conjunctivaV It is the most deadly
form of skin cancer. In 2008 it was estimated to be the 7'h
most common cancer diagnosis in Canada with an estimated
4600 Canadians diagnosed with the disease and 980
deaths.2 Metastatic disease from a cutaneous melanoma is
most commonly detected clinically in skin, subcutaneous
tissue and nodes, lung, liver, and brain. Although symptomatic Gl tract metastases occur in only 1-7% of individuals
with metastatic melanoma, autopsy studies report occult
metastasis in up to 60% of cases.3.4
Melanoma is the most common metastatic tumour
affecting the GI tract. All histological subtypes are capable of
metastasising to it, though superficial spreading melanoma
is the most common subtype found. 5 The small bowel is
most frequently involved (58-71 °/o), followed by the
stomach (27%), colon (22%), and esophagus (5%) .6•7
Common presenting symptoms are abdomina l pain,

Figure 1. Preoperative axial view (top) and coronal view
(bottom) of the computed tomography (CT) scan of the abdo men illustrating findings suggestive of a closed loop obstruction
in the mid -ileum.

bleeding (gross or occu lt), mass, or obstruction, with the
latter being most commonly a result of intussesceptio n.8
The timeframe from occurrence of a primary lesion to
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symptomatic metastatic disease is exceptionally variable.
Previous studies have shown median disease free s urvi vals
between 25.3 months and 24 years. 7·8 Medi a n s urvival after
Gl metastases is estimated to be 12.5 month s, with a 5 year
survival of only 14%.9
Surveillance for metastatic disease in individuals
with a primary melanoma is co ntroversia l. The role of
positron emission tomography (PET) scan ning is evolving. It
offers sensitivities of 79 to 100%, but is limited by accessibility and cost. 1 CT scans have only 60-70% sensitivity for
detecting small bowel mela noma, however th ey are often
the first line of imaging due to their accessibility.11 A
previous study of CT scanning for staging of primary
melanomas found positive results in 29 of 151 pati ents.
However, biopsies and follow-up studi es found only 2
patients with metastatic disease. 12 Currently, there are no
recommendations for intense follow-up in patients with
primary melanoma beyond 5-10 years except for lifelong
dermatologic surveillance due to the preva lence of seco nd
primary melanomas.U
Treatment of GJ metastas is largely depends on how
advanced the disease has become and the overall physical
condition of the patient. Therapeutic or pa lliative surgi cal
resection is almost always indicated for local lesions tha t
have become symptomatic. This is especially tru e for
patients with acute abdominal pa in and signs of obstru ctio n.
Numerous studies have demonstrated improveme nt in
symptoms and survival with GI resection a nd a low morbidity and mortality rate associated with th e procedure.6 ·8· 10
The role of adjuvant therapy (chemotherapy, immunotherapy) after resection of metastatic GI melanoma is unclear.
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Yams for breakfast, lunch, and libido? A critical look at bioidentical hormone
therapy
Justin Chia (Meds 2012)
Faculty reviewer: Dr. Ruth McManus, Department of Medicine, UWO
Background
It has only been in the recent past that the Women's Health
Initiative (WHI) changed how physicians and consumers
viewed postmenopausal hormone therapy (HT) . The
estrogen-progestin arm of the study, involving over 16,000
women, was stopped prematurely due to findings suggesting an associated increased risk of stroke, breast cancer, and
dementia without a reduction in cardiovascular risk. 1
Subsequently, women have been searching for
"safer" alternatives to treating their climacteric
(menopausal) symptoms- including hot flashes, decreased
libido, vasomotor changes, urogenital atrop hy, skin changes,
increased body weight and abdomina l fat, and psychophysiologic changes like mood changes, insomnia, and anxiety.2
One alternative that has been offered to women is
"bioidentical hormone" therapy (BHT), which is purported
to be safer, natural , and more efficacious compared to
standard post-menopausal HRT.
Defining bioidentical hormone therapy
BHT is a term used to describe plant-derived precursor
compounds (eg. diosgenin from Mexican yam, stigmasterol
from soy), which have been synthesized in the laboratory to
be structurally identica l to endogenous human hormones
such as estrogen (estrone, estradiol, estriol), progesterone,
testosterone and dehydroepiandosterone (DHEAV Perhaps
a more accurate name for bioidentical hormones should be
native synthetic hormones, as these hormones are not found
naturally in any plants 3 Proponents of BHT claim that it is
capable of restoring a balance between hormone levels, and
yet due to similarity to human hormones along with
individualized dosing, it is able to provide symptom relief
with minima l side effects. 4
Those who favour BHT affirm that the first step in
determining the usefulness of BHT is a sa livary hormone
profile, looking for deficiencies in sex hormones. Steroids
easily diffuse into the saliva and in some cases may accurately reflect free hormone levels. For instance, midnight
salivary cortisol is an evidence-based, validated test for
Cushing's syndrome. However, BHT proponents expand
their diagnostic range and offer an entire panel of various
hormone testing through mail-order kits. Interested
consumers can mail in a saliva sample (collected by chewing
on a cotton ball, placed in a plastic receptacle) and then they
will receive an extensive computer print-out with their
results as well as an explanation of findings and possible
correlated symptoms.5 The inexpensive nature of the test
and the relative ease of obtaining samples make this test
particularly popular with consumers and BHT advocates.

Once the salivary results are obtained, the BHT
practitioner will prescribe a course of bioidentical hormones, and tailor the dosage specifically to the individual's
hormone profile. In some cases, special preparations can
be created by pharmacists 5 . BHT comes in creams, gels,
pills, patches, self-injectors and pellet therapy. Within the
various treatments are hormones such as estrogen, progesterone, cortisol and "women testosterone." 6
According to one company's website, the cost of BHT
can exceed $5000USD per year. An initial consult is $400,
follow- up consu lts $185 (of which you need three), an d the
cost of treatment may range from $75-350 per month .
Further costs come with the treatment itself and laboratory
tests. 7 Because insurance companies do not cover the cost
of these treatments, this may be a limiting factor for many
patients. Keeping this in context, daily Premarin 0.625 mg
along with Provera 2.5 mg would be around $700USD per
year, even with the 800% increase in price in 2009.8· 9
Currently, there are numerous commercial as well as
individually prepared "natural" products. Formulations are
created by pharmacies according to prescriptions written
by referring practitioners, and cannot all be purchased
commercially. One such product is Biest (bioestrogen)
which is a combination estrogen contai ning 20% E2
(estradiol) and 80% E3 (estriol), expressed in a milligram
per milligram basis.10 Another such formu lation used
frequently is Triest (triestrogen) which contains 10% E2,
10% E1. and 80% E3 • It is important to note the relative
potencies of the estrogens: E1 (estrone) is the most potent,
followed by Ez, and E3 is the weakest of the three, being the
final end product of E2 and E1 metabolism. Th e presence of
such a high proportion of E3 in these mixtures is advertised
as the key to reducing adverse side HRT effects w hil e still
conferring symptom relief. 10
What is the evidence from medical literature?
There have been few evidence-based trials looking at the
safety, efficacy, and durability of BHT. According to proponents, because the steroids are found in nature, are not
extensively manufactured, and are dosed in a way that is
individualized, there is no need to research these compounds and therefore submit data to FDA for approva l and
5
regulation. In addition, pharmacies can mix their products
differently, which makes it difficult to standardize and
determine the risks associated with BHT.
Despite salivary hormone testing (SHT) developing a
medical literature showing usefulness in certain areas of
clinical practice, it is often criti cized for its lack of reliability
and inability to correlate symptoms and hormone levels.
Standard HRT prescribes estrogen and progestins in doses
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that provide symptom relief. In the BHT approach, SHT test
results may persuade asymptomatic women to take doses
they may not need and symptomatic women to take
excessive doses.11
In theory, saliva is similar to ultrafiltrate and shou ld
correlate with free/unbound serum concentrations.
However, it has been shown that these correlations vary
depending on the time of day, diet and the specific hormone
tested.10 Many hormone levels vary during the day, week.
month, season and therefore a one-time SHT may be
inadequate for diagnosis or monitoring dose adjustments,
particularly unless greater than 5 samples are taken daily.2
Traditional medicine uses individualized dosing for
drugs which have a narrow therapeutic index, as described
by population-based phamacokinetic studies ( eg. cyclosporine, digoxin). According to Jelliffe, true individualized
dosing must be predicated upon a known target serum
concentration, at a desired target time after the dose, for
each patientY However, proponents of BHT have no studies
dealing with important pharmacokinetics of their drugs
such as volume of distribution, protein binding, route of
elimination, among other factors. 10 Without a predictable
relationship between dose and response of the drug, it
becomes impossible to know how much medication to
prescribe.
As mentioned previously, the BHT hormones
typically used for menopausal symptoms are estrogen and
progesterone. But how much estrogen is really in these
compounds? In addition to inter-pharmacy differences of
product formulation, there appears to be another underlying problem--ratios may not be what they seem. Biest, an
80:20 ratio of E3 to E2, is not based on the estrogen potency
of each compound, but rather is based on the milligram
quantity of different agents added together. For examp le, if
a woman takes 2.5 mg of Biest (2 .0 mg E3, 0.5 mg E2), and
the potency of E3 is 1/SO'h of E2 , the equivalent content of E2
is actually 0.525 mg. 10 Some women may take 2.5 mg Biest
twice daily, increasing the E2 equivalent to 1.05 mg per day
which is a dosage exceeding most prescribed estrogen
therapies. The same applies for Triest, which is a combination of estriol, estradiol, and estrone. 2

With E3 being the least potent of the estrogens, its
high percentage in BHT formulations is believed to decrease
the incidence of breast cancer and endometrial hyperplasia.
However, past studies have shown equal endometrial
stimu lation from estradio l and estriol medications Y Estriol
was also found to partially overcome antiestrogen inhibition
from Tamoxifen, even when Tamoxifen is present in 1000fold excess. Therefore, estriol does not have a protective
role in human breast cancer, and all estrogens bind to an
equa l number of sites when saturating concentrations are
used. 14 It can be deduced that despite being the least potent
estrogen, E3 still carries risks of cancer that BHT tries to
avoid.
Much has been written about progesterone in BHT.
Although that extensive literature will not be reviewed here,
it should be noted that many of the health claims from BHT
practitioners have not been substantiated, but rather have
been overshadowed by evidence-based medicine. For
example, BHT practitioners claim progesterone increases
metabolism and causes weight Joss. However, no studies
are identified to s upport those claims. Indeed, weight gain,
rather than loss, has been shown w ith progestin therapy in
cancer-related anorexia. 15

Practice guidelines for the physician
In view of the evidence, how should the physician respond
to BHT practitioners and claims? The North American
Menopause Society, the American Association of Clinical
Endocrinologists, and the Endocrine Society have all
published positional statements expressing concern for the
safety of women using these products.16' 18 These groups are
currently advocating for FDA oversight in the standardization of drug purity, the need for mandatory reporting of
adverse events, as well as uniform labeling of precautions
on BHT formulations.
The bottom line from these groups involves strong
recommendations that BHT not be used in the treatment of
menopausal symptoms. It is argued that both "bioidentical"
and "traditional" hormone replacement treatments will
carry essentially the same risks and benefits if dosage and

Traditional hormone

Many "bioidentical hormones"

Molecular structure

Similar or identical to human

Identi cal to human

FDA oversight

Yes

No

Dosage

Monitored; accurate and consistent

Purity

Monitored; pure

Not monitored ; may be inaccurate or inconsistent
Not monitored; may be impure

Safety

Tested; risks known

Not FDA tested; risks unknown

Efficacy

Tested and proven

Not FDA tested; unproven

Scientific evidence

Existent; conclusive

Insufficient

Table 1. A comparison of traditional and bioidentical hormone therapy.
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purity are equal. Therefore, no matter the source or
hormone regi men, the "individ ualized" dosing must be
carefully controlled.
A summary of th e Endocrine Society's comparison of
BHT and HT is shown in Table 1. Overall, further research
and an evidence-based scientific approach must be appli ed
to BHT to validate or debunk its proposed health benefits.
Until then, it might be best to keep the yams on the Thanksgiving tab le instead of using them to treat human conditions.

15.

16.

17.

References

1.

2.
3.

4.

5.
6.

7.

8.
9.

10.

11.
12.

13.

14.

Rossouw )E, Anderson GL, Prentice RL, et al. Risks
and benefits of estrogen plus progestin in healthy
postmenopausal women: principal resu lts from the
Women's Health Initiative randomized controll ed
trial. )AMA. 2002;(288) :321-33.
Chervenak ). Bioidentica l hormones for maturing
women. Maturitas. 2009;(64) :86-9.
Dubin C.F Bioidentical hormones : what's in a name?
SmartNow. Available: http :/ ;www.s martnow.com/
page/8068 (accessed Dec 7 2009).
Aeron Biotechnology. Salivary hormone monitoring.
Available: http:/ /www.aeron.com/profess iona l.htm
(accessed Nov 25, 2009).
Francisco L. Is bio-identical hormone therapy fact or
fairy ta le? Nurse Pract. 2003;(28) :39-44.
Pellets and patches and pills ... Oh my! Available:
http :/ jwww. bodylogi cmd .com/ for-women/
treatment-option s (accessed Dec 2, 2009).
Griffin Medical Group. Costs associated with Bioidentical Hormone Rep lacement Therapy. 2006.
Available:
http :/ /www .griffi nm edica l. com/
bhrtcosts.htm (accessed Dec 2, 2009) .
Xpill s. Avail a bl e: http :/ ;www.xpi lls.org (accessed
Dec 7, 2009) .
Users of Prem arin drug stunned by price hike. CTV
News. 2009 jun 30. Available: http:/ ;www.ctv.ca/
servlet/ Articl e News/story /CTVNews/20090603/
premarin_090603/20090603 (accessed Dec 7,
2009).
Boothby LA. Doering PL, Kipersztok S. Bioidentical
hormone therapy: a review. Menopause. 2004;
(11) :3 56-67.
Rosenthal MS. Ethica l prob lems with bioidentica l
hormone therapy. In t J lmpot Res. 2008;(20):45 -52.
jelli ffe R. Goa l-oriented, mod el-based drug regim ens:
setting individualized goals for each patient. Ther
Drug Monit. 2000;(22) :32 5-9.
van Haafte n M, Danker GH, Sie-Go OM, Has pels AA,
Thijssen )H . Biochemical and histological effects of
vaginal estriol and estradio l a pplicatio ns on the
endom etrium, myometrium a nd vagina of postmenopausal women . Gynecol Endocrinol. 1997;(11) :17585.
Lippman M, Mon aco ME, Bo la n G. Effects of estrone
estradiol, a nd estriol on hormone-respons ive huma~

18.

breast cancer in long-term tissue culture. Cancer
Res. 1977;(37) :1901-7.
Boothby LA, Doe ring PL. Bioidentical hormone
therapy: a panacea that Jacks supportive evidence.
Curr Opin Obstet Gynecol. 2008;(20):400-7.
North Ame ri can Menopause Society. Bioidentical
Hormone
Therapy.
Available:
http ://
www.me nopause.org/bio identical.aspx
(accessed
Dec 4, 2009) .
Cobin RH , Petak SM, et al. American Association of
Clinical Endocrinologists positio n statement on
bioidentical hormones. 2007 jul 15. Available:
http :/ jwww .aace. com/pub I pdf I guide I i nes/
AACEBHStatement071507.pdf (accessed Dec 4,
2009).
The En docri ne Society.
Bioidentical hormones.
(position statement). Oct 2006. Available: http :/ I
www.endo-society.org/advocacy /policy /upload/
BH_Posi tion_S tatemen t_fi nal_1 0_2 5 _06_ w _Header. pd
f (accessed Dec 4, 2009).

www.sehealth.mb.ca

South Eastman Heanh/Sant~ Sud-Est Inc.

South Eastman Health!SanM Sud-Est Inc.
Is a Regional Health Authority located in the fastest growing
region of Manitoba where vibrant, progressive and multi-cultural
communitie.s offer a pace to suit your lifestyle. Minutes from Winnipeg,
home to beauttful golf courses, lakes and private beaches. Come home to 0
good life.

FAMILY PHYSICIANS
Our ~ecruitm_ent Officer wou ld be pleased to provide
further 1nformat1on about our Rural Physician opportunities.
For n;ore information, please contact: South Eastman Health/
Sante Sud-~st Inc. • Human Resources Department • Box 470
La Broquene MB ROA OWO • Fax: (204) 424-5888 •
Email: hr@sehealth.mb.ca

UWOMJ 179:1 I Spring 2010
42

Why did Harvey Cushing misdiagnose Cushing's disease? The en igma of
endocrinological diagnoses
Laura Hinz (Meds 2011)
Faculty reviewer: Dr. Ruth McManus, Department of Med icine, UWO
The case of Minnie G

The d iagnostic a pproa ch to Cushing's Disease

Minnie G's menses started at the age of 14 and were regular
for two years and then suddenly ceased. She began to grow
stout and in two years her weight had increased from 112 to
137 pounds. She suffered a great deal from headaches,
nausea and vomiting. She complained also of aching pains
in the eyes which latterly had become prominent, and there
had been occasional periods of seeing double. Other
noteworthy symptoms were insomnia, ti nnitus, extreme
dryness of the skin, frequent sore throats, shortness of
breath, palpitation, purpuric outbreaks, recurring nosebleeds, and marked constipation. A defi nite growth of hair
had appeared on the face with thinning of hair on the scalp.
She had become increasingly round-shouldered. Muscular
weakness had become extreme and there was constant
complain of backache and epigastric pains.'

Cushing's disease is one form of Cus hing's syndrome, a
group of symptoms that result from hypercortisolism.
Diagnosis of Cushing's disease depends on cli nica l, laboratory, and imaging modalities. For instance, a diagnosis of
Cushing's disease requires evidence of hypercortisolism; the
excess cortiso l must be the result of high ACTH levels; and
the high ACTH must be the product of a pituitary adenoma.
The fo ll owing algorithm aims to fulfi ll those three
criteria:4·5
1. Does the patient exhibit symptoms of cortisol excess?

Test

Case discussion
This case represents the original words of Harvey Cushing
in describing Case XLV, a woman who came to be known in
the literature as Minnie G or MG.' The description appeared
in Cushing's seminal work, The Basophil Adenomas of the
Pituitary Body and their Clinical Manifestations in 1932.
Cushing first saw MG in 1910 and originally attributed the
complaints of obesity, diabetes, hirsutism, and adrenal
hyperplasia to myxedema.2 He then changed his differential
to "pituitary, adrenal, or ovary?" 3 Over the next 20 years,
Cushing saw MG twice more and began an extensive review
of the literature. His previous work on acromegaly led him
to postulate that if acidophilia could lead to growth hormone excess, then perhaps basophilia could lead to cortisol
excess. 3 An 1898 case description by Cushing's mentor, Sir
William Osler, helped Cushing to finally determine in 1932
that MG's symptoms were the result of a cortiso l secreting
pituitary adenoma.
The case of Minnie G illustrates a common diagnostic
challenge in endocrinology: endocrine conditions often are
associated with a non -specific symptom set, which combined with individual variability can have the result that
some patients go undiagnosed or are misdiagnosed. If even
Harvey Cushing struggled with the diagnosis of Cushing's
disease, what hope is there for humble endocrinologists and
general practitioners? This article will use Cushing's disease
as a prototype to explore how and why symptoms are
grouped into diagnoses, and the associated perils and
advantages of this practice.
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Observation

History
La boratory t esting

Results s uggestive of
Cushing's syndrome
Truncal obesity
Facial plethora
Hirsutism
Acne
Skin bruisi ng
Edema
Muscle weakness
Hypertension
Mood disorders
Polyuria
Polydypsia
Glucose intolerance

2. Is there a ctually cor tisol excess?

Test

Res ults suggestive of
Cush ing's syndrome

11p m salivary cortisol

>4x increase

Serum cortisol after
low dose dexamethasone
suppression test

>54nmol/L

24 hour urine free
cortisol

>250nmo ljday
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3. Is the cortisol excess ACTH-dependent?

Test
SerumACTH

Results suggestive of
Cushing's syndrome
>40pmol/L

4. Is the excess ACTH from the pituitary?

Test

Results suggestive of
Cushing's disease

MRI

Pituitary adenoma

Petrosal venous
sampling

High ACTH levels in the
region of the pituitary

only by the clini cal manifestations of hypertension, obesity,
and glucose intolerance and by laboratory abnormalities.
In defining disease, establis hing criteria for a
syndrom e is perhaps the most difficult task. Syndromes are
collectio ns of symptoms, signs, and investigational results
that have a similar course and response to treatment.
However, syndromes are made up of sufficient rather than
necessary elements. That is, the symptoms make the
diagnosis more likely, but there is no one symptom that will
absolutely rule in or out the diagnosis. Endocrinology is
fraught with vague symptoms, largely because the definition
of normal is elusive. Hormone levels fluctuate throughout
the day, with age, with environment, with diet, and between
individuals. It is incredibly difficult to define 'normal' for a
measurement that is not only inconsistent between but also
within individuals.
Why do we define disease?

The enigma
Algorithms such as these suggest that diagnosis of disease
should be relatively straight-forward. However, the fact
that Cushing took 20 years to diagnose the disease that
bears his name combined with the fact that most patients
wait 6 months-10 years between symptom onset and
diagnosis of Cushing's disease suggests otherwise. 2 Cushing's disease is simply an example of a broader issue: how
and why do we group symptoms into categories, and what
problems do these groupings create?
How do we define disease?
A disease is a collection of recognizable symptoms that
result from a common cause. This definition is slightly
narrow, as diseases are defined not only by their symptomatology and pathology, but also by imaging and laboratory
results, response to treatment, and epidemiology. At first
glance, the definition of a disease should be fairly simple.
Even the layperson can recognize that diabetes is not the
same as influenza. The problem arises when symptom and
investigation differences are more subtle: even the most
experienced endocrinologist wi ll struggle with differentiating a pituitary basophilic microadenoma from ectopic ACTH
production. This struggle is analogous to the definition of a
species- biologists recognize that a cat is not a dog, but
grouping like micro-organisms is a different cha ll enge.
From this ana logy, we recognize that defining an
entity is much more difficult when we are unable to see it
clearly. The distinction between a cat and a dog is simple
because we can compare ear shape, bone structure, sounds
produced, and habits. Grouping micro-organisms requires
microscopic examination and molecular techniques.
Endocrinology is the micro-organism of the medical world:
it deals with conditions that are often visible only in their
clinical manifestations, not in their causative agents.
Cushing's disease is so mewhat unique in that an
anatomica l anomaly, a brain tumour, is the etio logic
mechanism. In contrast, hypercortisolism is recognized
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Because the symptoms that make up a syndrome are so
variable, it is perhaps appropriate that they are named after
the people who first described them. Diseases are, in
essence, a human creation. They are an attempt to impose
order and allow parsimonious treatment. Cushing argued
that defining disease was important because "a peculiar
clinical syndrome has first been described by someone with
a clarity sufficient to make it easi ly recognizable to others." 1
It is only by having an accurate definition that different
physicians are able to make the same diagnosis.
If a collection of symptoms has a common cause, it is
easier to treat the cause than it is to treat each individual
symptom. Consider the example of Cushing's disease:

Figure 1. Pathogenesis of Cushing's disease and diagnostic tests
for each level.

Note that the diagnostic tests described above detect
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the disease at different levels of disease progress ion.
Therefore, the test that is chosen will have an impact on the
part of the disease that is obse rved. If a n MRI reveals an
adenoma, this is not sufficient to make a diagnosis of
Cushing's disease. While it is high on the etiologic pathway,
the possibility of a non-secreting and therefo re asymptomatic incidentaloma remains.
Conversely, symptoms of obesity and hirsutism
could suggest Cushing's disease, but without the MRI and
ACTH tests, we are not justified in a pplying that label. These
two instances have treatment implications: the first requires no treatment if it is truly an incidentaloma. The
second requires treatment, but without knowing the cause
of the symptoms, our ability to intervene is limited to
symptomatic relief.

The elusive diagnosis
According to Gross eta/, "Although the initial presentation
of a patient with such a constellation of symptoms is
suggestive of Cushing Syndrome, most symptoms characteristic of the disease are nonspecific, resting the burden of an
accurate diagnosis on an appropriate diagnostic workup." 5
The diagnosis of Cushing's is fraught with perils at multiple
levels:

I

iThe DISease
• Atypical presentation'

Cushing's di sease is th e recognition of clinical symptom s.
However, when viewed in iso lation, these symptom s ca n be
characteristic of numerou s di seases. Many patients who are
ultimately diagnosed with Cushing's di sease find them selves
passed between specialties before an astute physician
finally integrates the symptom s into a whole. For instance,
Evans eta/ describe a woman who saw a dermatologi st,
cardiologist, orthopaedic surgeon, and psychiatrist before
ultimately diagnosing herself from information in the lay
press.2 Thi s illustrates a fundamental flaw with the current
medical system- subspecialisa tion ensures expert care of
specific symptoms, but it may neglect to view the patient as
a complete person. Diagnostic re-evaluation is needed as
time and symptoms evolve and a n astute phys ician looking
at the entire person may be seminal in putting the pieces
together. Optimal communication is required between
specialists to ensure that a common cause of symptoms can
be found if it exists.
Finally, note in Figure 1 that the final arrow in the
pathway is bidirectional. The effects of symptoms in turn
impact the patient's experience of the disease. This is
particularly true in Cushing's disease, as stress is an
additional cause of hypercortisolism. Therefore, worsening
symptoms can impact a patient's functioning, which in turn
increases stress levels which ultimately serve to worsen
symptoms. Therefore, the final step in any diagnostic
pathway must includ e an exp loration of the context in
which the patient experiences symptoms.

• Intermittent hypercortisolism
• Pituitary incidentalomas

Conclusions

• Adrenal incidentalomas

• Rare forms 4
• Macronodular adrenal hyperpla sia

The diagnosis of Cushing's disease can be enigmatic and
elusive, but, as evidenced by the following letter from
Minnie G to Cushing, ultimately rewarding:

• Abnormal sensitivity to glucocorticoids
• Pheochromocytoma
• Pseudo Cushing's
• Obesity

• Anorexia
• Alcohol

• Depression

• Stress

1

!The Pattent
• Symptoms are interpreted in light of education, culture. relationships. etc.

• Comorbidities
• Subpopulations present differently: pregnant women, children
• Lifestyle effects (diet. exerci se, exogenous hormones)

• The definition of 'norm al ' is not absolute
• Timing (symptoms require longterm glucocorticoid excess, and levels of cortisol
vary throughout the day)'
• Imperfect lab tests, none are 100% sensitive orspecific 6
• Tests require patient compliance (ex. 24 hour urine collection)

1

'The PhySictan

• Rare disease, may not con sider it 2

I

~he Medteal System
• Imperfect communication between specialists 2
• Ignoring parsimony: diagnosing the symptoms instead of the syndrome
• Specialty-specific care

Figure 2. Complicating factors in the diagnos is of
Cushing's disease.

As seen in Figure 1, the first step in the diagnosis of

"Dear Sir: Of course, I am very sorry to trouble you
again with letters, but I am taking advantage of your
own words. The great pains my body is forced to
bear can be honestly compared to the modern
German artillery .. .. And now I have told you most all.
I do believe sufficient amount and I ask you again,
what can you do? There must be some palliation in
my letters for I regard you as my best friend and
doctor. Yours sin cere ly, Minne G." 7
Cushing may have originally misdiagnosed the
disease that bears his name, but he was a brilliant physician
who was a frie nd to his patients. His devotion was such that
he actually resided in the hospital to better care for his
patients.
The case of Minnie G thus highlights a number of the
vital components of endocrinological diagnosis:

•

•

•
•

A high index of suspicion .
Careful vigilance and reassessment of diagnostic
assumptions.
Communication between specialists .
Thorough histories, physicals, and diagnostic
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workups.
An exceptional physician-patient relationship.

•

Grouping of symptoms into a diagnosis is not an
exact science but rather requires some of the art of medicine which can recognize variableness of disease presentation within a population of interest.
Harvey Cushing's
recognition of these lessons warrants remembrance of his
name not only in the context of hypercortisolism, but as an
example of how we should strive to practice medicine.
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Management of hyperlipidemia in patients with statin intolerance
Kareem Jamani (Meds 201 0)
Faculty reviewer: Dr. Tisha Joy, Department of Medicine, UWO
Why statins?
Statins, or HMG CoA reductase inhibitors, are among the
most commonly prescribed drugs in the world today. These
medications have been repeatedly shown to reduce lowdensity lipoprotein cholesterol (LDL-C) byl9-60% depending on the statin and dose used Y In patients with existing
coronary artery disease (CAD), statins have been shown to
decrease incidence of non-fatal myocardial infarction, 1
incidence of stroke/ mortality from CAD/ and all-cause
mortality. 1 These same benefits have also been found in
patients without CAD but with cardiovascular risk factors
including diabetes. 3 For this reason, statins are co nsidered
to be first line in the management of hyperlipidemia in
patients who, according to the Framingham risk calculator,
are at high risk for coronary artery disease as well as those
at medium or low risk who have failed to meet lipid targets
with lifestyle modification. 4
Adverse effects and statio intolerance
Despite the significant effect of these drugs on mortality and
morbidity, statins, like all drugs, have adverse effects.
However, the HMG CoA reductase inhibitors generally have
a favorable side-effect profile. 5 The most common adverse
effects and the primary contributors to statin-intolerance
are muscle symptoms and creatine kinase (CK) elevations. 6
There are many definitions in the literature regarding the spectrum of statin-induced muscle symptoms. One
commonly used set of definitions, from the National Lipid
Association (NLA) Statin Safety Assessment Task Force, is as
follows: (1) myalgia: muscle pain or soreness, (2) myopathy:
myalgias, weakness or cramps and CK >lOx the upper limit
of normal, and (3) rhabdomyolysis: CK >10 000 IU/L or CK
>lOX the upper limit of normal plus elevation of serum
creatinine or need for intravenous hydration. 6 The rate of
statin-induced myalgia in obse rvational studies is 10-15%
while the rate of myopathy is 0.1-0.2%. 7 Meanwhile,
rhabdomyo lysis is even less common and has been seen
mainly when statins have been used in combination with
fibrates or cyclosporine. 7
In the case of myopathy or rhabdomyolysis, the NLA
task force recommends discontinuing the statin. Restarting
the statin after these events is controversia l; nevertheless,
there is a general consensus that the clinician must weigh
the risks and benefits before making this decision. 8 However, most patients on a statin presenting with muscle
symptoms will fit the definition of myalgia. If these myalgias are intolerable, the NLA recommends discontinuing the
statin. Meanwhile, if the myalgias are tolerable, the statin
should be continued at the same or lower dose or a statin
holiday may be given. 6

When patients have recurrent myalgias after taking
a reduced dose of their statin or after restarting their statin
subseq uent to a drug holiday, alternative approaches to
lipid management are required. This presents a challenge
to physicians managing lipids in patients with or at risk for
vascular disease because non-statin lipid lowering medications have not been shown to have the same robust effect on
morbidity and mortality as statins and present their own set
of adverse effects. 5 In the recent literature, alternative statin
regimens aimed at those who have previously been intolerant to the medications have been proposed. Three such
regimens are reviewed below.
Modified statio therapy

Switching the statin
According to the Prediction of Muscular Risk in Observational Conditions (PRIMO) study, an observational trial of
nearly 8000 unselected patients using statins in France,
high dose fluvastatin (80mg) is associated with the lowest
rate of muscular sympto ms (5 .1 %) when compared to high
dose pravastatin (10 .9%), atorvastatin (14.9%) and
simvastatin (18.2%). 9 This had led many clinicians to
recommend a trial of switching patients intolerant to their
current statin to fluvastatin. 5·10 While this statin is considered to be lower in potency than others/ 1 a recent trial
showed fluvastatin 60mg reduced LDL-C by 31% and
sign ificantly reduced atherosclerotic plaque volum e in
patients with CAD Y Furthermore, fluvastatin XL has been
demonstrated to be well-tolerated among statin-intolerant
patients.13

Alternate day and weekly statin dosing
Given that atorvastatin and rosuvastatin have long halflives, alternate day dosing of these statins has recently been
attempted in statin intolerant patients to reduce the risk of
a~verse muscular effects.
While tolerated by 72% of
patients, a dose of 2.5-lOmg of rosuvastatin every other day
in previously statin-intolerant patients has been found to
reduce LDL-C by 34%.14 Similarly, a 23% reduction in LDL-C
has been reported in 74% of previously into lerant patients
now receiving once weekly rosuvastatin .15 However, these
studies have not yet addressed whether alternate day or
weekly statin dosing has the same effect on vascular event
rates and mortality rates that daily dosing does.

Statin and ezetimibe combination
Ezetimibe is a cholesterol absorption inhibitor that has
received a significant amount of attention since a double-
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blind study showed similar LDL-C red uctions between
ezetimibe (lOmgjday) combined with atorvastatin lOmg/
day and atorvastatin 80mgfday alone. 16 However, even WI'th
the lower dose of statin in this s hort trial, the combination
therapy did not have a lower rate of musculoskeletal sideeffects and CK elevations than the high dose statin therapy.
Further, in a more recent long-term (48 week) trial comparing the safety of ezetimibe combined with simvastatin and
simvastatin alone, there was no difference in musculoskeletal adverse-effects or CK levels. 17 However, a recent randomized controlled trial has revealed that the combination
of fluvastatin and ezetimibe is well-tolerated in statinintolerant patientsY
Non-statio therapy
When patients with hyperlipidemia can not tolerate any
form of statin therapy, non-statin alternatives can be
emp loyed. These include fibrates, niacin, bile acid absorption inhibitors, ezetimibe, and potentially omega-3 fatty
acids.

Niacin
Niaci n is perhaps the most potent of t hese drugs and has
been shown to raise high-density lipoprotein cholesterol
(HDL-C) and lower LDL-C as well as, in older st udies, to
reduce cardiovascular events and mortality.18 However, the
side effects, which include cuta neous flu shing and gastrointestinal upset, have limited its use. 18 Recently, there has
been renewed interest in niacin, including ongoing trials
evaluating mortality outcomes and investigation into
attenuation of these side-effects. 18

Fib rates
Fibrates are well studied and have been found to significantly reduce triglyceride level s and increase HDL-C levels
while havi ng a s mall er effect in reducing LDL-C levels. 19'20 In
terms of outcomes, P.Yo recent me ta -ana lyses found that
whi le currently available fibrates significantly reduce the
odds of non-fatal myocardial infarction (Ml), they had no
effect on cardiovascu lar mortality, rate of stroke, or a llca use mortali ty.19•20 Adverse effects in both of these trials
were primarily gastrointestinal, while myalgias occurred at
the same rate as in the pla cebo groups.

Bile acid and cholesterol absorption inhibitors
Bi le acid absorption inhibitors, sim ilar to ni acin, have been
studied mostly in older, pre-statin era trials. In these trials,
cholestyramine, a first generation bile acid sequestra nt,
mainly reduced LDL-C levels as well as cardiovascular
events and mortality.21 However, again like niacin, these
drugs have bee n limited by their gastrointestinal s ideeffects such as co nstipatio n.21 A newer bil e acid seq uestra nt,
colesevalam, is tolerated much better by patients and
delivers similar LDL-C reductions as the older medicatio ns,

but no outcome data are avai lable to this point.z.z Ez~timibe
alon e has been shown to deliver modest reductions m ~OL
e and, in two trials, has been well tolerated by patients
intolerant to statins. 13 ·23 However, there is currently no
evidence that this drug influences cardiovascular event or
mortality rateS.24

Omega-3 fatty acids
Recently, there has been some interest in the role of omega3 fatty acids in cardiovascular disease. A large (18000
patients), randomized trial in Japan fo und that omega-3
supplementation (eicosapentaeonic acid 1800mgfday)
significa ntly reduced triglyceride levels as well as non-fatal
coronary events. 25 However, we await replication of these
findings in randomized double-blind, placebo-controlled
settings. Adverse effects have included gastrointestinal
disturba nce, skin reactions, and hemorrhage.25
Conclusion
Statins have been widely studied and there is robust
evidence supporting their lipid lowering properties and
beneficial effects on cardiovascular morbidity and mortality.
These medications are generally safe and serious adverse
events are rare. However, the most common side-effects
that lead to stati n-intolerance are muscle symptoms. When
patients are unable to tolerate their current statin, there is
some evidence to support switching to fluvastatin, less
frequent statin dosing, or combination with ezetimibe.
However, it is currently unclear if the mortality benefits
associated with statins carry over to these modified statin
therapies. If patients are unable to tolerate any form of
statin therapy, non-statin medications may be used.
Unfortunately, many of them are not well tolerated a nd are
still awai ting convincing data for cardiovascular event
be nefit. Further investigation into the efficacy on cardiovascular o utcomes in alternate statin and non-statin regimens
in statin-into lerant patients is required. While medications
for hyperlipid e mia may be tai lored accord ing to adverse
effects experienced by patients as well as their particular
lipid profile, it is important to continually emphasize the
need for lifestyle modification including diet and exercise in
the management of hyperlipidemia.
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Backgroun d
Cystic fibrosis (CF) is an autosomal recessive disease that
occurs in one of every 3600 births in Canada. 1 It is caused by
a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which encodes a chloride ion
channel. Derangement in chloride transport results in
dysfunction of multiple organ systems, most notably the
lungs. Characterized by progressive obstructive lung
disease, the clinical course of CF is one of chronic and
recurrent pulmonary infections leading to inflammation and
remodeling of the airways. In addition to lung disease, the
majority of patients also exhibit malabsorption secondary to
exocrine pancreatic insufficiency. Whereas lung disease and
pancreatic insufficiency typically manifest in infancy, certain
complications tend to occur later in the course of the
disease. Cystic fibrosis-related diabetes (CFRD) is a feature
of CF that occurs in many patients as they reach adulthood.
CFRD was unheard of half a century ago when CF was
almost uniformly fata l in early chi ldhood. However, as the
median survival age has steadily increased, to where it
approaches 40 today/ this later onset complication is
becoming increasingly prevalent. Only 2% of children with
CF have CFRD but that increases to 20% of adolescents and
half of adults above the age 30. 3 Not only is the development
of diabetes an added burden to a patient population that
already faces a complex daily treatment regimen, it is
associated with a decline in pulmonary function and a
decrease in life expectancy. 4 •5

insulin secretion occurring early in the disease process.
Patients with CF without impaired glucose tolerance exhibit
a decrease in peak insulin concentration and a delay in
reaching peak insulin despite having normal glucose
tolerance. 10·11 As p-cell function continues to deteriorate,
patients show decreasing insulin concentrations and higher
plasma glucose concentrations following an oral glucose
12
load, eventually crossing the threshold into diabetesY·
Because the destructive process is not specific for P-cells,
there is also damage to other cell types of the islets and
patients with CFRD show impaired secretion of glucagon
and pancreatic polypeptide.13 There is evidence of a relative
increase in somatostatin secretion, which could further
decrease insulin and glucagon release. 8 •14
The role of peripheral insulin resistance in CFRD is
not clear and the insulin sensitivity of patients is variously
reported as normal, decreased, or even increased. Overall,
there is insufficient evidence that insu lin resistance plays a
major role in the pathogenesis of CFRD and whatever effect
it does have is certainly small in compariso n to p-cell
dysfunction. 15·16 Regardless of the overall role of insuli n
resistance in the pathophysiology of CFRD, there are
circumstances in which patients will experience at least
transient insulin resistance. Exacerbations of lung disease
and use of glucocorticoids are frequent occurrences for CF
patients. These situations lead to a decrease in insulin
sensitivity resulting in a sharp increase in insulin requirements.1 7
Diagn osis a nd managem e n t

Pathophysiology
Although CFRD shares certain characteristics with both type
1 diabetes and type 2 diabetes, it is a separate entity with a
unique pathophysiology. As in type 1 diabetes, insulin
deficiency is the primary defect but this is usually relative
rather than absolute. Similar to type 2 diabetes the onset of
CFRD is usually gradual and insidious. CFRD is classified
under other types of diabetes, falling into the category of
diabetes secondary to disease of the exocrine pancreas.61n
CF, absent or aberrant function of the CFTR chloride
channel on the pancreatic ducts leads to increased viscosity
of digestive secretions. 7 The viscous secretions obstruct the
pancreatic ducts leading to progressive fibrosis and fatty
infiltration of the pancreas. As a result there is a decrease in
the number of islets as well as structural disorganization of
remaining islets leading to loss of p-cell function .8·9
Loss of P-cell function is a gradual process and
patients pass through a continuum from normal glucose
tolerance to impaired glucose tolerance and eventually
diabetes. Impaired insulin secretion is seen in patients
before the onset of CFRD, with alterations in the kinetics of

Diagnosis of CFRD is not straight forward due to the
fluctuating health status of CF patients. Transient dysfunction of glucose metabo lism is frequent during disease
exacerbations and as such measures of glucose metabolism
must be interpreted in the context of the patient's current
18
health. The diagnostic criteria for CFRD are simi lar to that
for type 1 and type 2 diabetes except that in CFRD there is a
further subdivision of patients depending on whether or not
they exhibit fasting hyperglycemia. 19
Patients with CFRD are often asymptomatic at
20
diagnosis, which necessitates periodic screening of CF
patients for derangements in glucose metabolism. Although
fasting plasma glucose (FPG) is the recommended screeni ng
1
test for diabetes/ its use in screening for CFRD is not ideal.
The use of FPG as a screening test will fa il to identify the
large proportion of patients who have CFRD without fasting
hyperglycemia . Because an oral glucose tolerance test
(OGTT) can identify patients with CFRD without fasting
hyperglycemia, it is a much more sensitive test. Given that
CF~D tends to develop in the adolescent or early adult
penod, annua l OGTT screening beginning in early adoles-
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cence is a rational approach used in many centres to ensure
that patients with CFRD are identified early. 18 · 22 ·23
In patients diagnosed with CFRD with fasting
hyperglycemia, insulin therapy is indicated. Because many
patients with CF have a variable appetite and meal schedule
due to frequent illness, a basal-bolus insulin regimen
provides needed fle xibility. 24 Both nutritional status and
pulmonary function have been found to improve following
the induction of insulin therapy. 25 Currently, the best
treatment for patients who have CFRD without fasting
hyperglycemia is not clear. CFRD without fasting hyperglycemia has not been associated with acute or chronic
complications of diabetes; therefore, patients are often not
started on insulin therapy unless they have symptoms of
hyperglycemia. 19· 26 However, because the CFRD associated
decline in nutritional status and pulmonary function usually
precedes the onset of fasting hyperglycemia, it may be
beneficial to begin insulin therapy at an earlier stage.27
Observational studies have noted an increase in BMI a nd
improved measures of pulmonary function following the
initiation of insulin therapy in patients without fasting
hyperglycemia. 27·28 However, the only randomized, placebocontrolled trial to date found that although insulin therapy
improved BMI in patients with CFRD without fasting
hyperglycemia, there was no effect on pulmonary function
or frequency of lung disease exacerbations. 29 The potential
benefits of initiating treatment in patients prior to the
development of fasting hyperglycemia must be weighed
against the concern that insulin therapy will further
complicate the already demanding day-to-day self care to
which a CF patient must adhere.
Patients with CFRD are at risk of a subset of the
acute and chronic complications that occur in patients with
type 1 diabetes and type 2 diabetes. Beca use the pathophysiology of CFRD results in glucagon deficiency in
combination with residual endogeno us insulin secretion,
diabetic ketoacidosis is unexpected, and in fact has only
rarely been reported .30 ·31 As in all patients treated with
insulin, hypoglycemia is a treatment related concern.
Despite glucagon deficiency, patients with CFRD have not
shown an increased propensity for severe hypoglycemic
episodes, as they are able to generate a sufficient adrenergic
response to hypoglycemia.13 Chronically, patients with CFRD
are at risk of developing the microvascular compli cations of
diabetes. In patients who have had CFRD with fasting
hyperglycemia for at least ten years, rates of peripheral
neuropathy and diabetic retinopathy occur at a frequen cy
that approaches that seen in patients who have had type 1
diabetes for a similar duration; however, the severity of
both complications tends to be milder in CFRD. 26·32 There is
a high prevalence of mi croalbuminuria in patients with
CFRD but progression to renal failure is rare. 33 Screening for
diabetic nephropathy is complicated by the fact that many
CF patients regularly take medications known to be nephrotoxic and so the cause of the high frequency of microalbuminuria may be due to factors other than diabetes. 26 •34
Patients with CFRD do not appear to be at risk for the
macrovascular complications of diabetes, presumably

because of the low frequency of hypertension and dyslipidemia in th e CF population.32
Due to the decreased life expecta ncy of patients with
CFRD in compariso n to CF patients without diabetes, the
developm ent of CFRD has generally been regarded as a poor
prognostic indicator. However, the gap between the median
survival age of CF pati ents with and without CFRD is
beginning to narrow. Earlier diagnosi s and treatment has
bee n credited with thi s improved outlook. 3 This suggests
that routine scree ning and early initiation of insulin therapy
to achieve tight glycemic con trol may be important to
prevent the development of microvascular complications
during th e longer survival period. Howeve r, there is a lack
of randomized trials investigating the impacts of di agnostic
an d treatment strategies. Desp ite the increased life expectancy that advances in medical care have afforded pati ents,
CF remains a fatal disease. As patients ap proach end of life,
the goals of CFRD treatment should presumably transition
to controlling hyperglycemic symptoms while minimizing
the burden of treatment.
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Insulin glarglne

Prescribing Summary
Patient Selection Criteria
THERAPEUTIC CLASSIACATION: Antidiabetic Agent: Long-acting Recombinant Human Insulin Analogue
INDICATIONS AND CLINICAL USE
LANTUS ~nsulin glargine injeclion [rONA origin]) is anovel recombinant human insulin analogue indicated
tor once-daily subcutaneous administration in the treatment of patients over 17 years of age with Type 1
or Type 2diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.
LANTUS is also indicatedin the treatment of pediatric patients with Type 1diabetes mellitus who require
basal ~ong-acling) insulin for the control of hyperglycemia.
CONTRAINDICATIONS
LANTUS (insulin glargine injeclion [rONA origin]) iscontraindicated inpatients who are hypersensijive to
thisdrug or to any ingredient in the formulation or component of the container. (For acomplete listing,
see DOSAGE FORMS, COMPOSITION AND PACKAGING sections of the Product Monograph.)
SPECIAL POPULATIONS
Pregnant Women: Teratogenic effects: Patients wijh diabetes should be advised to inform their doctor if
they are pregnant or are contemplating pregnancy. There are no well-controlled clinical studies of the use
of insulin glargine in pregnant women. Only alimijed number of pregnancies were exposed during Post
Marketing Surveillance wM insulin glargine.As wM other insulins, adverse pregnancy outcomes did not
indicate any trends suggesting alink to insulin glargine. Insulin requirements may decrease during the
first trimester,generally increase during the second and third trimesters,and rapidly decline after delivery.
careful monitoring of glucose control is essential in such patients.
Nursing Women: nis unknown whether insulin glargine is excreted in significant amounts in human
milk. Caution should be exercised when LANTUS is administered to anursing woman. Lactating women
may require adjustments in insulin dose and diet
Pediabics (>6 years of age): Safety and effectiveness of LANTUS have been established inchildren over
6years of age wM Type 1diabetes mellitus.
Geriabics (>65 years of age): In clinical studies, the only difference in the elderly subpopulation
compared to the entire study population was an expected higher incidence of cardiovascular events in
both insulin glargine and NPH human insulin-treated patients.Hypoglycemiamay be difficun to recognize
in the elde~y. The initial dosing, dose increments, and maintenance dosage should be conservative to
avoid hypog~cemic reactions.Progressive deterioration of renal function may lead to steady decrease In
insulin requirements. careful glucose mon~oring and dose adjustments of insulin or insulin analogues
including LANTUS may be necessary.

Safety Information
WARNINGS
Hypoglycemia is the most common adverse effect of insulin, including LANTUS.As with alllnsulins, the
timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is
recommended for all patients with diabetes.
Any change of insulin should be made cautiously and only under medical supervision. Changes in insulin
strength, timing of administration, manufacturer, type (e.g., regular, NPH, or insulin analogues), species
(animal, human), or method of manufacture(recombinant DNA vs. animal-source insulin) may result in
the need for achange in dosage. Concomitant oral antidiabetic treatment may need to be adjusted. As
wM all insulins, when transferring to LANTUS, the e~y warning symptoms of hypoglycemia may be
changed, be less pronounced, or absent The prolonged effect of subcutaneous LANTUS may delay
recovery from hypoglycemia.
LANTUS must not be mixed with any other insulin or diluted with any other solution. nLANTUS is
diluted or mixed, the solution may become cloudy, and the pharmacokinetic/pharmacodynamic profile
(e.g., onset of action, time to peak effect) of LANTUS and/or the mixed insulin may be altered in an
unpredictable manner.
PRECAUTIONS: General: LANTUS Onsulin glargine injeclion [rONA origin]) is not intended for intravenous
or intramuscular administration. The prolonged duration of activ~ of insulin glargine is dependent on
injection into subcutaneous tissue.Intravenous administration of the usual subcutaneous dose could result
in severe hypoglycemia.

Hypog~cemia may occur ~ the insulin dose is too high in relation to the insulin requirement (see
Hypoglycemia seclion below). The use of too low insulin dosages or discontinuation of treatmen~
especially in Type 1 diabetes, may lead to hyperglycemia and diabetic ketoacidosis. Uncorrected
hypoglycemic or hyperglycemic reactions can cause loss of consciousness,coma, or death.
Hypoglycemia: As with all insulin preparations, hypoglycemic reaction, especially during initiation of
therapy, may be associated with the administration of LANTUS. Hypoglycemia is the most common
adverse effect of insulins. Ea~y warning symptoms of hypoglycemia may be differen~ be less pronounced
or absent under certain conditions, as for example, in patients whose glycemic control is markedly
improved, in elderly patients, in patients where an autonomic neuropathy is present, in patients whose
hypoglycemia is developing gradually, in patients with a long history of diabetes, in patients with
psychiatric illness, or in patients receiving concurrent treatment with certain other drugs such as beta·
blockers. Hypoglycemia may occur wM other substances including alcohol and psychiatric medications,
street drugs, birth control pills, injeclions and patches (see DRUG INTERACTIONS, Drug-Drug
Interactions). Such situations may result insevere hypoglycemia (and possibly, loss of consciousness)
prior to patients' awareness of hypoglycemia.
The time of occurrence of hypoglycemia depends on the action profile of the insullns used and may,
therefore, change when the treatment regimen or timing of administration ischanged.
As wM all insulins, additional caution (including intensified blood glucose monijoring) should be exercised
inpatient populations who are at greater risk for clinically significant sequelae from hypog~cemic episodes.
Injection Site and Allergic Reactions: As wM any insulin therapy, lipodystrophy may occur at the
Injection site and delay insulin absorption. Other injection sije reactions with insulin therapy include
redness, pain, itching, hives, swelling, and inflammation. Continuous rotation of the injection site within a
given area may help to reduce or prevent these reactions.Most minor reactions to insulins usually resolve
in afew days to afew weeks.
Immediate-type allergic reactions are rare. Such reactions to insulin (including insulin glargine) or the
excipients may, for example,be associated wM generalized skin reactions, angioedema, bronchospasm,
hypotension, or shock and may be l~e-threatening.
ADVERSE REACTION SERIOUSNESS AND INCIDENCE (see full listing)
Type 1and Type 2Diabetes in Adults: The adverse events most commonly associated wM LANTUS
(insulin glargine injection [rONA origin]) include the following: Body as a whole: allergic reaction;
Hypoglycemia; Skin and appendages: injection site reaction, lipodystrophy, pruritus, and rash; Other:
antibodies formation; Eyes: A marked change in glycemic control may cause temporary visual
impairment, due to temporary alteration in the turgidijy and refractive index of the lens.
Type 1 Diabetes in Children and Adolescents: Study 3003: The most commonly reported event was
lipodystrophy, aknown consequence of insulin injections. The intensijy was mostly mild. Injection sije
events were assessed as possibly related in 9 (5.2%) LANTUS subjects and 5 (2.9%) human NPH
subjects. However, none of these subjects discontinued due to these events.
Study 3013: Extension of Study 3003, uncontrolled long-term follow-up study of 143 patients who were
well controlled on LANTUS from 3003,for 201-1159 days.The most common adverse events were upper
respiratory infections, infection, and rhinitis. Note that when comparing safety findings between studies,
the difference in length of exposure needs to be kept in mind.
Study 4005: Controlled, randomized, double-crossover. 26 subjects (age range 12-20), regimen of LANTUS
+lispro vs.human NPH +human regular.Adverse events were equally distributed between the two treatment
regimens.The most common adverse events were upper respiratory tract infection and gastroenteritis.
To report an adverse event,contact Canada Vigilance by toll-free telephone:1.866.234.2345,toll-free fax:
1.866.678.6789, online: www.healthcanada.gc.ca/medeffect,or email: canadaVigilance@hc-sc.gc.ca; or
contact sanofi-aventisCanada Inc., Laval, Quebec H7L 4A8, at 1.888.852.6887.

Administration
Dosing Considerations: LANTUS (insulin glargine injection [rONA origin]) is anovel recombinant human
insulin analogue. Its potency is approximately the same as human insulin. nexhibits aglucose-lowering
profile with no pronounced peak with aprolonged duration of action that permijs once-daily basal dosing.
LANTUS is administered subcutaneously once aday. nmay be administered at any time during the day
as long as it is administered at the same time every day.
The desired blood glucose levels as well as the doses and timing of antidiabetic medications must be
determined and adjusted individually.
Dose adjustment may be required, for example,if the patient'stiming of administration,weight or l~estyle
changes or other circumstances arise that increase susceptibility to hypoglycemia or hyperglycemia (see
WARNINGS and PRECAUTIONS,Hypoglycemia).The dose may also have to be adjusted dunng Intercurrent
illness (see WARNINGS and PRECAUTIONS, Intercurrent Conditions). Any change in insulin dose should
be made under medical supervision.
The prolonged duration of activity of LANTUS is dependent on injection into subcutaneous space.LANTUS
is not intended for intravenous or intramuscular administration. Intravenous adm1mstration of the usual
subcutaneous dose couldresult in severe hypoglycemia (see WARNINGS and PRECAUTIONS).
In cases of insufficient glucose control or a tendency to hyper· or hypoglycemic episodes, pa~ent's
compliance with the prescribed insulin regimen,injection ffies and proper injection techniques,the handling
of injeclion devices and all other relevant factors must be reviewed before dose adjustment IS conSidered.
Blood glucose monijoring isrecommended for all patients wM diabetes.
. . .
LANTUS must not be used for the treatment of diabetic ketoacidosis. Intravenous short-actmg msuhn
should be the preferred treatment.

Recommended Dose and Dosage Adjustment Initiation of wmJS therapy: In clinical studies with
insulin-naive patients with Type 2 diabetes, lANTUS was started at a dose of 10 Uonce dai~. and
subsequently adjusted according to the patient's needs [see CLINICAL TRIALS section of the
Product Monograph).
Changeover to LANTUS: When changing from atreatment regimen with an intermediate or long-acting insulin
to aregimen with LANTUS, theamount and timing of short-acting insulinor fast-acting insulinanalogue or
the dose of any oral antidiabetic drug may need to be adjusted secondary to the risk of hypoglycemia. In
clinical studies when patients were transferred from once-daily NPH human insulin or ultralente human
insulinto once-dailyLANTUS,the initial dose was usuallynot changed.
However, instudies when patients were transferred fromtwice-daily NPH human insulinto LANTUS once
daily,the initial dose (U) was usually reduced by approximately 20%[compared to total daily Uof NPH human
insulin) andthenadjusted based on patient response.
Aprogram of close metabolic monijoring under medical supervision Isrecommended during transfer and in
the initial weeks thereafter. The amount and timing of short-acting insulinor fast-acting insulin analogue may
need tobe adjusted.Thisisparticulartytrue for patients with acquired antibodies tohuman insulinneeding
high-insulindoses and occurs with all insulinanalogues. Suchpatients may experience agreater insulin
response to LANTUS.
Wrth improved metaboliccontrol and resulting increase ininsulinsensijivity, further adjustment of the dose
of lANTUS and other insulins or oral antidiabetic drugs inthe regimen may become necessary.
Administration: LANTUS is administered by subcutaneous injection.The injection area must not be rubbed.
As with all insulins,injection sites within an injection area [abdomen,thigh or deltoid) must be alternated from
one injection to the next Patients should be rigorous with site rotation secondary to prolonged deposijion.ln
clinical studies, there was no relevant difference in insulin glargine absorption after abdominal, deltoid, or
thigh subcutaneousadministration. As for all insulins,therate of absorption,and consequentlytheonset and
duration of action, may be affected by exercise and other variables.
Preparation and Handling: LANTUS isaclear solution, not asuspension.
Parenteral drug products shouldbeinspected visuallyprior toadministration whenever the solution and the
container perrnit. l.ANTUS must onlybe used ~the solution isclear and colourtess with no particles visible.
To minimize local irrijation at the injection sije, it is recommended to allowthe insulin to reach room
temperature before injection.
Cartridge version only: ~ the injection pen malfunctions, LANTUS may be drawn from the cartridge into a
U100syringe and injected. Anew sterile syringe must be used.
Mixing and Diluting: LANTUS must not be mixed with any other insulin. Mixing can change the time/action
profileof LANTUS and cause precipitation.
LANTUS must not be diluted. Diluting can changethe time/action profile of l.ANTUS.
LANTUS [insulin glargine [rONA origin]) 100 unijs per mL [U100)isavailable inthe following package sizes:
• 10-ml vials.
• 3-ml cartridges in package of 5, for use wijhinjectionpens suitablefor lANTUS cartridges as
recommended inthe information provided bythe injection pen manufacturer only.
• 3-ml SoloSTAR' (pre-filleddisposable pen), package of 5.

Supplemental Product Information
PRECAUTIONS
HepaticiBillary/Pancreas: Alllwgh srudies have ool been performed n patJeots wllh diabe1es illd hepatic rnpalrmen~ lNffiJS
r~ may be dlmr.tmed due to re<iJced capacity lor ~ucooeogeoesls and reruced hwf11 melabollsm.
Immune: nsuin admijsbaUor may causa lrlSlJiil ~ to lorm. n dlrkal stOOies, antilodles lhal aoss-react wllh 11Jma1 klsuin and
iWn g~;rg~~e W!l'e OOserved n bolh NPH lllman nsuin illd iWil pgile trealmert ~ wllh smila' pe-cerrtages r1 ix:reased illd
decreased lAres. TlliJe was oo cooelaUor n eilhEJ treallnoot gr~ bei'M!el1 roeases or decreases n these a1tDldy ~~res illd dlanges n
elltoer A1c or trolllnsUil re<JJrements. n limy,llwl presence r1 su:h iWn lllllbolfe may re:ess1tate adjustment ol llwl W&Jin dose ~ or1ler
ID cooed a temerq 10 hyperglycem~ or hypoglycemia, bUt has oo1 been IIUld on review ol lNffiJS dlrkal trials illd available
~data.

ln1ercunen1 Coodltlons: i'aJi1

r~

may be aftered !Lmg rrterwrent antllons su:h as i'llectirl or itJess, emotiroal

llsbJtmces, or slress.
Renal :~ s1001es have oo1 been pel1ormed In patients wllh dlabeles and rmallmpalrment.WffiJS requremeo~ may be drnilisl'ed

we ID reruced mJii1 metabalsm Ca-elul ~ monilorilg illd dose ad~ olhsl*' or iWil anaklgues ndUdilg lNffiJS may

be nece5Sily il patients wllh rerel ~
As wllh all nsuln preparatilns, llwl ume COtKSe r1WffiJS acUor may vary In llf!erent lndMduals or at dilferent Urnes n llwl same ndvlrual
and !lwl rate o1 aJsorp11on ~ deperllen1 on bkiod supp~, lemperatr.re, and physl:al aellvity.
lnsutrl may I3.ISe illdl.m re1errt1on and edema. partiWarly Hprevloostj poor melabollc cootr~ ~ rnproverl by inlensllled lnsiJn itlerapy.
Pabenls wlllii.Jnm mJifl antibodies may be hyperSenlillw ID other i1sulins, wllh a rlsl< olllypol#ern~ anrlfor aoss-reaellvity.
In a dlnlcal sluay, symptoms d llypol#em~ or COLiller reg<Aatory hormone responses were similar after lntraverous lnsiJin glarglne illd
regtJar II.Jman l1sulin bolh In healthy subjects and adutt patlerrts wllh Type 1 diabeles.
When lNffiJS illd r~ ht.mM 1nsu1n were mixed kn~lely belore <iecUor n dogs, a delayed onset ol acUor illd time lo maxrnum
eflecllor regtJar 1una11 iWil was OOserved. The troll bloavallabllty ol llwl mi>Ue was also slijrlly decreased r:ornpa-ed to sepa-ate
frietiDls ollNffiJS illd regula' tunan nsulin. The relevance olltlese observa!lons n 001JS ID ii.Jmi!IIS ~ oo1 krov.lt
AOVEIISE REACTIONS

Mverse ewms lhal or:aned il a pediatric oorrlroled 1m! il at least 1'II r1 patients treated with lNffiJS are sto.\!1 n T<m~ 1.

Table 1 Ad'lem Eve~ by Body System ~1% Reported In Study 3003. (Percent IncidenCe)
·
Number (%) ol Subjects
Adveru Even! (diagnosis)
lNffiJS
1itJr1M NPH
Body System/Coded Tenn
n= 174
n= 175
Body as a whole

i'llectirl
Accklerllalinj.Jy
/obOOmnal pain
Allergic reaction
Flls,Monle
Pail in extremity
Digestive system
Gastroenteritis
Oia1toea

Sore llvoat
Endocrine symm
Oialleles mellius
Injection si1e ructions

(ieellonsitemass
(ieellonsitereaellon
llldllo site hemorrhage
Metabolic and nutritional dlsorde!S
H)1logt,-cemkreaellon'
~~

Kelosls
~

Mtrswloskeletal system
Bone lrai:Ue (rot S!lQr'daneOOS)
Bonerlsorder
Nervous system
Headadle
Resplra1Dry system
t.WEr respi'alory i'llectirl
f'har)IYlilis
ltlnltls
Bronr:hltls
SftJsl1is
Asllrna

Cooitlix:reased
Skin and appendages
ftrogaldertnati15
Sklnberql~

Eczema

Herpes mrur
ll1ic3il

24(13.8)
5(2.9)
2(1.1)
2(1.1)

31 (17.7)
4(2.3)
2(1.1)

-H
2(1 .1)

30.7)
- (-)

8(4.6)
2(1 .1)
2(1.1)

10 (5.7)
2(1.1)
- (-)

1(0.6)

4(2.3)

8(4.6)
5(2.9)
2(1 .1)

6 (3.4)
6 (3.4)
20.1)

3(1 .7)
1(0.6)
1(0.6)
3(1 .7)

7(4.0)
3(1.7)
5(2.9)
2(1.1)

3(1.7)
2(1 .1)

3(1.7)
-(-)

6(3.4)

5(2.9)

24(13.8)
13(7.5)
9(5.2)
6(3.4)
5(2.9)
1(0.6)
3(1 .7)

28 (16.0)
15(8.6)
9 (5.1)
7(4.0)
5 (2.9)
2(1 .1)

1(0.6)
1(0.6)
2(1 .1)
2(1 .1)
2(1 .1)

2(1 .1)
2(1 .1)
1(0.6)
1 (0.6)

-H

-H

-H

• 101-serixrs h)!xlglytem~ eplsOOes ara reprted separalely.
Patlerrls In !lwl pedia!Jic dllical trials r1WffiJS 1'1!1'1 trealed wllh a 11Jma1 NPII-based r~ presludy, and patlerrls asslplto receive
human NPH clmg !lwl s1uay lle!FJ1 s1udy trea1mert on h same tunan NPH regimen they had tMI prBSlUdy.Tlis may have been a lactor
n ""' roeased lnckleoce r1 ~~ seen n lAHTIJS-trealed patierts clmg lbUI oot ~~ ritiaJ tilrm1 n these trials, as M
roease ~ hypoglycemia may be expecled when switdlilg from one nsulil to anohir and tib'aliri;J llwl dose ct llwl new ilsulil.
Injection Site: Reportsr1 rjection sitepalnwere more~81J,en1v.flh lNffiJS lt1an NPH II.Jman i1Sl.i1 (2.711 nsutlnglargl'le vs. O.llltunan
NPH). The rep<IIS o1 pain at !lwl llldllo site 1'1!1'1 LW!Iy mid illd rid not resun n rlisalriilraliln r11herapy. Other posslllf nelated
treatment~ (ieCIIon site rear:1lorls or:aned a1 similar nddences wllh both iWn ~ illd NPH II.Jman lnsulil.
Eyes: Long-term Improved !1Yeemlc con1ro1 decreases llwl r1s1< r1 ~ r1 dllbetlc relincJ!lalhy. However, as lor all nsun regknens,
ilteoslllca!lon o1 iWin 111erapy wllh a1rup1 knprovement n !1Yeemic corto1 may be associated v.flh temporary worsenilg ct
dllbetic retiqmhy.
n patients wllh prolferalive retilopalhy, par1iculartf Kootlreated With ~ severe h)!xlgt,-cemk episodes may reSlit n
l1anSieol amaurosis.
Retlnopalhy was evaluated n llwl drkal sWes by means d reliral adveBe events reprxted illd hlldus ptotography.The rllmbers ol retilal
adVerse everis reprted lor lNffiJS illd tunan NPH treatment~ 1'1!1'1 sknllar lor patients v.flh Type 1and Type 2diabetes. i'ro!resslon
ol relnlpalhy was nvestlgaled by luW; ~ U!ilg a plilg protocol derived from llwl Early Treatmeol 0~ Relirqlalhy SMiy
(ETDRS).In one rftllcal s1Udy lnllllltlg patlerrls wllh Type 2 diabeles, a llf!erence In llwl rmber ol subjem wllh 23-step progression In ETllRS
sc3e over a &-monl!l period was noled by hlldus ~ (7 5'111 n lNffiJS Qrot.ll vs. 2.7'111 n human NPH treated 9rrll.lll-The owrail
relevance ollhls isolated lillir9 omo1 be determr.ed we iD llwl smal ntlrlber o1 patients ilvol.-ed. llwl stmlollow-141 perbd, illd llwl lac!
tllallhls llndi1g was oot observed n other diical studies
DRUG INTERACTIONS: Arvrnber ol Sl.lls1aA::es allecl gl.alse melabollsm illd may reiJ)ie lnsuil'l dose ac!ustmeol and particularly
OOse mriorlng.
Orug-Orug ln1eractlons: Substances that may Increase the blood-glucose-lowering effect end susceptibility to hypoglycemia,
lor emple. oral ~ jXOOtdS, ta W1ililors. ~. !bates, !Ulxetlne, t.Wl ilhllitors. pentoKifyli:le, propoxjltlene,
salicylates, malostllln analogue (e.g ,octreotlde). sullonamlde lllllbkltlc1
Substances that may rt<luce tha blood-glucose-lowering effect. lor example: cortlco5terolcls, danalol, rjazoxlde, dliletlcs,
sympalhlmlmetlc agtrrts (eg., ~. sa11utamo1. terOOilllne), ~- i!mlazil, pheooiNazile derlvalives, scrnalro!*l. lh)roil
hormones, eslrogeoS, progestogeos (e g. n oral corrtrar:eptlves), protease ilhllitors and atypical antlpsyctotlc medlcatOOs (e.g., IJiivllajb
illdcklmplne)
Bela-bklckers, cton~ine. littium salts, and alcoOOI may eilher poleotiate or weaken llwl blood-glucose-lowerilg eHecl o1 ilsull\. Penlam~ne
may cause h)!xlgt,-cem~. wtW:h may sometimes be lolklwed by hypergt,-cemla. n addiUor, ll1der llwl i1l'lleoce r1 sympatrolytlc medicinal
prociJcts such as beta-llklckeffi. donldile, gwnethldine, and~- llwl signs ol hypoglycem~ may be rerM:ed or <ilsen1.
Other lnteracUons: lnleractklns wllh lood, OOrtlal proWcts, and laborat~r~ t~ have oot been eslabllshed.
OVERDOSAGE: Symploms: An excess ollnsulil relative to lood ntake, energy e)(jlerlditlre or both may ~ to severe illd sometim!IS
prolorY,jed illd lde-ltreatenlr.J hypoglycemia (see WARNINGS illd PRECAUTIONS).
Management Mild episodes d h)!xlglycem~ can uswlly be ~ealed v.flh oral carbohydrates. AlfitJStmeols In aug dosage, meal patterr6, or
exercise may be needed.
More severe episodes wil!1 coma. seizura, or netlOilglc rnparmenl may be treated wllh lntramusariar/suliaJtnlous gkrcagon or
r:orcentrated ntraverous gU:ose.
Alter apparent dkllcai reoovery from h)!xlglytemla, oonlilled obsavaliJl illd additilnal r:albol1ylhle Intake may be necessary to a-QI
reor:wrence ol h)!xlgt,-cemla.
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Rapid action . Mealtime efficacy.

Prescribing Summary
Patient Selection Criteria
THERAPEUTIC CLASSIFICATION: Antidiabetic Agent: Short-acting Recombinant
Human Insulin Analogue
INDICATIONS AND CLINICAL USE:
APIDRATlo! (insulinglulisine [rONA origin]) is a recombinant human insulin analogue
indicated for the treatment of adu~ patients with Type 1or Type 2diabetes mellitus
where treatment wtth insulin is required.
APIDRATlo! has a more rapid onset of action and a shorter duration of action than
regular human insulin. APIDRATlo! should normally be used in regimens that include
a longer-acting insulin or basal insulin analogue to maintain adequate glucose
control (see ADMINISTRATION, Dosing Considerations). API ORA'" can also be used
wtth oral hypoglycemic agents.
CONTRAINDICATIONS:
APIDRATlo! (insulin glulisine [rONA origin]) is contraindicated in patients who are
hypersensitive to this drug or to any ingredient in the formulation or component of
the container. (For a complete listing, see DOSAGE FORMS, COMPOSITION, AND
PACKAGING section of the Product Monograph.)
SPECIAL POPULATIONS
Pregnant Women:
There are no well-controlled clinical studies of the use of APIDRA'" in pregnant
women. Animal reproduction studies have not revealed any differences between
APIDRA'" and human insulin regarding pregnancy, embryonaVfetal development,
parturition, or postnatal development.
It is essential for patients wtth pre-existing or gestational diabetes to maintain good
metabolic control before conception and during pregnancy. Insulin requirements may
decrease during the first trimester and generally increase during the second and third
trimesters. Immediately after delivery, insulin requirements decline rapidly.
Careful monttoring of glucose control is essential.
Patients wtth diabetes must infomn their doctor if they are pregnant or are
contemplating pregnancy.
Nursing Women:
It is unknown whether APIDRATlo! is excreted in human milk. Many drugs, including
human insulin, are excreted in human milk. For this reason, caution should be
exercised when APIDRATlo! is administered to anursing woman. Lactating women may
require adjustments in insulin dose and diet.

Pediatrics:
Safety and effectiveness of APIDRA'" in pediatric patients have not been established.
Geriabics (~ 65 years of age):
Hypoglycemia may be difficu~ to recognize in the elderly. In Phase Ill clinical trials
(rr-2,408),APIORAllo! was administered to 147 patients~ 65 years of age and 27 patients
~ 75 years of age. The majortty of these were patients wtth Type 2 diabetes. The
change in glycated hemoglobin (A1C) values and hypoglycemia frequencies did not
differ by age, but greater sensitivtty of some older individuals cannot be ruled out.

Safety Information
WARNINGS AND PRECAUTIONS
General
APIDRATlo! differs from regular human insulin by tts rapid onset of action and shorter
duration of action. When used as a mealtime insulin, the dose of APIDRA'" should
be given wtthin 15 minutes before or wtthin 20 minutes after starting a meal.
Because of the short duration of action of API ORA'", patients with diabetes also
require a longer-acting insulin or insulin infusion pump therapy to maintain
adequate glucose control.
Hypoglycemia may occur if the insulin dose is too high in relation to the insulin
requirement (see Hypoglycemia section). The use of too low insulin dosages or

discontinuation of treatment, especially in Type 1 diabetes, may lead to
hyperglycemia and diabetic ketoacidosis. Uncorrected hypoglycemic or
hyperglycemic reactions can cause loss of consciousness, coma, or death.
Any c~a.nge of i~sulin should be made cautiously and only under medical
superv1s1on. As With other insulins, additional caution should be exercised in
patients with a long history of diabetes on insulin who might be prone to develop
hypoglycemia and in patients with a previous history of cardiac ischemic
~isorders who might be prone to develop cardiac adverse events. Changes in
msul!n stre~gth , manufacturer, type (e.g., regular, NPH, or insulin analogues), or
spec1es (ammal, human), or method of manufacture (recombinant DNA versus
animal-source insulin) may result in the need for a change in dosage.
Concomitant oral antidiabetic treatment may need to be adjusted.
As with all insulin preparations, the time course of APIDRA'" action may vary
in different individuals or at different times in the same individual and is
dependent on site of injection, blood supply, temperature, and physical activity.
Adjustment of dosage of any insulin may be necessary if patients change their
physical activity or their usual meal plan.
Glucose monitoring is recommended for all patients with diabetes.
Hypoglycemia
As with all insulin preparations, hypoglycemic reactions may be associated wtth
the administration of APIDRATlo!. Early warning symptoms of hypoglycemia may be
different, be less pronounced or absent, under certain condttions, as for example if
glycemic control is markedly improved, if hypoglycemia is developing gradually, in
elderly patients, in patients with along history of diabetes, in patients with diabetic
nerve disease, in patients using some medications such as beta-blockers, or
intensified diabetes control (see DRUG INTERACTIONS). Such sttuations may result
in severe hypoglycemia (and possibly, loss of consciousness) prior to patients'
awareness of hypoglycemia.
Severe hypoglycemia may require the assistance of another person. Patients who
are unable to take sugar orally or who are unconscious may require an
intramuscular/subcutaneous injection of glucagon or should be treated wtth
intravenous administration of glucose by medical personnel. Without immediate
medical help, serious reactions or even death could occur.
Hypoglycemia is the most common adverse effect of insulin therapy, including
APIDRA'".As with all insulins, the timing of hypoglycemia may differ among various
insulin formulations.
The time of occurrence of hypoglycemia depends on the action profile of the
insulins used and may, therefore, change when treatment regimen is changed.
ADVERSE REACTION SERIOUSNESS AND INCIDENCE (see full listing):
Adverse events commonly associated with human insulin therapy include
the following:
Body as a Whole:
Local Allergy
As with other insulin therapy, local allergy in patients may occur as redness,
swelling, or itching at the site of insulin injection. These minor reactions usually
resolve in afew days to afew weeks. In some instances, these reactions may be
related to factors other than insulin, such as irritants in a skin-cleansing agent or
poor injection technique.
Systemic Allergy
Less common, but potentially more serious, is generalized allergy to insulin,
which may cause rash (including pruritus) over the whole body, shortness
of breath, wheezing, reduction in blood pressure, rapid pulse, or sweating. Severe
cases of generalized allergy, including anaphylactic reactions, may be
life-threatening.
Localized reactions and generalized myalgias have been reported with the use of
cresol as an injectable excipient.
Hypoglycemia:
Hypoglycemia, a frequent adverse reaction to insulin therapy, may occur if the
insulin dose is too high in relation to the insulin requirement.
As with all insulins, prolonged or severe hypoglycemic attacks, especially if
recurrent may lead to neurological damage, loss of consciousness, coma, or death.
Skin and Appendages:
As with other insulin therapy, lipodystrophy may occur at the injection site and
delay insulin absorption. Continuous rotation of the injection site within a given
area may help to reduce or prevent these reactions.
To report an adverse event, contact Canada Vigilance by toll-free telephone:
1-866-234-2345, toll-free fax: 1-866-678-6789, online: www.healthcanada.gc.c/
medeffect, or email: CanadaVigilance@hc-sc.gc.ca; or contact sanofi-aventis
Canada Inc., Laval, Quebec H7L 4A8, at 1-888-852-6887.

Administration
Dosing Considerations
The dosage of APIDRA"' should be individualized and determined based on the
physician's advice in accordance with the needs of the patient.
APIDRA"' (insulin glulisine [rONA origin]) is arecombinant human insulin analogue that
has been shown to be equipotent to human insulin. One unit of APIDRA"' has the same
glucose-lowering effect as one unit of regular human insulin. After subcutaneous
administration it has a more rapid onset and a shorter duration of action.
APIDRA"' should be given by injection within 15 minutes before or within 20 minutes
after starting a meal. APIDRA111 should normally be used in regimens that include a
longer-acting insulin or basal insulin analogue.
APIDRA111 is intended for subcutaneous administration by injection and for use as
a continuous subcutaneous insulin infusion (CSII) in pump systems suitable for
insulin infusion.
APIDRA"' should be administered by subcutaneous injection in the abdominal wall,
the thigh, or the deltoid, or by continuous subcutaneous infusion in the abdominal
wall. As with all insulins, injection sites and infusion sites within an injection area
(abdomen, thigh, or dettoid) should be rotated from one injection to the next.
As for all insulins, the rate of absorption, and consequently the onset and duration of
action, may be affected by injection site, exercise, and other variables. Blood glucose
monitoring is recommended for all patients with diabetes.
Preparation and Handling
APIDRA111 must only be used if the solution is clear, colourless, with no solid particles
visible, and if it is of awater-like consistency.To minimize local irritation at the injection
site, it isrecommended to allow the insulin to reach room temperature before injection.
The instructions for using the APIDRA111 in a pump or with an injection pen must be
followed carefully.
An empty vial or SoloSTAR3 must never be reused and must be properly discarded.
Vials
Before withdrawing insulin from the vial for the first time, remove the plastic
protective cap.
Do not shake the vial vigorously as this may cause frothing. Froth may interfere with
the correct measurement of the dose.
Mixing of lnsulins:
APIDRA'" can be mixed with NPH human insulin (except when administered with
pump [see below, Continuous Subcutaneous Insulin Infusion Pump]).
If APIDRA™is mixed with NPH human insulin, APIDRA™should be drawn into the
syringe first. Injection should be made immediately after mixing.
No data are available on mixing APIDRA™with insulin preparations other than NPH
human insulin.
Mixtures should not be administered intravenously.
Continuous Subcutaneous Insulin Infusion Pump
APIDRA™may be used for continuous subcutaneous insulin infusion (CSII) in pump
systems suitable for insulin infusion.
When used with an insulin infusion pump, APIDRA'" should not be mixed with any
other insulin or diluted with any other solution.
Patients using CSII should be comprehensively instructed on the use of the system
pump. The infusion set and reservoir should be changed every 48 hours using
aseptic technique.
Patients administering APIDRA'" by CSII must have an alternative insulin delivery
system available in case of pump system failure.

ADVERSE REACTIONS
.
.
•
The risk o1 all categortes ot symptomatic hypog~cem~ did not differ betWeen APIORA and shorl·acting nsulin comp;ntors In
subjects with Type I or Type 2diabetes.
lable 1 - Numbel of subjects with at leas! one episode a1 symptomatic hypogtycemla in studies In type 1 and type 2 dlalfts
!We 2 Diabetes
-Tille 1 Diabetes
Com! ratof
Glullsine
Comoatator*
Glulislne

n/N
%
n/N
n/N
n/N
5781883
84.5 5621883 63.6
5161611
85.0
7831921
StJbcutlneous lnlectlon
80.0
24130
89.7
26129
Con!Jnuous' Subcutaneous
ln1uslon
11 =number ol subjects with at least 1 episode ol hypoglycem~ N-- total number ol evaluable msubjects.
• lnsul~ l~pro, regu~r human lnsul~ t regu~ human lnsul~ ; Insulin aspart

"'

"'

ourlng dinlcal si!Jdles, there were oo dlnlcally noteworthy differencesbetWeen Insulin glul~ine and comparator 500rt·acting lnsulins
1n the overall Incidences ol adverse events. The adverse events observed were those known In this p!latmacological class and
CMseQtJefllly commor1 to nsulins.
Table 2 Com mon (~ 1%) advem drug ructions In pooled type 1 and 2 studies
Aspart
Regular Insulin
Uspro
lnsul~ Glullslne
Advem Event
n=30
~1 ,1 61
n=333
(all studies)
(% of subjects) (% of subjects)
(% of subjects)
System orvan ClasS/

-

1% :~)

Pre~Tenn

General Disorders and

~~~:dltlon
In
siteh

910.51

712.11

-(-)

-H

Metabolism and Nutrition Disorders
Hypog~cem~ NOS'

83(4.5)

22 (6.6)

~::~~~seizure
cern~ unawaoeness

Nervous Syttem DISO<Hrs
Hypog~cem~ coma

33(2.8)

2 (6.7)

16

1 t~i~

:g:~l

9~~~~

2(6.7)

49 (2.7)

13 (3.9)

19(1.6)

-H

WARNINGS AND PRECAUTIONS
HepaUc/81/lary/Pancms SI!Jdles have oot been pert(J111ed ~ palieflls with hepatic lmpalnnent. APIORA" requirements may be
diminished due to reOOced capacity lor gluconeogenesis and reduced lnsul~ me1allol~m. ~mlm loobservalloos found with otoor lnsulins.
lntercu~nt CondiUons Insulin requwements may be altered dur~g Illness, emotional d~turbances , or stress.
IIISulin Pumps
Wllen used In an external insulin pump tor subcutaneous lntuslon, APIDRA" should not be mixed wltll any other Insulin or
diluted wltll any otller solution. Patients usng external pump ln1usioo therapy Shou~ be trained apprupnately. Physicians and
patients s/iookl careful~ eval.rale ln1ormalloo or1 pomp use In the APIORA" Prodocl Mooograpll, pad(age Insert, and the pomp
maoofac1Urer'smanual.
APIORA" specillc ln1ormabor1 smuld be lolklwed lor perkld of use, frequency ol ctw.glng lntuslorl sets, or other delal~ specific to
APIORA" usage,because APIORA" specilk iltormatlorl may lfrtfer trom general or other ~sulln's pump manual lnstructlorls Pump or
ln!usioo set mallt.netioos or nsulin degradalloo can lead to hyperglycem~ and ketosb In ashort tlme. Th~ ~ especial~ pertinent lor
rapld·acting Insulin analogues that are more rapid~ absorbed and have a shorter duralloo ol aclloo. Prompt ldentfficallorl and
correciX!n olthe cause of hyperglycemia or kelo~s ~ necessary. Interim therapy wrtll subcutaneous lnjeclloo may be required (see
ADMINISTRATION, Continuous StJbaJianeous lnsulli ln1u~n Pump).
Renal The p!latmacoklnetlc properties ol APIORA" were general~ malnlaloed In subjects with renal Impairment However, as with all
lnsullns, the requirements lor APIORA" may be reduced ~ patlenls with renal lmpalnnent.
Occupational Hazards The pallenfs ability to cooceotrale and react may be Impaired as arestJII ot hypog~cemla or hyperglycem~
or, lor examp~. as aresun ol Yisuallmpalnnent This may aJOS!rtute ar~k In ~alloos where these abll1ties are ot special importance
(e g , drMng acar or operating machinery).
Patients Should be ad'llsed In lake precauUons to avoid hypoglycem~ Will~ driY~ Th~ ~ partlcularly Important in those who have
reduced or absent awareness ollhe lmling symptoms ot hypoglycem~ or have kequeot episodes ot hypoglycemia. n sOOukl be
ronsJdered wllelher n Is advlsab~ to drive or operate machinery In these c~rumstances

- (-)

Less Common Clinical Tltal Adverse Drug Ructions (<1!'1
Gastrointestinal disofdeB: nausea
General disorders administration &Ill conditions: fatigue, ~eclloo site reactilorl NOS', ~eral edema, as1tlenla, llcreased fat
tissue, lnjectklnsitestlnglng
ln1ectlons and ln1estatlons: ce~lrlis
Injury, poisoning, and procedural (complications): overdose NOS'
Metabolbm and nutrition dlsorden: hyperglycem~ NOS'
Nerwus system d~ders: par~
Skin and subcutaneous tissue dltorders: lipodystrophy acquired
• Not otherwise ~
DRUG INTERACTIONS:
Onrg·Orug lntmctions The lol~wtng are examples ot potential drug-drug Interactions that may OCctJr with APIORA" treatment:
Table 3- Established or potentlal dnrg·dnrg Interactions
Proper name
Ref
Effect
T
Oral antidiabetic agents
May enhance the blOod·
ACE Inhibitors
glucose·~werlng etfect
and lrlcrease susetptlbllity
O~yram lde
to hypoglycem~
Flbrates
Auoxetlne
MADinhiMors
Pentoxitylllne
Propolf)llhene
Sallc)1ales
sunor1amlde li'rtlblotlcs
T
May reduce the bloodCor11costerolds
Oanazol
glucose·klwerlng etfed.
Olazoxlde
May enhance or dectease
Okretlcs
the nsulin requirements
GlucagM
Isoniazid
Estrogens and progestogens
(e g., In oral contraceptives)
Phenothiazine derivatives
Somatropln
Sympalhomlmetlc agents
(e.g., eplnepllrlne, sallutamol,
lerbutallne)
Protease Inhibitors
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May cause hypoglycemia, Wlllch
may sometimes be lol~wed by
hyperg~cemla

Supplemental Product Information

%
65.5

Sympatholytic medicinal products
such as bela·b~ckers, cloniOine,
guanethidine and reserpine

T

Thes~ns ot hypog~cemla may be
reduced or absent

May require dose monnortng ot blood glucose
level and dose adjustment (Increase or
dectease) ot APIORA"
May require dose monnortng ot blood glucose
level and dose adjustment Qncrease or
decrease) ot APIORA"
May requiredose monnortng ot blOod glucose
level and dose adjustment pncrease or
decrease) ot APIORA"
May require dose monilortng ol blOod glucose
level and dosage adjustment (lnQ'llilse or
decrease) of API ORA••

l egend: T= Theoretical
Onrg·Food tnteracUons lntetac#ons wrth food have not been estllbl~hed.
Onrg·HertJ lntersctlons lnteraclloos wtth herflal products have not been estllbllshed.
Onrg·uboratory tnteracUons lntetactlons wfflllaboratory lests have not been estJJblfshed.
OVEROOSAGE
Hypoglytemla may OCQJr as aresun ot an excess ot Insulin relative tolood intake, energy exposure, or both.
Mil4fmoderate episodes ot hypoglycem~ can usual~ be treated with oral carbohydrates. All)ustments 1o dosage olthe medicinal
product, meal patterns, or physical activity may be needed.
Severe ep~es with coma, seizure, or neurolog~ lmpalrrnen1 may be ~eated with lntramuscularlsubculaneous glucagon or
CMcentraled Intravenous glucose.
Sustained carbohydrate Intake and observation may be necessary because hypog~cem~ may recur aner apparent dlnlcal recovery.
Product MOflOQraph available or1 request or at www.sanotl-aventls.ca.
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type (insulin lispro, regular, NPH, etc.), species (beef, pork, beef-pork, human). and/
or method of manufacture (recombinant DNA versus animal source insulin) may
result in the need for a change in dosage.
PRECAUTIONS
General: Humalog~~~> (insulin lispro injection) had a similar safety profile to
Humulin~~~> R over the course of the clinical studies although its efficacy has not
been studied in clinical trials beyond one year. Humalog~~~> has been shown to control

25% insulin llspro injection (rONA origin)
75% insulin lispro protamine suspension

50% insulin lispro injection (rONA origin)
50% insulin lispro protamine suspension

Suspension for Injection, Lilly Standard
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PRESCRIBING SUMMARY

PATIENT SELECTION CRITERIA
INDICATIONS AND CLINICAL USE
(insulin lispro injection), Humalog~~~> Mix25® (25% insulin lispro injection,
75% insulin lispro protamine suspension), and Humalog Mix50®(50% insulin lispro
injection, 50% insulin lispro protamine suspension) are indicated for the treatment
of patients with diabetes mellitus who require insulin for the maintenance of normal
glucose homeostasis. Humalog~~~> insulins are also indicated for the initial stabilization
of diabetes mellitus. Humalog ~~~> (insulin lispro injection) is a short-acting insulin
analogue and is for use in conjunction with a longer-acting human insulin, such as
Humulin~~~> N except when used in a subcutaneous insulin infusion pump.
Humalog~~~>

CONTRAINDICATIONS
The Humalog~~~> (insulin lispro) family of insulins are contraindicated during episodes
of hypoglycemia (for details see SYMPTOMS AND TREATMENT OF OVERDOSAGE)
and in patients sensitive to insulin lispro or any of the excipients they contain.
SPECIAL POPULATIONS

Renal Impairment: Some studies with human insulin have shown increased
circulating levels of insulin in patients with renal failure. In a study of 25 patients
with type 2 diabetes and varying degrees of renal function (from normal to severe
impairment, including endstage renal failure) , the pharmacokinetic differences
between Humalog~~~> and human regular insulin were generally maintained. However,
the sensitivity of the patients to insulin did change, with an increased response
to insulin as the renal function declined. Careful glucose monitoring and dose
adjustments of insulin, including Humalog~~~> , may be necessary in patients with renal
dysfunction.
Hepatic Impairment: Some studies with human insulin have shown increased
circulating levels of insulin in patients with hepatic failure. In a study of 22 patients
with type 2 diabetes, impaired hepatic function did not affect the subcutaneous
absorption or general disposition of Humalog~~~> when compared to patients with no
history of hepatic dysfunction. In that study, Humalog® maintained its more rapid
absorption and elimination when compared to human regular insulin. Careful glucose
monitoring and dose adjustments of insulin, including Humalog~~~>, may be necessary
in patients with hepatic dysfunction.
SAFETY INFORMATION
WARNINGS

Due to their quick onset of action, the Humalog~~~> (insulin lispro) family of insulins
should be given within 15 minutes before a meal.
When necessary, Humalog~~~> (insulin lispro injection) may be given shortly after a meal
instead (within 20 minutes of the start of the meal). When used in a subcutaneous
insulin infusion pump, Humalog~~~> should not be diluted or mixed with any other insulin.
Patients should carefully read and follow the insulin infusion pump manufacturer's
instructions and the INFORMATION FOR THE PATIENT insert before use.
Hypoglycemia is the most common adverse effect associated with insulins, including
the Humalog~~~> family of insulins. As with all insulins, the timing of hypoglycemia may
d1ffer among various insulin formulations. Glucose monitoring is recommended for
all patients with diabetes.
Any change of insulin or human insulin analogue should be made cautiously and
only under medical supervision. Changes in purity, strength, brand (manufacturer),

hemoglobin A1C levels as effectively as human insulin in comparator studies
specifical ly designed to study meal-time therapy without optimization of basal
insulin regimens. Once a patient Is using Humalog~~~> , reassessment and adjustment,
as necessary, of the basal insulin regimen (dosage and number of injections) have
been shown to optimize overall glycemic control.
ADVERSE REACTIONS
Rarely, administration of insulin subcutaneously can result in lipoatrophy (depression
in the skin) or lipohypertrophy (enlargement or thickening of tissue). Patients should
be advised to consult their doctor if they notice any of these conditions. A change in
injection technique may help alleviate the problem.
To report any adverse events, please contact Eli Lilly Canada Inc. at 1-888545-5972.
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ADMINISTRATION

DOSAGE
The dosage of Humalog~~~> (insulin lispro injection), Humalog~~~> Mix25® (25% insulin
lispro injection, 75% insulin lispro protamine suspension), or Humalog Mix50®(50%
insulin lispro injection, 50% insulin lispro protamine suspension) is determined by a
physician in accordance with the requirements of the patient.
Although Humalog~~~> insulins have a quicker onset of action and shorter duration of
activity, dosing is comparable to regular human insulin. The dosage of a Humalog~~~>
insulin, like all other insulin formulations, is dependent upon the individual patient
requirements. The dose and number of insulin injections should be adjusted to
maintain blood glucose concentrations as close to normal as possible.
Additional adjustment of dosage may be required in diabetes patients with renal
impairment, during intercurrent illness and/or emotional disturbances.
Adjustment of dosage may also be necessary if patients undertake increased
physical activity or change their usual diet.
New Patients: Patients receiving insulin for the first time can be started on a
Humalog~~~> insulin in the same manner as they would be on animal-source or human
insulin.
Patients should be monitored closely during the adjustment period.
Transfer Patients: When transferring patients to a Humalog~~~> insulin, use the same
dose and dosage schedule. However, some patients transferring to a Humalog~~~>
insulin may require a change in dosage from that used with their previous insulin.
Analysis of a database of type 1 diabetic patients indicated that basal insulin
requirements increased by 0.04 U/kg, while Humalog~~~> requirements decreased by
0.03 U/kg , after one year of treatment. For type 2 diabetic patients, both short-acting
and basal insulin requirements increased slightly after one year of treatment with
both Humalog~~~> and Humulin~~~> R.
Optimizing Glycemic Control: In order to achieve optimal glycemic control,
changes in total daily dosage, the number of injections per day, and/or timing of
injections may be necessary when using a Humalog~~~> insulin.
Once a patient is using Humalog~~~>, reassessment and adjustment, as necessary, of
the basal insulin regimen (dosage and number of injections) have been shown to
optimize overall glycemic control.
STUDY REFERENCES

1. Humalog~~~>JHumal og~~~> Mix25®JHumalog
Canada Inc. June 11 , 2009.

M ix5o~~~>

Product Monograph, Eli Lilly

SUPPLEMENTAL PRODUCT INFO
THERAPEUTIC CLASSIFICATION

Anti-Diabetic Agent
PHARMACOLOGY

Humalog'"
Humalog'" Onsulln llspro Injection) Is absorbed more rapidly than regular soluble Insulin from s.c. sites of injection and
also has a shorter duration ol action. Due to its quick onset of action, Humalog'" should be given within 15 mmutes

before a meal When necessary, Humal~ may be given shortly after a meal instead (w1thin 20 minutes of the start
of the meaQ
s.c. Injected regular 1nsuhn typically results In serum insulin concentrabons that peak later and remain elevated for
a longer time than those following normal pancreatic insulin secretion In non-diabetics. When regular insulin Is used
to control postp<and1al blood glucose, adequate control 1s often not achieved because the amount of regular Insulin
needed to normalize postprandial glucose excursion often leads to late hypoglycemia. By producing more rapid and
higher serum Insulin concentrations with a shorter duraMn of activity (2 to 5 hOurs), Humalog• decreases glucose
excursion dunng and aher meals with less chance for hypoglycemia.
A glucose clamp study was performed, In healthy volunteers, in which a 10 U dose of Humalog• was compared
to Humunn• R. Doses were g1ven s c.; an add1bonal 10 u dose of 1.v. regular Insulin was given as an absolute
reference.
Humalog• shOwed statistically higher peak concentrations (C,.,J which occurred earlier than Humulln• R (L...). Total
absorptiOn was comparable, with area under the curve (AUC) values of serum concentration vs lime wh1ch were not
statistically different (see Table 1 and Table 2).
Table 1: Humatog"
Pharmacokinetics of Humalog• Compared with Humulln• R In Healthy Volunteers
Mean:tSD

Humalog"

Humulln" R

t...(mln)

53:t30

101±40

C...(ng/ml)

320:t1 .33

1.79:t0.77

AUC (ng•min/ml)

380:t52 2

423:t71 .8

Table 2: Humalo
Pharmacodynamics of HumalogS Compared with Humulln" R In Healthy Volunteers
Mean:tSD

Humalog"

Humulln" R

Duration ol Achon (h)'

3.5-4 75 h

5.0-7.5h

Onset ol Action lhr

0.5-0.75 h

0.5- t.Oh

Time ol Maximum Effect (hr

0.75 -2.5 h

0.75-45h

a Results predicted from a pharmacokinetic-pharmacodynamlc link model.
Subsequent pharmacokinebc studies in type 1 patients confirmed that a Significantly faster Increase in serum
Insulin levels and a shorter plasma hall-life resulted !rom an Injection ol Humalog" when compared to Humulln• R
(see Rgure 1j.
Figure 1: Hum alog"
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Mean Serum Insulin Concentrations In Type 1 Patients Following Injection of Humulln" R and Humalog"
(Basal 0.2 mU/mln/kg Insulin lrrfuslon)
Postprandial and overall glycemic control
In clinical studies alter 1 year, the decrease In glucose excursion during and alter meals with Humalog• was
consistent, although not always significant, when compared to Humulln• R. However, there was no significant
difference In hemoglobin A1Clevels between the two treatment groups. These studies were specifically designed to
study meal-time therapy without optimization ol basal Insulin regimens.
Subsequent clinical studies have demonstrated that In an Intensive Insulin treatment regimen with basal Insulin
optimization, Humal~ controls postprandial glucose and contributes to lower hemoglobin A1C levels to a greater
degree than regular human Insulin, withOut increasing the risk ol hypoglycemia

in to human
A few patients who have experienced hypoglycemic reactions after transfer from animal-source insul_
Insulin have reported that the early warning symptoms of hypoglycemia were less pronounced or d1ffere".' from
those expenenced With thelf previous 1nsulin. However, the counterregulatory and symptomatic (auton?miC and
neuroglycopenic) responses to hypoglycemia were studied and found to be supenmposable for Insulin lispro and
regular human insulin.
Patients whose blood glucose is greatly improved, e.g. by intensified insulin therapy, may lose_some or all of the
warning symptoms of hypoglycemia and should be advised accordingly. Uncorrected hypoglycemiC or hyperglycemic
reactions can cause loss of consciousness, coma, or death.
Renal Impairment: The requirements tor Insulin may be reduced in patients with renal impairment.
Hepatic Impairment Although impaired hepatic fu~ct10n does not affect the absorption or disposition of Humal~.
careful glucose mon~oring and dose adjustments of 1nsul1n, 1nclud10g Humalog", may be necessary.
Allergic Reaction: Prompt recognition and appropriate management of the allergic complications of Insulin therapy
are Important tor the safe and effect1ve control of diabetes mellitus. Antibodies Io Insulin are frequently cross-reactive.
Therefore patients who have demonstrated an allergic reaction to other 1nsullns may demonstrate an allergiC
reaction t~ a Humalog"' insulin. Local allergy In patients occasionally occurs as redness, swelling, and Itching ~t
the site of 1nsulin in1ectlon. This cond1hon usually resolves in a few days to a few weeks. In some Instances, th1s
condition may be related to factors other than Insulin, such as Irritants In the skfn cleansing agent or poor Injection
technique. Systemic allergy may cause rash Oncluding pruritus) over the whOle body, shortness of breath, wheezing,
reduction In blood pressure, fast pulse, or sweating Severe cases of generalized allergy may be hie-threatening (see
CONTRAINDICATIONS)
use In Pregnancy: Humalog" can be used 1n pregnancy 1f clinically indicated. Data on a large number of exposed
f)fegnancles do not Indicate any adverse effect of Humaloge on pregnancy or on the health of the foetus/newborn.
It Is essential to maintain good glucose control In both gestational diabetes and throughOut pregnancy In type 1 and
type 2 patients. Insulin requirements usually decrease during the first trimester and Increase during the second and
third trimesters.
Patients with diabetes shOuld be advised to Inform their doctor If they are pregnant or are contemplating pregnancy.
Careful monitoring of glucose control, as well as general health Is essential in pregnant patients with diabetes.
Nursing Mothers: The use of Humalog" lnsuhns In nursing mothers has not been studied. Diabetic patients whO are
nursing may require adjustments In lnsuhn dose and/or diet.
Pediatric Use: Clinical trials have been performed In children (61 patients aged 3 to 11) and children and
adolescents (481 patients aged 9 to 18 years), comparing Humalog" to regular human Insulin. Humal~ showed
bener postprandial blood glucose control while maintaining a similar safety profile.
As In adults, Humal~ shOukf be given Within 15 minutes before a meal When necessary, Humalog• may be given
shOrtly after a meal instead (wrthln 20 minutes of the start of the meal).
The safety and effectiveness of Humalog" Mlx25" (25% Insulin llspro Injection, 75% Insulin lispro protamine
suspension) and Humalog Mlx50• (50% Insulin llspro Injection, 50% Insulin llsf)fo prolamine suspension) In Children
have not been established
Orug Interactions: Drug Interactions with Insulin formulations includ1ng Humalog'" insullns may Include the
following:
Insulin requirements may be decreased In the presence of agents such as oral antidiabetic agents, sallcylales, sulfa
antibiotics, certain antidepressants (monoamine oxidase Inhibitors), beta-adrenergic blockers, alcohOl, angiotensin
converting enzyme IOhibitors and angiotensin II receptor blockers
Insulin requirements may be Increased by medications with hyperglycemic activity sUICh as corticosteroids, Isoniazid,
certain lipid-lowering drugs (e.g. niacin), estrogens, oral contraceptives, phenothiazlnes, and thyroid replacement
therapy.
Hormones that lend to counteract the hypoglycemic effects of lnsultn Include growth homnone, corticotropin,
glucocortlcolds, thyroid homnone, and glucagon. Epinephrine not only Inhibits the secretion of Insulin, but also
stimulates glycogen breakdown to glucose Thus, the presence of such diseases as acromegaly, Cushing 's syndrome,
hyperthyroidism, and pheochromocytoma complicate the control of diabetes.The hypoglycemic action of Insulin may
also be antagcnlzed by diphenylhydantoin.
Insulin requirements can be Increased, decreased. or unchanged In patients receiving diuretics.
The physician shOuld be consulted when using other medications In addition to a Humalog• Insulin.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
With the rapid onset of activity of the Humal~ Onsulln llspro) family of lnsullns, It Is Important that the Insulin
analogue be given close to mealtime (within 15 minutes before a meal). When necessary, Humalog• (insulin llspro
Injection) may be g1ven shortly after a meal Instead (within 20 minutes of the start of the meal). A significant deviation
could put the patient at risk of hypoglycemia
lnsullns have no spec1fic overdose definitions because serum glucose concentrabons are a result of complex
Interactions between Insulin levels, glucose availability and other metabolic processes. Hypoglycemia may occur as a
result ol an excess of Insulin or Insulin llspro relative to food Intake and energy expenditure or in patients who have
an Infection or become Ill (especially with diarrhea or vomiting).

Hypoglycemia

Symptoms are hkely to appear anytime when the blood sugar concentration falls below 3.0 mmolll (50 mg/1 00 ml) but
may occur with a sudden drop tn blood glucose even when the value remains above 3.0 mmolll (50 mg/1 oo ml).

The frequency of hypoglycemia was not statistiCally s1gnllicant In 1-year parallel studies (Humalog•, n=543;
Humulin• R, n=561 ), but was significantly less w1th Humalog" therapy In a 6-month crossover study 1n type 1patients
(n= 1008) which also demonstrated a significant reduction In nocturnal hypoglycemia with Humalog• .
Use In Pumps

Mild hypoglycemic eptsodes Will respond to oral administration of glucose or sugar-containing foods.

When used In subcutaneous Insulin Infusion pumps, treatment with Humalog has been shown to result In lower
hemoglobin A1Clevels compared to regular human Insulin without Increasing the risk of hypoglycemia. In clinical trials
that compared Humalog• with regular human Insulin, Humalog" consistently shOwed significant HbA 1c Improvement
In the range of 0.33% to 0.65%.
PRECAUTIONS
Visual disturbances In uncontrolled diabetes due to refractive changes are reversed during the early phase ol
effective management. However, since alteration In osmotic equilibrium between the lens and ocular fluids may
not stabilize for a few weeks alter Initiating therapy, It ISw1se to postpone f)fescrlblng new corrective lenses for 3
to 6 weeks.
Addibonal adjustment of dosage may be reqwred during Intercurrent Illness and/or emotiOnal disturbances such
as stress
Any rapid - or shOrt-acting 1nsulln formulation shOuld be used with caution 1n pahents with gastroparesls However,

some patients w1th gastropares1s may benefit from postprandial administration ol Humalog•, which has been shOwn
to PfOVIde postprandial glycemic control similar to that provided by human Insulin Injected 30 minutes pre-prandlally.
Using the postprandial dosing awoach. the Insulin dose can be adjusted according to the actual caloric Intake and/
or the observed rise In blood glucose following a meal.
Transferring Patients from Othe~ lnsullns: Patients taking a Humalog" Insulin may require a change In dosage
from that used with thelf usual lnsul1ns. lf an adjustment Is needed, It may occur with the first dose or dunng the first
several weeks or months.

Hypoglycemia may be associated with listlessness, confusion, palpitations, headache, sweating and vomiting
Correction of moderately severe hypoglycemia can be accomplished by Intramuscular or subcutaneous administration
ol glucagon, followed by oral carbohydrate when the patient recovers sufficiently. Patients who fall to respond to
glucagon must be given glucose solution Intravenously.
Patients who are unable to lake sugar orally or who are unconscious should be treated with Intravenous administration
ol glucose at a medical facility or should be given an Injection of glucagon (either Intramuscular or subcutaneous). The
patient should be given oral carbohydrates as soon as consciousness is recovered.
See Product Monograph for complete prescribing Information.
Full Product Monograph is available at www.lllly ca.
Ell Lilly Canada Inc
3650 Danforth Ave
Toronto, ON M1N 2E8
HumaPen•. Humalog'", Humaiog• MIX25•. Humalog Mlx50" and Humulln* are registered trademarks of Ell Ully and
Company; used under license
Date of Revision- June 11 , 2009
Q 20 10, Eli Lilly and Company. All rights reserved.
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Give your patients another option
towards glycemic control.
Humalog®Mix25®twice-a-day - basal and mealtime
insulin analogues conveniently combined in a single
pen - may be just what they have been looking for.
Open the dialogue to Humalog®

25% insulin lispro injection (rONA origin)
75% insulin lispro protamine suspension

Humalog Mix25 (25% ~nsulin lispro Injection, 75% Insulin lispro protamine suspension) Is 1nd1cated tor
the treatment ol pat1ents with diabetes mellitus who require 1nsulin tor the maintenance of normal glucose
homeostasis. Humalog ~nsullns are also Indicated for the 1nit1al stabilization of diabetes mellitus Humalog
(Insulin lispro Injection) Is a short-acting Insulin analogue and Is for use In conjunction w1th a longer-acting
human InSulin such as Humulin• N except when used In a subcutaneous Insulin lntus1on pump
The Humalog family ollnsullns is contraindicated during ep1sodes ol hypoglycemia and In patients sensitive
to Insulin hspro or any of the excipients they contain. Any change In insulin or human Insulin analogue should
be made cautiously and only under medical supervls1on. M1xlng of Humalog with e1ther anlmallnsulins or
Insulin preparations produced by other manufacturers Is not recommended '
Humalog MIX25 and HumaPen LUXURA are reg1stered trademarks of Ell Lilly and Company, used under license.
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See prescribing summary on page 57
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